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Abstract 
This thesis investigates transcutaneous electrical nerve stimulation (TENS), and in 
particular its role in the treatment of overactive bladder (OAB), which has been of interest 
for several decades. A standardization and an evaluation of various TENS parameters of 
stimuli would be beneficial to optimize the techniques used and to achieve the maximal 
effectiveness. Previously, Hoffman reflex (H reflex) inhibition was interpreted as a 
surrogate measure of bladder afferent nerve activity, and thus showed a potential to be 
useful for such evaluations. However, an influence of other factors, such as pelvic floor 
muscle contraction on this H reflex inhibition makes this surrogate measure unsuitable.   
In general TENS techniques are usually implemented in the patient’s treatment pathway 
as secondary treatment options. This is presumably due to a lack of effectiveness. 
Therefore a thought was given to enhance the effectiveness of the stimuli by producing a 
larger sensory input with a spatial temporal pattern. This lead to a development of a novel 
‘Sensory Barrage Stimulation’, as introduced in this thesis. The technique showed 
promising effectiveness in comparison to a conventional type of TENS in the patients 
with elbow spasticity.  
Other researcher groups have tried to enhance the effectiveness by stimulating deep nerve 
structures (usually only targetable by implanted devices) using non/invasive 
transcutaneous stimulation and a specific waveform. However the “Transdermal 
Amplitude Modulated Signal” waveform introduced for the treatment of OAB symptoms, 
which claimed to pass through the skin more easily did not appear to be any different to 
a conventional stimuli and thus it is not of benefit for the routine clinical practice.  
Specifically, on the treatment for OAB syndrome symptoms, the most promising seems 
to be the Posterior Tibial Nerve Stimulation (PTNS) applied near the ankle. A well-
established form of PTNS, which uses a needle to stimulate the nerve have disadvantages 
of being invasive and expensive due to the patient’s clinical sessions. The transcutaneous 
form of PTNS was investigated here in a home based randomized pilot trial of idiopathic 
overactive bladder patients. A promising effect indicates that there might be patients who 
can benefit from this type of non-invasive and low cost approach of PTNS. Additionally 
a numerical modelling of both types of PTNS showed that both techniques achieve a 
stimulation comparable in a way of physiological effects. Thus suggesting the evidence 
of percutaneous form of PTNS is plausible to be present in the transcutaneous form.    
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1.1.  General introduction & terminology 
We all drink fluid. As we drink the body expels waste and excess fluid in the form of 
urine, which is temporarily stored in the bladder. Most people do not consider the 
physiological and neurophysiological process that are involved in the sensation which 
leads them (at a socially acceptable time) to visit a toilet. However, for a significant 
proportion of the population, the signals and sensations prompting them to go are 
different. They have urgency (a sudden compelling desire to pass urine) which is a pivotal 
symptom of what is known as overactive bladder (OAB) syndrome. 
OAB is a set of symptoms, which patients experience during the storage phase of a 
micturition cycle. Urgency, present in majority of the patients, is usually accompanied by 
frequency (the patient passes urine at short intervals during the day) and often by a 
nocturia (the patient has to wake up one or more time at night to pass urine) (Abrams et 
al., 2002). One third of patients experience urinary incontinence (any involuntary leakage 
of urine) (Chapple et al., 2005). The term “urgency incontinence”, “urge incontinence” 
or “wet OAB” are often used in the literature for this group of patients. The 
standardization of terminology by the International Continence Society (Abrams et al., 
2002) suggests the additional use of the terms ‘urge syndrome’ or ‘urgency-frequency 
syndrome’. However, it is important to differentiate between urge, a normal sensation of 
the desire to void, and urgency, a pathological abnormal sensation of OAB syndrome 
(Chapple et al., 2005).  
OAB syndrome has a great impact on patients’ quality of life. There are over 5 million 
people (19%) in the UK over the age of 40 for whom quality of life is affected by the 
symptoms of overactive bladder (Milsom et al., 2001). The first-line treatment is bladder 
training or fluid intake management (National Institute for Clinical Excellence, 2015). 
Alternatively, medication may be advised and usually start with various antimuscarinics 
agents. However, nearly half of these patients discontinue therapy due to lack of efficacy 
in reducing the symptoms or side effects, such as dry mouth or constipation (Benner et 
al., 2010). Recently a new class of drug Mirabegron, a ß3-adrenoceptor agonist has been 
introduced into the clinical practise with promising efficacy and good tolerability (Vij 
and Drake, 2015).   
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It is important to investigate alternative therapies which may offer a different or additional 
treatment pathway and which may have a substantial impact on patients’ quality of life. 
One such alternative therapy is electrical stimulation, which has been used for the 
treatment of various lower urinary tract symptoms for several decades. Except the 
examples included further in this thesis, Sacral Anterior Root Stimulation has been 
intended to be used to improve micturition (Brindley et al., 1986) and formed a precursor 
for today widely available Sacral Neuromodulation.  
1.2.  Basis of electrical stimulation 
The term ’electrical stimulation’ is used to refer to stimulation of nerves and/or their 
respective muscles for therapeutic, diagnostic or research purposes (Reilly, 2011).  
Stimulation can be delivered to the body in a variety of ways. These include non-invasive 
(transcutaneous techniques), where electrodes are placed on the surface of the skin, the 
use of probes inserted into body orifices (semi-invasive), and to more invasive stimulation 
approaches using needles to penetrate the tissue (percutaneous techniques) or long-term 
implantation of electrodes. The technology of electrical stimulation presented in this 
thesis is mainly focused on non-invasive techniques due to their advantages of being more 
patient-acceptable, non-invasive and of potentially low cost.  
Electrical stimulation using surface electrodes is usually referred to as transcutaneous 
electrical nerve stimulation (TENS). This term is often used in conjunction to describe a 
widely-used therapy for pain relief; however the terminology can be used to describe any 
application of electrical stimulation delivered using surface electrodes. TENS is 
commonly applied via self-adhesive hydrogel surface electrodes with the stimulation 
being generated by small, hand-held, battery-operated and relatively inexpensive devices 
which are widely available to the general public. Usually, the stimulus intensity is set 
below the level which causes muscle to contract, in contrast to neuromuscular electrical 
stimulation (NMES) and functional electrical stimulation (FES) where motor level 
stimulation is used. The suggested mode of action is not fully understood but the gate-
control mechanism is often proposed for pain management (Melzack and Wall, 1965).  
A schematic diagram of electrical stimulation of a nerve, applied using two surface 
electrodes on the skin is shown in Figure 1.1.  A voltage applied between these two 
electrodes causes current to flow into the tissue. The conventional direction of the current 
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flow is from the positive to the negative electrode. Most of the current flows just below 
the skin, however some will penetrate deeper into the tissue, enter the nerve fibre and 
change the nerve membrane voltage. When nerve membrane threshold voltage has 
exceeded an action potential is created and thus causes stimulation. This action potential 
travels along the nerve fibre in both directions.  
 
Figure 1.1 A diagram of electrical nerve stimulation  
Electrical stimulation is often perceived as an alternative therapy option to conventional 
therapies (e.g. drug medication) and offered as a secondary treatment pathway. It is used 
frequently when standard therapy cannot be tolerated or is not effective. This secondary 
role is primarily due to the lack of comprehensive clinical trials evaluating its efficacy.  
Clinical guidelines currently therefore only recommend its utilisation within certain 
constraints; however, given the increasing body of evidence to support it, there may be a 
significant opportunity to bring benefit to a greater number of patients and their families 
in the future using this technology. 
1.3.  What do we already know about electrical stimulation as a 
treatment for the symptoms of overactive bladder? 
Studies of electrical stimulation to treat symptoms of OAB can be divided into four main 
groups, based on their stimulation technique:  
 Percutaneous stimulation using needle electrodes. The needle is usually inserted near 
the posterior tibial nerve (PTN) 5 cm proximally from the medial malleolus. In 
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commercial use, this is known as Stoller Afferent Nerve Stimulation (SANS) 
technique (Stoller, 1999), which has been improved from the original method by 
McGuire (McGuire et al., 1983a).  
 Anal, penile or vaginal stimulation. This technique can use surface electrodes or 
particular semi-invasive electrodes to stimulate specifically localised areas (Bristow 
et al., 1996). 
 Implanted stimulation devices. These devices usually consist of an implanted 
stimulator and implanted electrodes placed near a nerve root in the spinal cord, 
coupled with an external control device. The most common approach is known in the 
literature as sacral neuromodulation (Siddiqui et al., 2010). The well-established 
Finetech-Bridley Sacral Anterior Root Stimulator (Brindley, 1994), an electrical 
stimulator of sacral roots for emptying the bladder, formed a  precursor to today’s 
widely used sacral neuromodulation (Schmidt et al., 1999, Tanagho, 1993). The S2-
S4 nerve roots provide the principle motor supply to the bladder. The S3 root mainly 
innervates the detrusor muscle and is the main target of sacral neuromodulation 
 Transcutaneous electrical nerve stimulation. This uses surface electrodes at various 
stimulation sites on the body.  
As stated previously, the work in this thesis focuses on transcutaneous electrical nerve 
stimulation. The primary reason for focussing on this modality is that it has a number of 
practical advantages in its delivery. The method is completely non-invasive. Surface 
electrodes, connected to a battery-operated low-cost stimulator, are applied to an 
appropriate site of the body. The stimulators are simple to operate. Inexpensive hydrogel-
based electrodes and batteries are the only on-going treatment costs. TENS treatment 
itself should not require regular patient visits to clinics and is usually self-administered at 
home, which is convenient for the patient.  In general there are minimal or no side effects 
from TENS, although sometimes redness or skin irritation may occur around the 
electrodes. This usually resolves once the stimulation session is finished. TENS has been 
used for pain control but its use in the treatment of OAB or in lower urinary tract diseases 
is less well established. 
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1.3.1. Review of TENS for the treatment of OAB 
The literature review in this section will focus on TENS techniques where the electrical 
stimuli is passed through the intact skin. Other minimally invasive electrical stimulation 
techniques such as anal, vaginal stimulation plugs (Bristow et al., 1996, Tellenbach et al., 
2012), percutaneous stimulation (needle is inserted near a targeted nerve) or implanted 
stimulation devices are beyond the scope of this review and thesis (Tanagho, 1993, 
Schmidt et al., 1999). In particular, plugs are often refused by the patient because of 
embarrassment and a sense of uncleanliness (Yokozuka et al., 2004).  
The studies identified in this review can be subdivided into categories according to the 
site of stimulation used. A summary follows, with a particular focus on stimulation site, 
stimuli parameters, neural structures thought to be targeted, and the clinical and 
urodynamic outcomes achieved. 
1.3.1.1.  Sacral site 
In 1996, Hasan et al. (Hasan et al., 1996) compared S3 neuromodulation using implanted 
devices with TENS applied over the perianal region (S2 – S3 dermatomes). Improvement 
in more than 50% of idiopathic detrusor overactivity (IDO) patients suggested the 
potential of using TENS at a sacral site.  
In a study by Walsh et al., one week of continuous stimulation for 12 hours per day at S3 
dermatomes significantly improved both frequency and nocturia. However only 3/32 
patients continued with the therapy, and only on an intermittent basis, for up to 6 months 
of follow up (Walsh et al., 1999). The authors did not evaluate whether the patients found 
using TENS for 12 hours a day to be inconvenient and whether this may have led to 
discontinuation of therapy.  
Following this study, an urodynamically assessed group of 33 patients with detrusor 
overactivity (DO) and symptoms of OAB reported similar effects for self-administered 
stimulation over the sacral site twice a day when compared to oxybutynin in a 14 week 
crossover trial (6w + 2w washout + 6w) (Soomro et al., 2001). The stimulation group also 
reported far fewer side effects in comparison to oxybutynin.  The authors non-specifically 
documented some degree of difficulty in applying the stimulation in 30% of patients. This 
might reflect the inconvenience and difficulty of placing electrodes over the S2-S3 
dermatomes or the length of the daily treatment session (up to 6 hours). 
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A heterogeneous group of neurogenic patients with urinary symptoms were investigated 
in a non-randomized trial using a TENS stimulator with electrodes placed above the natal 
cleft twice a day in a home setting (Skeil and Thorpe, 2001). 19/44 patients decided to 
keep the stimulator after this trial, consistent with the beneficial treatment effect size 
reported although no data is available on their subsequent usage of it.  
Another small trial of 18 patients (7 neurogenic bladder, 5 overactive bladder, 6 nocturia) 
reported improvement in 10/18 patients after one month of stimulation over the posterior 
sacral foramina (Yokozuka et al., 2004). The authors suggested that this type of therapy 
causes less discomfort then vaginal or anal plug stimulation. However, this might partly 
be explained by their additional comment that in some cases, the intensity was not set to 
a high enough level to produce significant effects in all of the patients.  
In addition to this up to date literature, a commercially available system VERVTM Patient-
Managed Neuromodulation System (PMNS, Ethicon Endosurgery Inc.) (Monga et al., 
2011a) has been launched into the clinical practise in 2012. The system used so called 
Transdermal Amplitude Modulated Signal (TAMS) and claimed to stimulate deep nerve 
structures on the sacral site. However, subsequently this system was withdrawn and 
evaluation of TAMS waveform in this regards is discussed in Chapter 4.  
1.3.1.2.  Posterior tibial nerve stimulation (PTNS) 
The posterior tibial nerve (PTN) is a branch of the tibial mixed nerve containing L5-S3 
fibres, originating from the same spinal segments (S2-S4) as the parasympathetic 
innervations of the bladder (Figure 1.2). 
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Figure 1.2 The posterior tibial nerve originates from the same spinal segments as the 
parasympathetic innervations of the bladder 
McGuire et al. first used peripheral electrical stimulation to stimulate the PTN (McGuire 
et al., 1983b) in OAB patients. In this initial study a positive electrode was placed over 
the common peroneal or PTN and a ground electrode was placed over the contralateral 
equivalent site. They reported positive results in 8/11 DO patients who became dry after 
the treatment and in 7 neurogenic disease patients (Multiple Sclerosis MS, Spinal Cord 
Injury SCI) of which 5 became dry or improved. Sixteen years later, the Stoller Afferent 
Nerve Stimulator (SANS) was introduced, using a 34-gauge needle electrode inserted into 
the same place as used in electro acupuncture (the so-called SP6 point – 5 cm above the 
medial malleolus), with a surface electrode placed behind the medial malleolus. This 
position differed from the original description by McGuire et al., however further studies 
of either percutaneous or  transcutaneous posterior tibial nerve stimulation have used 
electrodes placed on the same area as the SANS (Stoller, 1999). Currently a commercial 
device Urgent-PC (Uroplasty, Inc.) which uses the percutaneous technique is available. 
Usually 12 sessions of the percutaneous posterior tibial nerve stimulation, at weekly 
intervals, are used and a large randomized placebo controlled trial showed significant 
improvement in overall overactive bladder symptoms (60/110) compare to sham (23/110) 
(Peters et al., 2010). It was shown that Posterior Tibial Nerve Stimulation (PTNS) 
responders can benefit from the therapy over 12 additional months of regular PTNS 
sessions (MacDiarmid et al., 2010). The exact mechanism of PTNS remains unclear and 
further multidisciplinary studies are needed to clarify this. Based on these studies 
Posterior Tibial Nerve 
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Transcutanoeus Posterior Tibial Nerve Stimulation (TPTNS) has been investigated as a 
non-invasive alternative approach.   
The clinical effects of TPTNS and oxybutynin, assessed by questionnaires, were reported 
in 5/9 women with overactive bladder, although more robust assessment tools and known 
pathology of the patients would be desirable in this study (Svihra et al., 2002). A 
significant improvement in elderly women with urgency urinary incontinence (Schreiner 
et al., 2010) was reported after 12 weeks of once a week stimulation in combination with 
Kegel exercises and bladder training. However this improvement was not superior to 
those patients with no stimulation. A self-administrated TPTNS non-randomized study 
where remarkably 83% MS patients reported clinical improvement in urgency (de Seze 
et al., 2011) also confirmed patients’ acceptance of this therapy for use at home. In similar 
home based study later (Ammi et al., 2014) also reported positive response in 
anticholinergic refractory overactive bladder patients. In a separate placebo controlled 
trial, 37 women with symptoms of idiopathic OAB were randomized into a treatment or 
to a sham group with electrodes on the same site, but with no stimulus applied (Bellette 
et al., 2009). Urinary frequency significantly improved both in the treatment group 
(p=0.002) and in the sham group (p=0.025). Statistical significance between these groups 
was not achieved but this might be explained by unequal micturition episodes in the 
baseline (13.88 vs 11.35 per day) (Bellette et al., 2009), pointing to the desirability of 
stratifying the patient groups based on micturition frequency. Another placebo control 
trial was conducted in residential care home setting (Booth et al., 2013). Although the 
participants were only assessed by questionnaires urinary symptoms (frequency) 
improved significantly more in compare to sham stimulation (electrodes placed on the 
lateral side of the ankle and stimulation current reduced to 2 mA – this is likely to be 
below the sensation level). 
In comparision to percutaneous PTNS, transcutaneous PTNS has the advantage of being 
completely non-invasive and can be self-administered by patients at home, which greatly 
lowers the overall cost of treatment. Stimulation can be delivered using a conventional 
TENS machine (Figure 1.3). Although two small placebo controlled trials have been 
conducted (Bellette et al., 2009, Booth et al., 2013), there is a need for more placebo 
controlled studies.  In addition, its longevity of therapeutic action remains unknown.  
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Figure 1.3 Transcutaneous Posterior Tibial Nerve Stimulation can be applied using a conventional 
TENS machine 
The National Institute for Clinical Excellence (NICE) currently does not recommend 
percutaneous tibial nerve stimulation for the treatment of OAB symptoms unless there 
has been a multidisciplinary discussion, failure of conservative management including 
OAB drugs, and the patient does not want botulinum toxin or percutaneous sacral nerve 
stimulation (National Institute for Clinical Excellence, 2013). Further, the transcutaneous 
form of PTNS should not be offered, because there is insufficient evidence for it to be 
recommended. 
1.3.1.3.  Other site of stimulation 
One of the first techniques for the treatment of lower urinary tract storage dysfunction 
stimulated the suprapubic region in patients with painful bladder syndrome (Fall et al., 
1980, Fall, 1987). This method was used to relieve abdominal pain, similarly to the 
principle of TENS when used for the relief of pain. Subsequently these patients also 
experienced reduced urinary frequency (Fall, 1987). Two later studies documented an 
improvement in urodynamic parameters in patients with detrusor overactivity, sensory 
urgency or neurogenic problems. However, based on the literature, the efficacy of 
stimulation of a suprapubic site in patients with OAB symptoms is unproven (Bower et 
al., 1998, Radziszewski et al., 2009).   
Another reported approach has used stimulation of the thigh muscle in spinal cord injury 
patients to relieve spasticity. In some of these cases, this has led to improvements in 
urgency incontinence (Shindo N, 1987) as well as an increase in the maximum 
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cystometric capacity (MCC) and reduced maximum detrusor pressure (MDP) (Okada et 
al., 1998, Wheeler et al., 1986). Further to this 6/19 patients reported clinical 
improvement in urinary incontinence and frequency extending out to 3 months after 
treatment (Okada et al., 1998).  
Based on this literature overall, and the (at best) limited evidence for stimulation at other 
sites, the most promising transcutaneous electrical stimulation technique appears to be 
either sacral stimulation or PTNS as they either directly or indirectly target the S3 spinal 
cord root.   
1.3.1.4.  Are acute effects of stimulation of clinical significance? 
An obvious approach to answer this question would be to assess the effectiveness of 
electrical stimulation in suppressing detrusor overactivity, as it presents in many patients 
with OAB symptoms (Wyndaele et al., 2004). This has led researchers to investigate the 
acute effects of electrical stimulation during an urodynamic study. These studies are 
summarised in Table 1.1. 
In total, 146 patients with IDO, sensory urgency, or (DO) secondary to neurogenic 
diseases, showed improvements in MCC (p=0.0009) compared to controls (without 
stimulation) when stimulation was applied over the S3 dermatomes (Walsh et al., 2001). 
Similarly effects were demonstrated by (Hasan et al., 1996).  However, comparison of 
suprapubic, sacral and sham stimulation by Bower et al. (Bower et al., 1998) did not 
clearly demonstrate these immediate effects on MCC. The authors concluded that the 
observed improvement in first desire to void (FDV) in DO patients may not be 
functionally important, although a significant reduction in maximum detrusor pressure 
may suggest potential efficacy in DO. Another approach used conditional stimulation 
(stimulation only turned on when a certain detrusor pressure was increased) to supress 
bladder contractions in 12 MS patients with neurogenic detrusor overactivity (NDO) at a 
sacral site (Fjorback et al., 2007a) and in 8 MS patients at the PTN (Fjorback et al., 2007b) 
using a needle electrode. However none of these patients had a positive response, in 
contrast to dorsal penile stimulation in which 10/12 patients were able to suppress 
detrusor contraction (Fjorback et al., 2007a). The dorsal penile nerve is a division of the 
pudendal nerve and similar effects of electrical stimulation have been shown when 
stimulating the pudendal nerve both in human studies (Spinelli et al., 2005, Vodusek, 
1986) and in cat animal models (Tai et al., 2011, Tai et al., 2012). This nerve is a deep 
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nerve in the pelvic region.  Although it has been suggested that it could be targeted using 
surface electrodes and a specific stimulation waveform (Tai et al., 2011, Tai et al., 2012) 
the exact mechanism by which this waveform would be more effective needs to be 
explored further. 
Similarly inconsistent effects have been reported in acute TPTNS studies, although 
Amarenco et al. reported positive results in half of the neurogenic disease (MS, SCI, 
Parkinson’s disease) patients he studied (Amarenco et al., 2003). These patients showed 
a 50% improvement in volume at the first detrusor contraction and/or MCC of more than 
50% of the baseline value. A previous urodynamic study showed no significant 
differences in any of the urodynamic parameters in 36 detrusor overactivity patients 
(Hasan et al., 1996). These differing result might arguably be due to the different 
pathologies of the patient groups.  
Neither of the two approaches to the investigation of acute effects, at either stimulation 
site, has clearly and robustly demonstrated effectiveness. Nevertheless, the balance of the 
literature indicates that patients may benefit from neuromodulation effects which could 
result from repeated stimulation sessions rather than a single application. In addition, de 
Seze et al. concluded that repeat treatment may be effective even in patients who did not 
respond to an acute sessions of TPTNS applied during urodynamic testing (de Seze et al., 
2011).  
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Table 1.1 Literature reviewing the acute urodynamic effects of TENS 
Abbreviations: DH – detrusor hyperreflexia, DO – detrusor overactivity, DP – detrusor pressure, DPCN – dorsal penile/clitoral nerve, FDV – first desire to void, FIDC – first 
involuntary detrusor contraction, IDI – Idiopathic detrusor instability, MCC – maximum of cystometry capacity, MS – multiple sclerosis, PD – Parkinson’s diseases, PTN – 
posterior tibial nerve, SCI – spinal cord injury, SU – sensory urgency 
Study Diagnosis 
No. 
Pts 
Site 
Stimulus pulse parameters Study 
details 
Urodynamic outcome 
Frequency Pulse width Intensity 
(Hasan et al., 
1996) 
IDI 
36 
PTN 
Suprapubic 
50 Hz 200 μs 
Tickling 
sensation 
Part of a large 
study 
No significant difference in any of the 
parameters 
59 
S2-S3 
T12 (sham) 
Control 
50 Hz 200 μs 
Tickling 
sensation 
3 groups, sham, 
control 
MCC significantly improved in S2-S3 
stimulation in compare to sham and 
control 
(Bower et al., 
1998) 
DO, sensory 
urgency (SU) 
79 
Sacral 10 Hz 200 μs Max. 
tolerable 
sensation 3 groups, sham 
↑ Max DP and FDV 
Suprapubic 150 Hz 200 μs ↑ Max. DP and FDV 
Sham no stimulation ↑ MCC in sensory urgency pts. 
(Walsh et al., 
2001) 
IDI, SU, DH 
(SCI, MS) 
146 
Perianal 
dermatomes 
10 Hz 200 μs - Control group 
FDV (p=0.002) and Max CC. 
(p=0.0009) improved in compare to 
control 
(Amarenco et 
al., 2003) 
MS, SCI, PD, 
IDI 
44 PTN 10 Hz 200 µs 
Below motor 
response 
Acute effect 
48% (21/44) increased volume at  
FIDC, 34% (15/44) increased MCC 
(Fjorback et al., 
2007a) 
MS 12 
Sacral 20 Hz 500 μs 50-60 mA 
Conditional 
stimulation 
0/12 were able to supressed detrusor 
contraction 
DPCN 20 Hz 500 μs 50-60 mA 
10/12 were able to supressed detrusor 
contraction 
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1.3.2. Which stimulation parameters? 
The literature on the stimulation parameters used is summarised in Tables 1.1 (acute 
urodynamic effects) and Table 1.2 (clinical and urodynamic effect of long-term 
applications). The location of electrodes and range of stimulus parameters are likely to be 
critical factors in all forms of stimulation. Relevant stimulus parameters include pulse 
width; pulse repetition frequency; burst length (if applicable) and stimulus intensity. In 
some studies the technical description of the stimuli used does not give all of these details. 
To achieve sacral stimulation, Yokozuka et al. (Yokozuka et al., 2004) instructed patients 
to put surface electrodes on the posterior sacral foramen and to increase stimulation 
intensity until an anal contraction could be felt. They speculated that, in cases where there 
was no improvement, electrodes were not placed in the correct position or the intensity 
was not high enough due to associated discomfort. There is support for this in the results 
of Takahashi et al. (Takahashi, 2001) where slight changes in electrode location produced 
considerable apparent changes in urethral pressure response (Yokozuka et al., 2004). The 
sacral stimulation studies reported to date usually have electrodes positioned at the sacral 
foramina or on the buttocks overlying the S2 and S3 dermatomes. The precise positioning 
of electrodes on sacral sites varies between studies, presumably because the location of 
the sacral dermatomes is uncertain (Lee et al., 2008, Greenberg, 2003).  
The intensity of the stimulation current was usually set to the maximum tolerable, dictated 
by pain threshold. In other studies, patients were instructed to set an intensity that 
produced only a tickling sensation (Hasan et al., 1996, Skeil and Thorpe, 2001, Soomro 
et al., 2001). Nerve trunks (roots) in these areas are located deep within foramina and it 
is unlikely that these were being directly stimulated at the stimulus intensity level being 
used by the latter studies. However, cutaneous nerves within the dermatomes are easy to 
stimulate and hence superficial sensory fibre stimulation, which may lead to both direct 
and indirect modulation of spinal cord reflex mechanisms, may explain the reported 
effects. Furthermore, the intensity which produces anal sphincter contraction (Yokozuka 
et al., 2004) involves the stimulation of motor nerves thus activating different 
mechanisms and indeed may cause significant discomfort to patients. The clarification of 
the exact site of stimulation and of the intensity required needs to be addressed in future 
work.  Based on this evidence available it is not possible to conclude which stimulation 
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parameters are best for use in sacral stimulation. The original description of PTNS by 
McGuire et al. (McGuire et al., 1983b) has not been repeated in terms of the location of 
electrodes. Most studies place electrodes near the medial malleolus, where the PTN is 
relatively superficial. It is uncertain as to which leg the electrodes need to be placed on 
for optimal response, and whether this matters; some authors placed electrode on the left 
leg (Svihra et al., 2002, Amarenco et al., 2003, Bellette et al., 2009), while others on the 
right leg (Fjorback et al., 2007b, Schreiner et al., 2010, de Seze et al., 2011). It may also 
be more effective to place the electrodes bilaterally although no studies have yet looked 
at this. In describing the setting of current intensity, some of the studies reported motor 
responses during stimulation (Schreiner et al., 2010, Svihra et al., 2002). In other studies, 
the stimulation intensity was set either just below the motor threshold (Amarenco et al., 
2003) or just above the perception threshold (de Seze et al., 2011).  
The study reporting the most promising therapeutic results is  that  of de Seze et al. (de 
Seze et al., 2011), which reported PTNS to be successful for OAB symptoms in MS 
patients. Stimulation intensity in this study was set just around the perception threshold 
and patients did not report motor responses as a consequence of the stimulation. Hence 
only sensory fibres or cutaneous nerves overlying the PTN are likely to have been 
stimulated, which suggests this may be sufficient for the treatment of OAB rather than 
direct stimulation of PTN trunk itself. If the treatment is self-administered, it is likely that 
the patient would prefer lower stimulation levels, which may then lead to stimulation of 
only cutaneous nerves rather than the posterior tibial nerve itself.  
Probably the biggest potential for widespread use is in transcutaneous techniques, which 
because of their non-invasive nature might be applied by patients in their own home 
environment and lower the related cost of the treatment. Dorsal penile / clitoral nerve 
(DPCN) stimulation using surface electrodes was investigated in several studies 
(Dalmose et al., 2003, Fjorback et al., 2006, Opisso et al., 2011), but there is not a great 
interest in these techniques, mainly because of inconvenience caused to patients (Opisso 
et al., 2008). Hence this stimulation site was not discussed in this review.  
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Table 1.2 Literature reviewing the clinical and urodynamic effects of TENS during long term applications 
 
Study 
Diagnosis/ 
patients 
characteristics 
No. 
Pts 
Site 
Stimulus pulse parameters 
Scheme of 
treatment 
Clinical improvement 
(% of patients) 
Urodynamic assessment 
Frequency 
Pulse 
duration 
Intensity 
(McGuire 
et al., 
1983b) 
MS, SCI, 
detrusor 
instability, IC 
22 
PTN/common 
peroneal 
nerve 
- - - - 
80% became dry or 
improved after the 
treatment 
- 
(Hasan et 
al., 1996) 
IDO 59 
S2-S3 
dermatomes, 
perianal 
50 Hz 200 μs 
Tickling 
sensation 
2-4w, 2 
groups 
69% Urge incontinence, 
73% enuresis, 37% 
urinary frequency (all 
defined as 50% benefit) 
MCC. voided volume, no. 
of unstable contractions 
(p>0.05) 
(Okada et 
al., 1998) 
DH, IDI 19 Thigh region 
30 Hz, 
pattern 
200 µs 
Max. below 
pain 
2w, 1/d  
20 min 
32% clinical 
improvement in urinary 
incontinence and 
frequency. 
11/ 19 patients MCC 
increase of more than 
50%. 
(Walsh et 
al., 1999) 
Refractory IVD 32 
S3 
dermatomes 
10 Hz 200  µs - 
1w, 1/d, 12h a 
day 
76% in frequency, 56% 
reduction in nocturia, 
urgency symptom score 
on VAS not significantly 
improved 
- 
(Skeil and 
Thorpe, 
2001) 
Neurological 34 
Sacral 
dermatomes 
20 Hz 200 μs 
Comfortable 
level 
6w, 2/day 
 90 min 
Significant improvement 
in incontinence episodes 
and frequency 
Not significantly changed 
(Soomro et 
al., 2001) 
IDI 43 
S3 
dermatomes 
20 Hz 200 μs 
Tickling 
sensation 
6w/up to 360 
min daily 
crossover 
56% (24/43) improved 
by more than 25% in 
number of daily voids 
Not significantly changed 
in the stimulation study 
arm. 
(Svihra et 
al., 2002) 
OAB 28 PTN 1 Hz 100 µs 
70% of 
motor 
response 
5ses,1/w 
30 min. 
3 groups 
control 
56% (5/9) patients in 
questionnaires score, 
control group no sign 
diff. 
- 
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Table 1.2 (continue) Literature reviewing the clinical and urodynamic effects of TENS during long term applications 
Abbreviations: DH – detrusor hyperreflexia, DP – detrusor pressure, IC – interstitial cystitis,  IDI – Idiopathic detrusor instability, IVD – irritative voiding dysfunction, MCC – 
maximum of cystometry capacity, MS – multiple sclerosis, OAB – overactive bladder, PD – Parkinson’s diseases, PTN – posterior tibial nerve, SCI – spinal cord injury, SU – 
sensory urgency, UUI – urge urinary incontinence  
 
Study 
Diagnosis/ 
patients 
characteristics 
No. 
Pts 
Site 
Stimulus pulse parameters 
Scheme of 
treatment 
Clinical improvement 
(% of patients) 
Urodynamic assessment 
Frequency 
Pulse 
duration 
Intensity 
(Yokozuka 
et al., 
2004) 
Neurogenic, 
unstable 
bladder, 
nocturia 
18 
Sacral S2-S4 
dermatomes 
20 Hz 
10s on  5s 
off 
300 µs 
 
Anal 
sphincter 
contr. 
4w, 2/day,15 
min 
55%  improved in UUI 
and frequency 
44% increased MCC. and 
inhibited contraction 
(Bellette et 
al., 2009) 
Non 
neurogenic 
OAB, women 
37 PTN - - - 
8ses,2/w, 
sham group 
Frequency and urgency 
improved significantly in 
both groups. 
- 
(Schreiner 
et al., 
2010) 
UUI, elderly 
women 
51 PTN 10 Hz 200 µs 
Some motor 
response 
12ses, 1/w, 
30min, control 
UUI improved 
significantly in 76% vs. 
26.9% patients in the 
control group 
- 
(de Seze et 
al., 2011) 
MS 70 PTN 10 Hz 200 µs 
Below motor 
response 
3m, 1/day, 
20min 
83.3% (58/70) improved 
in urgency based on 
warning time, the 
urgency MHU subscale 
and frequency 
Only % of classified 
overactive detrusor 
patients decreased 
significantly by 13%. 
(Booth et 
al., 2013) 
Bladder/Bowel 
dysfunction, 
elderly 
30 PTN 10 Hz 200 µs 
Comfort 
level 
12 ses., 2/w, 
30min., sham 
group 
Frequency: 74% vs. 42%  
Urgency: 74%  vs. 31%  
Incontinence: 47% vs.15%  
- 
(Ammi et 
al., 2014) 
OAB 43 PTN 10 Hz - 
Comfort 
level 
1 month, daily 
20 min. 
Bladder capacity and 
urgency scale improved 
significantly 
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1.3.3. Review conclusions 
The choice of stimulation parameters, the location of the TENS in the treatment of OAB 
symptoms, the outcome measures used and the underlying conditions and symptoms 
studied are very diverse in the literature to date. There is little long-term follow-up data 
published in the literature and hence the treatment regimen to produce ongoing benefits 
is unclear. 
The current consensus is that the most promising site of stimulation is the stimulation of 
S3 area of the spinal cord over the sacral region or over the posterior tibial nerve, but it is 
not clear which approach to stimulus delivery is the most effective. Little is known about 
the underlying mechanisms of action and which exact structures need to be stimulated. 
However there is tantalising evidence for the efficacy of the transcutaneous stimulation 
approach, although further large placebo controlled studies are required to provide a 
robust evidence base. The standardisation of future trial methodology is important to 
allow comparisons to be made between studies and stimulation protocols. 
1.4.  Outline of the thesis 
As concluded in the literature review, there is some evidence of efficacy in the treatment 
of OAB with a transcutaneous stimulation approach. Standardisation of methodology in 
this area will be important in helping to define the best way to deliver the stimuli, using 
which parameters (such as frequency, pulse width, treatment duration, number of 
treatment sessions etc.), at which sites and with which intensity setting. Ideally methods 
to evaluate this multi-dimensional parameter space would be quick and straightforward 
because of the large number of combinations which need to be considered. However in a 
condition such as overactive bladder, the clinical improvement of urgency, frequency and 
urgency incontinence reported using various outcome measures will probably occur only 
over several days or longer, thus making an evaluation of multiple options a lengthy 
process. In addition, a large number of patients would be required to evaluate all possible 
stimuli settings, which is not practical and is beyond the scope of this work.  
Therefore this thesis took an alternative route by initially trying to identify a surrogate 
measure for the effectiveness of the stimuli. It was hoped that finding such a measure 
would decrease the time needed to evaluate the stimuli options. Following this, an 
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evaluation using a clinical trial with identified stimuli parameters by such a surrogate 
measure would take a place. A further literature review identified several candidates for 
this measure, of which the most promising seemed to be the magnitude of the H reflex. 
However, piloting showed a large influence of other factors which made this potential 
surrogate measure unreliable and not suitable for this purpose. 
The evidence of the TENS effects in OAB treatment remains limited. Despite the lack of 
clarity with regard to the stimulus parameters, it has been hypothesized that the lack of 
great effect may be due to a decrease in response following repeated exposure to the same 
stimulus. Therefore a stimulus methodology which produces more variable stimulation, 
both temporally and spatially, was investigated. At the same time it has been hypothesised 
that the effects might be also enhanced if a large surface area sensory stimulation input is 
produced. Therefore a novel form of stimulation called “Sensory Barrage Stimulation” 
was developed. In order to deliver this type of stimulation the existing ShefStim, 64-
programmable stimulator (previously developed in the Department of Medical Physics, 
Sheffield) was modified. 
For the first hypothesis of this novel concept of stimulation, a study investigating 
habituation effects was conducted. Although the results of this study did not clearly 
demonstrate habituation effects, importantly for further studies, the sensations produced 
by SBS were distinguishable.  This allowed producing a sensation which mimics various 
subject recognisable sensations. Subsequently a stroking sensation pattern was developed 
and a pilot trial was conducted on patients with elbow spasticity, where stroking is used 
as a part of rehabilitation. This sensation in combination with larger sensory stimulation 
input produced by Sensory Barrage Stimulation demonstrated the feasibility of this 
approach and indicated that in comparison to a conventional TENS stimuli this might be 
more effective.  
Other research groups have tried to enhance the effectiveness by stimulating deep nerve 
structures (usually only targetable by implanted devices) using non/invasive 
transcutaneous stimulation with a specific electrical waveform. However the 
“Transdermal Amplitude Modulated Signal” waveform introduced for the treatment of 
overactive bladder symptoms, which claimed to pass through the skin more easily did not 
appear to be any different to a conventional stimuli as tested in this thesis.  
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Further on in this thesis and as a major area of interest in the investigation of non-invasive 
electrical stimulation for the treatment of overactive bladder symptoms an investigation 
of posterior tibial nerve stimulation was carried out. Two approaches for stimulating the 
posterior tibial nerve were identified. The percutaneous approach is more established in 
the literature and in current clinical practice, but it is invasive and expensive. On the other 
hand the non-invasive approach of transcutaneous PTNS seems to be more readily 
deliverable, particularly in a home setting, although there is a lack of evidence of efficacy. 
Thus, the aim of this work was to study the field distributions of both methods in order to 
compare these two types of stimulation and to investigate whether evidence for the 
percutaneous form of PTNS thus might be applicable to the transcutaneous form.  
Further, a pilot clinical trial exploring the effects of home-based application of posterior 
tibial nerve stimulation in comparison to sham stimulation was conducted. Although the 
effects reported in the trial seem to be small, they are comparable to the results obtained 
in the recent clinical trials for the treatment of overactive bladder symptoms using drug 
therapies. Additionally the trial patients studied here were refractory to various drug 
therapies and there are benefits of this modality as mentioned previously (can be done by 
patients at home, no side effects, low cost). 
 
Figure 1.4 Outline of the thesis 
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1.4.1. Summary of the main hypotheses 
 Is H reflex a suitable surrogate measure of bladder nerve activity?  
 Is it feasible to produce larger and more “salient” sensory stimulation using a 
multichannel stimulation approach? Can this be a more effective type of 
stimulation in comparison to conventional single channel stimulation?  
 Does the TAMS waveform pass through the skin more easily when compared to 
a conventional stimulation waveform? 
 What stimulation current is needed in order to produce the same physiological 
effect obtained with percutaneous stimulation when the transcutaneous form of 
PTNS is used?  
 Should self-administer home based transcutaneous PTNS be considered for 
further, larger, studies and subsequent deployment into clinical practice? 
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Potential surrogate measures for 
overactive bladder symptoms 
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2.1.  Introduction 
The literature review in Chapter 1 has identified the potential of using transcutaneous 
electrical stimulation techniques for the treatment of OAB. However, there are some 
uncertainties in the optimal parameters of stimuli that should be used. The frequency and 
pulse width settings vary across the literature in both sacral and PTN stimulation 
techniques. Some studies used parameters based on the previous literature without 
primary evidence of their efficacy and without direct comparison to other possible 
settings. Uncertainties in the description of the intensity setting may have an impact on 
treatment effect.  Different intensity settings may stimulate various types and depths of 
nerve structures (cutaneous, sensory or motor nerve fibres for example) and may produce 
different effects. The sacral site stimulation used in some studies also requires 
clarification in terms of the exact position of electrodes.  
In addition to changes in the basic stimuli parameters, stimuli might also be delivered in 
bursts/trains of pulses. Furthermore, there is also the potential to produce more variable 
stimulation using a multichannel stimulation technique as discussed in Chapter 3. This 
technique can produce variable patterns of stimuli, but can also target a larger area of the 
tissue at the same time. This may hypothetically enhance the effect of stimulation.  
Thus there are large numbers of possible stimuli parameters and protocol modifications, 
which may potentially improve the treatment of OAB. It would be desirable to investigate 
this spectrum of variables and determine what impact they have on the treatment effect.  
Ideally the evaluation of these different variables should be quick and straightforward, 
and this is a challenge. The metrics of OAB symptoms such as frequency, urgency or 
number of incontinence episodes change over several days and thus making the 
evaluation of multiple options a lengthy process. An alternative approach is to find a 
surrogate measure for the effectiveness of the stimuli. A suitable surrogate measure could 
decrease the time of evaluation for the variables involved. 
Any surrogate measure should ideally be easy to acquire, and preferably be useable in 
normal subjects to aid the collection of initial data. Although further clinical investigation 
will be required, this would allow a hypothesis relating to the optimal parameters to be 
formed.  
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Urgency, the pivotal symptom of overactive bladder syndrome is difficult to measure 
objectively. The majority of the clinical guidelines regard urinary diaries as the best and 
most essential tool for assessing the symptoms of overactive bladder (Chapple, 2014). 
However, urinary diaries still rely on patients understanding their importance and 
compliance with completing them. Therefore there has been research interest in using 
biomarkers as a measure of normal and pathological processes. In particular, increased 
Nerve Growth Factor in urine has shown some promise, but many criteria for a robust 
biomarker still need to be evaluated (Seth et al., 2013, Agilli et al., 2015). Bladder wall 
thickness is another potential biomarker, but also with contradictory results across studies  
(Cruz, 2012). Overactive bladder symptoms are complex and a single biomarker may not 
be sufficiently sensitive or selective.  Additionally, for the purpose of this project, 
biomarkers might not provide easily detectable surrogate measures of different stimuli 
parameters in healthy volunteers. Hence different options for surrogate measure are 
explored here. 
The lower urinary tract is closely coupled with the sympathetic and parasympathetic 
nerves of the autonomic nerve system. Heart rate variability (HRV) is frequently used as 
a measure of autonomic nervous system balance. Some studies suggest alternation of 
HRV related to bladder sensations (Ben-Dror et al., 2012, Mehnert et al., 2009). However, 
the autonomic nervous system balance measured by HRV is unlikely to be specific 
enough for bladder activity and OAB symptoms as it can be readily affected by emotional 
arousal or anxiety often also presented in patients with lower urinary tract symptoms. 
Instead, attempts have been made to find a surrogate measure linked with urgency, the 
pivotal symptom of overactive bladder.  
Urgency is defined by the International Continence Society (ICS) as a sudden desire to 
pass urine, which is difficult to defer. The causal mechanism of this bothersome symptom 
remains unclear, but one possibility is that the urgency is caused by alterations in bladder 
afferent nerve activity. Based on this assumption the sympathetic skin response was 
studied as a potential way of objectively assessing sensory bladder function in healthy 
volunteers (Reitz et al., 2003), but further investigation in overactive bladder patients is 
needed. Another, potentially more attractive approach for investigating bladder nerve 
activity has been identified as H reflex calf muscle measurements (Conte et al., 2011).  H 
reflex changes were presented as a putative measure of bladder nerve activity and were 
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shown to be modulated by treatment with Botulinum toxin A injections into the 
neurogenic overactive detrusor. This therefore has potential as a surrogate measure for 
this project and has been investigated further in the remainder of this chapter.  
2.2.   H Reflex of the soleus muscle 
The Hoffman Reflex (or H reflex) has been investigated for several decades as a research 
and clinical tool. It has some similarity to stretch reflexes (e.g. knee jerk reflex), in which 
a muscle spindle of the quadriceps muscle is stretched and a signal travels to spinal cord 
via Ia nerve fibres. These afferent fibres activate efferent fibres (Alpha motor fibres) at 
the synapses and a signal travels back to the quadriceps muscle. Subsequently this signal 
contracts the quadriceps muscle spindles and causes a swing movement (stretch reflex).  
The H reflex differs in terms of how the afferent signal is triggered. The signal is activated 
by using electrical stimulation of the sensory nerve fibres in the popliteal fossa and a 
reflex activates the soleus muscle, as in the knee jerk reflex (Edgoldbe, 2013) (Figure 
2.1).  The Electromyography (EMG) activity of the calf muscle group is recorded and H 
Reflex peak to peak amplitude measured.  
 
Figure 2.1 H Reflex pathway. Stimulation electrodes are placed in the popliteal fossa and active 
recording electrode on the belly of soleus muscle, with reference electrode on Achilles tendon.  
If the strength of the stimulus is large enough to stimulate the motor fibres, then a direct 
motor contraction of the soleus muscles is produced (Figure 2.2, M wave). The 
26 
 
amplitudes of these two responses are dependent on the strength of the stimuli and are 
characterised by a recruitment curve (Figure 2.3). Clinically, the H reflex is used mainly 
for the evaluation of the calf muscle, where changes in bilateral responses may be an early 
sign of spinal stenosis (Palmieri et al., 2004).  
 
Figure 2.2 Typical normal EMG response at the soleus muscle 
2.2.1. H-reflex recruitment curve 
H reflex responses are activated at a relatively low intensity of stimulation. With 
increasing intensity of stimulation, more afferent fibres are activated and therefore 
produce a greater H reflex response (Figure 2.3). At the same time the direct stimulation 
of motor fibres produces the M wave signal. The H reflex magnitude reaches its maximum 
(Hmax) at approximately 20% of the maximum of the motor response (Mmax) stimulation 
intensity level. Further increases in intensity gradually decrease the H reflex magnitude 
until it completely ceases. This H reflex inhibition is due to antidromic collisions. An 
antidromic volley (electrical activity traveling in the opposite to normal direction) in a 
motor fibre collides with orthodromic activity (electrical activity travelling in the normal 
direction) activated as the H reflex (Palmieri et al., 2004).  
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Figure 2.3 Recruitment curve as a percentage of Mmax in one normal subject 
2.2.2. H Reflex changes during bladder filling 
Inghililleri et al. explored changes in the H reflex magnitude during bladder filling in 
normal subjects, spinal cord injury (SCI) patients and in multi-infarct encephalopathy 
(ME) patients (Inghilleri et al., 2001). The H reflex pk-pk magnitude evoked by 
stimulation in the popliteal fossa was measured with an empty bladder, at a medium 
bladder filling, at the maximum bladder filling and 10 minutes after voiding.  A 
significant decrease in H reflex magnitude was observed in normal subjects and in ME 
patients at the maximum bladder fullness. However, in SCI patients the H reflex 
magnitude slightly (but not significantly) increased. After the voiding phase the H reflex 
size returned to the baseline value in all subjects. In 2002, Carbone et al. expanded their 
study to a group of non-neurogenic and neurogenic OAB and underactive bladder patients 
with similar results (Carbone et al., 2002). H reflex magnitude decreased at maximum 
bladder filling in normal subjects and non-neurogenic OAB patients. In contrast, 
neurogenic OAB patients (spinal cord injury) showed an increase in H reflex amplitude. 
It has been suggested that H reflex magnitude decrease is caused by an activation of spinal 
interneurons of bladder afferent input, which may change the level of spinal 
motorneurone excitability (Carbone et al., 2002).  They suggested these findings may 
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help to determine the pathogenesis of voiding dysfunctions. The same researchers showed 
that H reflex inhibition at maximum bladder filling is supressed after itravesical 
Botulinum toxin type injection (BoNT/A) in Parkinson’s disease patients (Conte et al., 
2011). This is consistent with BoNT/A injected into the detrusor muscle modulating 
bladder afferent activity. These finding thus may have potentials for a surrogate measure 
of overactive bladder symptoms as needed in this thesis.  
For the purpose of this work it was necessary to confirm the observations obtained by 
Conte et al. in a healthy subject. In addition it is important to consider other confounding 
factors, which may influence H reflex amplitude (Mai and Pedersen, 1976, McNulty et 
al., 2008, Sibley et al., 2007).  
2.3.  Pilot trial 
Based on the literature discussed above, a pilot trial was carried out to investigate the H 
reflex magnitude changes in relation to bladder afferent nerve activity. Urodynamic 
cystometry evaluation is an invasive procedure and would not be practical for this work 
as a direct measure of bladder filling, therefore natural bladder filling via slightly 
enhanced water intake was used. A disadvantage of this approach is the relatively 
prolonged time required for the experiment.  
Measurements of the H reflex in the soleus muscle has been described elsewhere (Knikou, 
2008) however, more importantly, the problems of long term monitoring of the H reflex 
needs to be addressed. The angle of the hip is reported to be critical for H reflex recording 
(Conte et al., 2011, Knikou and Rymer, 2002) and initial pilot data showed that slight 
changes in the position of the leg caused a significant change in H reflex amplitude. 
Additionally, change in back posture may cause a stretch in the hamstring muscle tissue 
and cause a change in the position of the stimulation electrodes relative to the targeted 
structures. Therefore it is important to keep the position of both the electrodes and the 
body constant throughout the experiment. Interestingly it has been shown that Mmax and 
Hmax typically decrease during a long-term experiment (Crone et al., 1999), which might 
influence the overall findings for the purpose of this trial. However, such a decrease was 
not confirmed by McNulty et al. in whose study stable maximum amplitudes were 
obtained during 100 minutes measurements (McNulty et al., 2012). Additionally, the 
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study by (Crone et al., 1999) could have shown the decrease related to the bladder 
fullness, because the participants might not have been specifically instructed to empty 
their bladders before the H reflex measurements. 
The H reflex amplitude is relatively sensitive to various other factors, such as anxiety 
(Sibley et al., 2007), alertness (Hodes, 1967), eye closure (Kameyama et al., 1989), 
turning of the head (Kameyama et al., 1989), previous muscle activity (Knikou, 2008) 
and so on. Therefore the participant must limit any movements and be as relaxed as 
possible.  
Consecutive H reflex measurements are known to produce a progressive inhibition in H 
reflex magnitude, therefore inter-stimulus intervals of 10 seconds are recommended to 
suppress this inhibition (Aymard et al., 2000).   
The time of the experiment was estimated to be 2 hours, therefore an automatic system to 
acquire the data was developed.  
2.3.1. Recording system   
To monitor the H reflex signal in an extended (as longer in duration) study ideally requires 
an automated process to simplify operator involvement and to consistently and 
objectively acquire data. The system is required to incorporate two essential functions:  
 Deliver stimuli to generate the H reflex signal at predefined intervals. 
 Record and automatically measure the signal H reflex magnitude.  
 
Figure 2.4 A purposed designed automatic measurement system  
30 
 
There are two signal flows in this system (Figure 2.4). These are a delivery of the stimuli 
through stimulation electrodes and a recording of the H reflex using the recording 
electrodes. Both parts are controlled by a computer running a LabView (National 
Instruments Ltd, UK) purpose-written application by Martin Slovak. This application 
synchronises the stimulator and measurement of the H reflex at a predefined interval. The 
measurement of M wave and H reflex magnitudes are made automatically by the software 
and saved along with the time of the measurement to a csv. file.  The signal captured had 
similar latencies and thus allow to capture magnitude of M wave and H reflex (Figure 
2.2) in predefined intervals.  
The isolation amplifier (CED 1902, Cambridge Electronic Design, UK) feeds the EMG 
signal to the A/D converter of a Multifunction data acquisition unit (NI DAQpad-6015, 
National Instruments, Hungary). The digitised signal is then acquired using the LabView 
application and visualised on a laptop or PC screen.  
The stimulation is delivered using an inbuilt constant current stimulator of the EMG Xltek 
system (XLTEK Neuromax 1004, Canada). A hardware interface unit was designed and 
constructed to enable the stimulator intensity and timing to be controlled by the LabView 
application and synchronised with the EMG measurement. 
2.3.2. Position of leg and M wave monitoring 
From the initial piloting it was observed that it is not critical at what angle the leg is kept, 
as long as the position is constant during the whole experiment. A convenient position of 
approximately 120° at hip, 30° at knee and 120° at foot was chosen and kept at this angle 
throughout the experiment in order to suppress any changes due to leg position. The 
participant’s foot was supported by a footrest.  To ensure that the same fibres are recruited 
in each of the measures, the M wave was monitored throughout the experiment and the 
stimulation intensity level adjusted if the M wave was significantly changed. The stimuli 
intensity was set to produce a small (compared to the supra-maximal response) M wave 
response of typically 1 mV.  A stimulation interval of 10 s between recordings and a pulse 
width of 1 ms were adopted from methodology of (Carbone et al., 2002).  
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2.4.  Pilot trial results 
The pilot trial was carried out on a single healthy subject to test the feasibility of the 
protocol. During the first stage the stability of the measurements was recorded with an 
empty bladder over a duration of 90 minutes in a single experiment (Section 2.4.1). 
Following this recording, a natural bladder filling was evoked by an increased fluid intake 
(Section 2.4.2). At this stage it was observed that the H reflex was decreasing.  
The bladder volumes have not been measured in this experiment, because an ultrasound 
bladder scan would require the subject to be in supine position and thus complicate the H 
reflex protocol measurements. Instead the subject recorded the perceived sensation 
according to the standardise terminology used for filling cystometry (Abrams et al., 
2002).  
All Figures in the following sections use the same legend – blue circles are single H reflex 
pk-pk amplitudes, green circles are single M wave pk-pk amplitudes, and a red line 
denotes the changes of H reflexes in 30 seconds intervals. 
2.4.1.  Stability of H reflex magnitude measurement (empty bladder)   
To investigate the changes of H reflex magnitude with time measurements of H reflex 
with an empty bladder were recorded for approximately 90 minutes (Figure 2.5). This 
showed that the magnitude of H reflex does seem to be relatively stable. The unpaired 
Student’s T-test showed no significant difference (p = 0.344) between the means of the 
first 30 minutes (mean = 6.79 mV, SEM = 0.11 mV, n = 180) and the last 30 minutes 
(mean = 6.65 mV, SEM = 0.10 mV, n = 180).  
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Figure 2.5  Example of stability of H Reflex measurement over 90min period. Green points – M 
wave pk-pk, Blue points – H reflex pk-pk, red line – changes of H reflex in 30s intervals 
Two significant decreases at 5 minutes and 30 minutes, were caused by an involuntary 
movement or contractions of the leg muscles. Other obvious decreases at 28. minutes 78. 
minutes min and 85. minutes were unknown origin, however it is likely that they were 
related to involuntary movements.  
2.4.2. H reflex during bladder filling 
The H reflex magnitude gradually decreased during natural bladder filling and this 
decrease correlated with the sensation of bladder filling (Figure 2.6).  
The regular water intake of 250 ml every 5 minutes started immediately after the start of 
recording and altogether 1.5 l of water was drunk. The first sensation of bladder filling 
(FSF) appeared at 40 minutes.  The first desire to void (FDV) was sensed at 53 minutes, 
and a strong desire to void (SDV) was sensed from 67. minute. The maximum sensation 
occurred at approximately 88 to 90 minutes. Despite the fact that the sensation could be 
suppressed, this was considered as the maximum (MAX) and the subject went to the toilet 
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to void, with the electrodes still attached to their leg. The recording started again after the 
voiding at 93. minute and continued for another 30 minutes.     
The baseline data were considered as the first 20 minutes (water intake should have had 
no effect as yet on the bladder fullness), followed by periods of sensation (FSF, FDV, 
SDV, MAX). Each sensation interval contained the measurement data until the next level 
of sensation (Table 2.1).  A one-way ANOVA – Dunnett’s multiple comparisons showed 
a significant difference between the baseline as a control and all period groups (including 
after the voiding period). There was no significant change between the first 10 minutes 
of baseline data in compare to the second 10 minutes of baseline (p = 0.760).  
 
Figure 2.6 An example of individual H reflex (blue circles) and M wave (green circles) recordings 
during nature bladder filling. 
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Table 2.1 H Reflex pk-pk [mV] amplitude group data and mean change from baseline  
 
Baseline 
0-10min 
Baseline 
10-20min 
FSF 
40-53min 
FDV 
53-67min 
SDV 
67-88min 
MAX 
88-90min 
After 
93-123min 
Mean 12.1 11.8 10.6 9.8 9.9 6.7 8.8 
SEM 0.08 0.08 0.2 0.2 0.1 0.6 0.1 
n 60 60 61 102 125 13 178 
95% CI 11.9-12.2 11.6-11.9 10.3-10.9 9.5-10.2 9.7-10.1 5.4-8.1 8.6-9.1 
        
Change from baseline 
0-10 min 
      
Mean 0.3 1.4 2.2 2.1 5.3 3.2 
SEM 0.2 0.2 0.2 0.2 0.4 0.2 
95% CI -0.4 to 0.9 0.8 to 2.1 1.6 to 2.8 1.6 to 2.7 4.2 to 6.3 2.7 to 3.7 
P values 0.760 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
        
Although the experiment was interrupted at the maximum sensation, it has been noted 
that if this urge sensation can be suppressed then there is a return of the H reflex inhibition 
as well as the sensation.   
This experiment was repeated three times on different days on the same subject and it 
was noted that the H reflex magnitude decrease might be related to a gradual increased 
activity of the pelvic floor muscle (PFM) during bladder filling. As it is pointed out above 
it was noted especially towards the end of the bladder filling cycle, when the bladder was 
full, and a more frequent and intense intensity of desire to void occurred. Therefore the 
following experiments investigated the influence of voluntary PFM contraction and 
cough, as an involuntary activation of PFM.   
2.4.3. Effect of Pelvic floor muscles / sphincter contractions and cough on H reflex 
In a further single experiment (Figure 2.7 and 2.8) H reflex baseline values were recorded 
for 3 minutes, then in a random order, voluntary contractions of the pelvic floor 
muscles/sphincters or cough was performed. Transcutaneous Posterior Tibial Nerve 
Stimulation (TPTNS) was applied as a feasibility test of practicality to use the H reflex 
as a surrogate measure of different stimulation settings simultaneously with voluntary 
contractions of the pelvic floor muscles/sphincters. The TPTNS (10 Hz, 200 µs pulse 
width, intensity below the motor contraction of toes) was applied using a TENS stimulator 
(TENStem Eco Basic, SchwaMedico, Germany) and surface electrodes (50x50 mm, 
Stimex, France) were placed below and above medial malleolus. There was a subjective 
observational feeling that PTNS may help to contract the PFM.  The mean baseline value 
was 15.5 mV (SEM = 0.1 mV, calculated from first 3 minutes of the recording). Mean 
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contraction 10.9 mV (SEM = 0.2 mV) and mean contraction PTNS 10.9 mV (SEM = 0.3 
mV) showed a significant difference (one-way ANOVA) to baseline, however these were 
not significantly different to each other nor to the mean of cough, 8.45 mV (SEM = 0.2 
mV). 
 
Figure 2.7 Inhibition of H reflex by cough and by contractions of pelvic floor muscles. Black - 
Contractions, Green - Contractions + PTNS, Blue - cough 
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Figure 2.8 Effect of different actions on H reflex, mean ± SEM  
2.5.  Discussion of the pilot experiments  
H Reflex inhibition during the bladder filling has been interpreted as an action of bladder 
afferent activity (Conte et al., 2011). This could make it a useful surrogate measure for 
the evaluation of different stimulation parameters in both normal subjects and patients. 
The pilot experiments demonstrated that the H reflex significantly decreases during 
natural bladder filling. However, such a decrease might not be caused only by the bladder 
afferent activity as originally suggested.  
During bladder filling a gradual increase in the contraction of the external urethral 
sphincter and pelvic floor muscles is presented. The experiment involving contractions 
of PFM and cough (a cough causes reflex contraction of PFM to suppress leakage due to 
an increase of intra-abdominal pressure) demonstrated that the H reflex is significantly 
decreased by these interventions and therefore may be significant confounding factors. In 
addition, the H reflex amplitude might be influenced by various processes including 
discomfort or alertness. Sibley et al. 2007 identified decreases in H reflex amplitude due 
to anxiety (Sibley et al., 2007), which might slightly correlate with anxiety about leaking 
at the end bladder filling, hence the decrease during bladder filling.   
This initial experiment has shown that H reflex amplitude might be sensitive to PFM or 
sphincters and therefore might not be an ideal surrogate measure of bladder afferent 
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activity. Transcutaneous PTNS applied during PFM contraction did not have an influence 
on the H reflex magnitude when compare to PFM contraction alone.  
These initial experiments do not favour H reflexes as surrogate measure. However, the 
absence of other obvious candidates justified the study of these confounding factors in a 
larger group of healthy volunteers before any conclusion can be made. Therefore further 
investigations were carried out.   
2.6.  Healthy volunteer study – is H reflex inhibition related to PFM? 
The pilot observations have been made on a single subject, therefore to assess if there is 
a significant influence of pelvic floor muscles on the H reflex magnitude, a group of 
healthy volunteers was studied. Similarly, Mai and Pedersen asked medical students to 
contract their sphincter during the H reflex measurement and a significant decrease in 
amplitude of H reflex was observed (Mai and Pedersen, 1976).  
During the bladder filling cycle the bladder increases its volume and the bladder wall 
stretches. This causes an activation of stretch receptors in the bladder wall and increases 
the bladder afferent activity. The parasympathetic innervation of the detrusor is inhibited 
and the pelvic floor muscle group along with the urethral sphincter are activated to 
prevent the bladder from an involuntary emptying (Fowler et al., 2008).  The aim of this 
study is to determine if H reflex inhibition mechanism is entirely due to the bladder nerve 
activity (Pathway 1, Figure 2.9) or if there might be an additive influence of PFM 
(Pathway 2, Figure 2.9). The study will not be able to determine if H reflex is a 
combination of these two pathways. However it will be able to determine if the pathway 
2 exists and determine if the H reflex should be considered to be use as a surrogate 
measure.   
External input for the activation of PFM might be voluntary or involuntary, of which the 
latter usually relates to an increase in the intra-abdominal pressure.  
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Figure 2.9 Possible pathways underlying the H reflex inhibition 
2.6.1. Materials and methods of the study 
The study was approved by the University of Sheffield ethics committee and the 
experiments were carried out at the Clinical Research Facility, Royal Hallamshire 
Hospital, Sheffield (Appendix A).  
2.6.1.1.  Participants  
Potential participants were approached via the University email advertisement or directly 
by Martin Slovak. They were provided with an information sheet about the study. If they 
decided to participate, a study visit was arranged. As part of the study visit all the 
participants were checked against the inclusion and exclusion criteria (Appendix B) and 
signed the informed consent form.   
2.6.1.2.  H reflex measurement   
The H reflex measurement system used in the piloting was used for the study (Section 
2.3.1). A pair of stimulation electrodes was placed behind the knee at the popliteal fossa. 
The reference recording electrode was placed at the distal site of the achilles tendon. The 
active recording electrode was placed approximately half the distance between the 
reference electrode and the stimulation electrodes on the medial gastrocnemius muscle. 
The stimulating and recording electrodes were 3 cm2 “duck-foot” shaped standard 
neurology electrodes (70010-K/C/12, Neuroline 700, Ambu, Malaysia). A 4x5 cm oval 
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shaped ground electrode (019-400500, CareFusion, USA) was placed between the 
stimulation electrodes and the active recording electrode.  
One milliseconds, rectangular, constant current stimulation pulses of an intensity 
generating an M wave of around 1 mV and producing a clearly recognisable H reflex 
were delivered every ten seconds. To set achieve this optimal level of stimulation 
intensity, the stimulation electrode might have been slightly repositioned.  
2.6.1.3.  Test process 
The participants were instructed about each of the test conditions (below) and asked to 
empty their bladder before the electrodes were placed on the skin. The participant sat on 
a comfortable adjustable chair with their knee flexed 30 degrees from full extension and 
the ankle kept approximately at a right angle to the lower leg, rested against a foot support.  
Only the participant and the experimenter were present in the room to keep any 
distractions to a minimum. The participants were asked to relax, keep the leg in a stable 
position and to focus on the experiment throughout.   
 
Figure 2.10 Participant’s position on the adjustable chair during the H reflex recording 
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2.6.1.4.  Test conditions  
The test conditions were chosen to activate PFM either voluntarily or involuntarily. The 
voluntary activation was achieved using two types of exercise:  
Isolated Pelvic Floor Muscle contraction (IPFM) – for this exercise, the following 
description from an advisory leaflet was used (Bladder and Bowel Foundation, 2008) .  
“Sit comfortably with your knees slightly apart. Now imagine that you are trying to stop 
yourself passing wind from the bowel. To do this you must squeeze the muscles around 
the back passage. Try squeezing and lifting that muscle as if you really do have wind. 
You should be able to feel the muscle move. Your buttocks and legs should not move at 
all. You should be aware of the skin around the back passage tightening and being pulled 
up and away from your chair. Really try to feel this squeezing and lifting.” 
It was emphasised to the participants that they should try to avoid contractions of 
abdominal and buttocks muscles.  
Maximal Pelvic Floor Muscle contraction (MPFM) – the same instructions as for the 
IPFM were provided, however this time the participants were asked to produce maximal 
contraction and were allowed to contract buttocks and/or abdominal muscles.  
The involuntary pelvic floor muscle exercises consisted of:  
Light cough (LC) – this was described as a gentle, light cough. 
Deep cough (DC) – this was described as the strongest maximal cough that the participant 
is able to produce.  
Valsalva Manoeuvre (VM) – the participant was asked to pinch their nose and perform 
a maximal attempt to forcibly exhale against the closed nose and mouth. This manoeuver 
should cause a modest activation of PFM (Thompson et al., 2006), although this was not 
assessed objectively in any of the test conditions.  
2.6.1.5.  Test procedure 
All the measurements of H reflex and M wave and full EMG waveforms were recorded 
consecutively every 10 seconds and saved in the file. Each of the test conditions was 
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performed five times, in a randomized order. Five consecutive data measurements prior 
to each of the test conditions were used to calculate baseline values of H reflex. The 
participants were warned what the next required contraction type would be in advance. 
Five seconds before the measurement was trigged, the investigator counted down the time 
to ensure synchronisation between the test condition and the measurement. The 
experimenter recorded the time of each test and the next test condition was performed 
after another five baseline data measurements.        
2.6.1.6.  Data analyses  
The complete data set for each of the participant consisted of 25 tests. To ensure brevity 
of the analyses, the following glossary of the terms used has been created.  
Glossary of the terms used:  
Participant Dataset (PDS) – each dataset consisted of 25 Test Datasets (TD). This is 
because each of the five test conditions was repeated five times. 
Test dataset (TD) – these are data of one test (Table 2.2). The dataset consisted of the five 
baseline measurements (BM) and one test condition measurement (TCM).   
Table 2.2 Example of the test data for one participant at one test condition 
BM1 BM2 BM3 BM4 BM5 TCMIPFM,1 
9.35 mV 8.06 mV 7.77 mV 5.8 mV 8.12 mV 4.28 mV 
Baseline Measurement (BMi)– the H reflex magnitude at the baseline measurement i (e.g. 
BM1, BM2, BM3, BM4, BM5) 
i – the ordinal number of the baseline measurement for a particular N and TC 
Test Condition Measurement (TCMTC,j) – the H reflex magnitude for a specified TC (e.g. 
TCMIMPFM,1 –  TCM at Isolated Pelvic Floor Muscle test condition, test one) 
j – the ordinal number of the particular test for TC 
Test Condition (TC) – the type of the test condition as defined in Section 2.6.1.4 
Baseline Test Mean (BTM) - mean of the five baseline measurements prior to each of the 
test conditions. 
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Single change – this is a percentage change in the magnitude of H reflex for a test 
measurement from the baseline test mean. 
Mean change – mean of the single changes for a particular TC 
 
𝐵𝑇𝑀𝑇𝐶,𝑁 =  
∑ 𝐵𝑀𝑇𝐶,𝑁,𝑗
𝑗=5
𝑗=1
𝑗𝑀𝐴𝑋
 (2.1) 
   
 
𝑆𝑖𝑛𝑔𝑙𝑒 𝐶ℎ𝑎𝑛𝑔𝑒𝑇𝐶,𝑁 =  
𝑇𝐶𝑀𝑇𝐶,𝑁 
𝐵𝑇𝑀𝑇𝐶,𝑁
× 100 (2.2) 
   
 
𝑀𝑒𝑎𝑛 𝑐ℎ𝑎𝑛𝑔𝑒𝑇𝐶 =  
∑ 𝑆𝑖𝑛𝑔𝑙𝑒 𝐶ℎ𝑎𝑛𝑔𝑒𝑇𝐶,𝑁
𝑁=5
𝑁=1
𝑁𝑚𝑎𝑥
 (2.3) 
jMAX – number of the baseline values measured, default five values 
Nmax – number of the tests for each test condition 
The primary outcome measure was the mean change of the H reflex from the baseline for 
each test. The Wilcoxon test was used to compare the mean of BTM with TCM.     
The single change was expressed as percentual change of test condition measurement 
(TCM) with baseline test mean (BTM) of the same test. This normalised value is a result 
of one test.  The mean of five tests for each of the conditions was taken for each participant 
and compared to the control values of 100% (no change) using Wilcoxon tests.  
Two way ANOVA test with Sidak’s multiple comparison with post hoc analyses was 
used to compare the magnitude values of H reflex of mean BTM values with TM for each 
test condition and participant. The result of each multiple comparison was indicated as 
Increase – post hoc significant difference and increase from BM (>100% of baseline) 
Decrease – post hoc significant difference and decrease from BM (<100% of baseline) 
No statistically significant difference was considered as no change.  
2.6.2. Results 
A total of 13 participants were recruited and finished fully the study protocol. Out of 325 
total tests, 319 tests were analysed. Six tests from five participants have not been included 
into analyses due to a technical fault in the data collection.  
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2.6.2.1.  Demographics 
The participants consisted of five males and eight females. The majority of the 
participants were native English speakers, however, four participants had English as their 
second language. The demographic data of the group are summarised in the Table 2.3. 
Table 2.3 Demographic data 
Pt no. Sex Age 
Body mass 
index 
1 M 24 
 
23.0 
2 F 31 20.8 
3 F 47 26.7 
4 M 37 28.1 
5 M 64 26.6 
6 F 25 21.5 
7 F 23 20.4 
8 F 31 18.3 
9 M 45 30.4 
10 F 24 19.1 
11 F 31 22.5 
12 M 28 21.1 
13 F 27 19.0 
Mean (SD)  33.6 (11.9) 22.9 (3.9) 
2.6.2.2.  Change of the H reflex magnitude 
The primary outcome (the mean change of H reflex amplitude during each of the test 
conditions) is summarised in Table 2.4. Statistically significant decrease in the H reflex 
amplitude were obtained in MPFM (p = 0.0479) and DC (p = 0.0034) with LC 
approaching significance (p = 0.0681). 
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Table 2.4 H reflex amplitude change  
 
H reflex amplitude pk-pk [mV]    
IPFM MPFM LC DC VAL 
Baseline      
Mean (SD) 6.2 (3.3) 6.0 (3.1) 6.1 (3.2) 6.3 (3.2) 6.2 (3.2) 
Range 2.5 to 11.4 2.2 to 11.3 2.2 to 11.5 2.2 to 11.5 2.1 to 11.5 
Test      
Mean (SD) 6.2 (2.9) 4.2 (2.6) 5.1 (2.9) 4.0 (3.0) 6.5 (3.2) 
Range 1.1 to 11.4 1.0 to 8.9 2.2 to 10.6 0.5 to 9.4 2.5 to 11.5 
Change      
Mean (SD) -0.008 (1.4) -1.8 (2.7) -1.0 (1.7) -2.3 (2.7) 0.3 (1.3) 
Range -2.5 to 2.4 -7.2 to 1.6 -4.9 to 0.9 -9.7 to 1.0 -2.1 to 2.4 
CI 95% -0.8 to 0.8 -3.4 to -0.2 -2.1 to 0.02 -4.0 to -0.6 -0.5 to 1.2 
      
P value P > 0.999 P = 0.0479 P = 0.0681 P = 0.0034 P = 0.273 
* IPFM- isolated pelvic floor muscle contraction, MPFM - maximum pelvic floor muscle contraction, VAL - Valsalva manoeuvre, 
LC - light/gentle cough, DC - deep/strong cough 
Table 2.5 and Figure 2.11 summarise the H reflex amplitude changes expressed as a 
change from the baseline in the mean of the five tests in each participant. Confidence 
interval of 95% indicates significant changes again in MPFM and DC.  
 
Table 2.5 H reflex amplitude change from the baseline 
 
H reflex amplitude (% baseline)   
IPFM MPFM LC DC VAL 
Mean ± SD 106.8 ± 35.3 75.6 ± 37.4 88.2 ± 27.9 64.9 ± 35.5 112.4 ± 34.5 
Range 49 - 176 26 – 142 33 - 130 5 - 120 60 - 194 
CI 95% 85.4 - 128.1 53.0 - 98.3 71.3 - 105.0 43.4 - 86.36 91.5 - 133.2 
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Figure 2.11 H reflex amplitude change in each of the participant 
2.6.2.3.  Analyses of individual participant responses 
It has been noted that, in some participant, H reflex magnitude slightly increased rather 
than decreased and in some participant did not change significantly. A typical significant 
decrease is shown on Figure 2.12 (Participant #6, DC). A typical significant increase, 
which by its size was not as dramatic is shown on Figure 2.13 (Participant #11, MPFM). 
Therefore further analyses has evaluated the number of participants with a trend towards 
decreasing the H reflex magnitude and number of participants with a trend towards 
increasing. The trend of change is defined in the methodology (Section 2.6.1.6) as a 
significant change using Two way ANOVA test with Sidak’s multiple comparison (Table 
2.6) 
 
Figure 2.12 A typical decrease of H reflex magnitude during a test condition exercise 
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Figure 2.13 A typical slight increase of H reflex magnitude during a test condition exercise 
 
Table 2.6 Summary of statistically significant changes of H reflex in each of the participant  
Participant 
Trend of change in the H reflex magnitude  
IPFM MPFM LC DC VAL 
1 - Decrease Decrease Decrease Decrease 
2 - - - - - 
3 - Decrease - Decrease - 
4 - - - - - 
5 - - - - - 
6 - Decrease Decrease Decrease Decrease 
7 Decrease Decrease - Decrease - 
8 Increase - - - Increase 
9 - Decrease - - - 
10 Decrease Decrease Decrease Decrease Increase 
11 Increase Increase - - Increase 
12 - Decrease - - - 
13 - - Decrease Decrease - 
      
Decrease 2 7 4 6 2 
Increase 2 1 0 0 3 
No change 9 5 9 7 8 
The participants #1, #3, #6, #7, #9, #10, #12 and #13 had a trend towards decreasing the 
H reflex magnitude during the test conditions exercises, whereas participants #8 and #11 
has a trend to increase it. However these observations were not been observed in all of 
the test conditions. Participants #2, #4 and #5 did not show a significant difference during 
the test conditions in comparison to baseline in any of the test conditions exercises.  These 
inconsistences are difficult to explain, but could be caused by the participant’s insufficient 
activation of PFM. The level of PFM activation was not objectively assessed and relied 
on the subject compliance. The differences in the trend could be caused by natural 
variance across the population.  
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2.6.3. Further analyses of the data  
Significant decrease of the H reflex magnitude during activation of pelvic floor muscles 
has been observed only during MPFM and DC (Table 2.4). As mentioned above it has 
been noted that, in some participant, H reflex magnitude slightly increased rather than 
decreased. At the same this changes have not been observed in all of the exercises, raw 
data for each participant are shown in Appendix C. Figure 2.14 shows a typical raw data 
set (for the Participant #1).  
 
Figure 2.14 Typical dataset obtained during the experiment 
The analyses up-to this point only considered the mean of each test condition. However, 
if the aim of this study remains to investigate H reflex variability, as opposed to 
movement in one direction, during PFM activation, then a different analysis is needed.   
Therefore, further analyses will investigate the variation of the H reflex magnitude in each 
test condition, compared to the baseline values obtained without an activation of PFM. 
To do this the baseline variation has been compared with that of the test variation. 
2.6.3.1.  Coefficient of variation 
The coefficient of variation (Wikipedia, 2016) from a sample of the data is calculated as:   
 
𝐶𝑣 = (1 +
1
4 ∗ 𝑁
) ×
𝜎
𝜇
 
(2.4) 
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µ - Sample mean  
σ – Sample standard deviation 
2.6.3.2.  Does the H reflex magnitude variation change during the exercise?  
To answer this question the variation of baseline sample is compared to the variation of 
the baseline and test data combined. In other words, the analyses should look for a 
difference if one measurement in the baseline data collection is replaced with a test 
condition. As there are five baseline measurement and one test condition per group, the 
coefficient of variation would be relatively insensitive to the contribution of the test 
condition if all measurements in the group are combined. Instead, a novel test in which a 
comparison of a pair of baseline measurements with a pair of baseline measurement and 
test condition measurement has been developed 
The “Baseline data” are defined as two baseline measurements (B4 and B5). The “Test 
data” are defined as one baseline measurement (B5) and the test measurement (Figure 
2.15). The mean coefficient of variation in Table 2.7 is expressed as mean of the five tests 
for each the test condition in each participant.    
The Table 2.7 shows that the IPFM, MPFM, LC, DC test conditions significantly 
influence the change in the variation of the baseline data. VAL test condition has not 
shown to have an influence on the variation of the baseline measurement.    
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Figure 2.15 Illustration of the data used for calculation of the coefficient of variation 
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Table 2.7 Coefficients of variation 
Pt IPFM MPFM LC DC VAL 
 Base Test Base Test Base Test Base Test Base Test 
1 0.11 0.12 0.08 0.57 0.06 0.58 0.11 0.58 0.12 0.27 
2 0.07 0.06 0.12 0.05 0.11 0.16 0.09 0.21 0.12 0.11 
3 0.20 0.43 0.18 0.62 0.19 0.16 0.38 0.90 0.29 0.25 
4 0.10 0.13 0.10 0.14 0.06 0.19 0.06 0.22 0.07 0.12 
5 0.14 0.17 0.15 0.15 0.12 0.14 0.17 0.24 0.10 0.17 
6 0.18 0.22 0.24 0.43 0.23 0.51 0.16 0.49 0.26 0.38 
7 0.05 0.12 0.05 0.31 0.05 0.07 0.04 0.21 0.04 0.04 
9 0.26 0.29 0.08 0.29 0.27 0.29 0.18 0.54 0.29 0.31 
10 0.07 0.06 0.05 0.14 0.04 0.06 0.05 0.09 0.05 0.07 
11 0.11 0.24 0.21 0.70 0.09 0.27 0.21 0.98 0.13 0.07 
12 0.20 0.25 0.20 0.19 0.39 0.23 0.25 0.50 0.24 0.14 
13 0.15 0.18 0.21 0.43 0.09 0.11 0.21 0.22 0.16 0.14 
Mean 0.137 0.185 0.150 0.334 0.146 0.233 0.166 0.427 0.157 0.172 
SEM 0.016 0.028 0.021 0.056 0.028 0.043 0.027 0.076 0.024 0.028 
P value 0.0044 0.0049 0.0378 0.0002 0.4648 
2.7.  Conclusions 
Previously reported studies of H reflex changes during bladder filling have suggested a 
linkage between bladder afferent nerve activity and H reflex magnitude (Conte et al., 
2011, Carbone et al., 2002). However, the pilot experiments have challenged these 
findings and raised a question as to whether the H reflex magnitude changes are likely to 
be caused by a concomitant activation of PFM during bladder filling rather than the 
bladder nerve activity alone. The further volunteer study has shown that the H reflex 
magnitude is significantly decreased during maximum pelvic floor muscle contractions 
and during deep cough. In comparison to the bladder filling studies this effect has not 
been observed in all of the participants. Isolated pelvic floor muscle contraction and 
Valsalva manoeuvre seem to either decrease or increase the H reflex magnitude 
inconsistently, which first was one has also been observed elsewhere in the literature (Mai 
and Pedersen, 1976). Finally, it has been shown that all of the PFM activities except those 
related to Valsalva manoeuvre have an impact on the variation of H reflex magnitude 
when compared to the variation of baseline measurements, thus destabilising it. Despite 
the best effort to explain the IPFM and VAL exercise to the participants the inconsistency 
in these observations might also be linked to the inability of the participants to perform 
the tests consistently.  
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The main limitation of the volunteer study presented here was the inability to objectively 
measure the performance of each of the test conditions which may have varied in each of 
the test condition and across the participants.  
The results of the studies presented in this chapter do not lead to a robust conclusion that 
H reflex would be a useful surrogate measure for overactive bladder symptoms. Previous 
claims about its usefulness for observing modulation of bladder nerve activity need to be 
clarified in relation to the findings in this chapter. 
Further work to find a suitable surrogate measure was not carried out during this thesis 
because the literature did not support any alternative avenues of investigation. Instead, 
the focus of the next chapter is directed towards producing more physiologically effective 
electrical stimuli.   
 
 
 
 
 
 
 
 
 
 
 
 
 
51 
 
 
Sensory Barrage Stimulation – a 
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3.1.  Introduction  
As described in Chapter 2, a surrogate measure leading to a tool to determine optimal 
stimulation parameters for OAB therapy could not be identified using the resources 
available and within the timescale of this project. Therefore the project moved onto the 
development of a potentially more effective general purpose stimulation technique. 
Electrical stimulation for therapeutic purposes remains an active research area. Variants 
of electrical stimulation waveforms combining various features with an aim to enhance 
the effect of currently available techniques are regularly introduced (Neurocare, 1993, 
Shen et al., 2011). However these developments are rarely supported by any robust 
rationale and do not involve a direct comparison with currently available techniques.  
TENS is a well-established form of electrical stimulation therapy (Khadilkar et al., 2008)  
usually uses a single pair of electrodes placed on a specific site and delivers a continuous 
stream of repeated stimuli at a low intensity level, below that which causes muscle 
contraction. The development presented in this chapter hypothesised that the effects of 
TENS may be enhanced with a form of stimulus delivery encompassing the following 
two features. 
The first feature addresses the hypothesis that it would be beneficial to stimulate a larger 
area of skin and hence target more sensory fibres. This could be potentially important in 
sacral site stimulation for the treatment of OAB symptoms, where the area to be targeted 
is relatively large, the optimal site of stimulation is unclear and where existing methods 
are not likely to be stimulating the deep sacral nerve roots themselves. It would be 
possible to target a larger area of tissue/nerve structures by using larger electrodes. 
However the stimulus current density would not be distributed evenly over the electrode 
and, in particular, would be expected to be greater at its edges (Reilly, 1992). An 
alternative approach is to use a number of discrete electrodes distributed over the area of 
tissue to be stimulated, each driven by a constant current generator. To achieve this a 64-
channel programmable electrical stimulator previously developed for use in foot drop 
therapy (Heller et al., 2012) has been modified to allow  delivery of stimuli using an array 
of 64 small individually controlled electrodes.  
The second feature addresses the hypothesis that constant frequency (monotone) TENS 
might cause participants to habituate to the stimuli and for it therefore to become less 
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effective. The concept for addressing this habituation process has its origin in our 
understanding of neuroplasticity. This has been studied partly in the context of post-injury 
plasticity. Whilst the mechanisms involved are not completely understood, it is postulated 
that neural networks are undergoing a ‘rewiring’ process (Nudo, 2006). Electrical 
stimulation is widely used as an aid to return functioning post-stroke. Areas of the cortex 
can take on new functionality in response to injury or as a natural process following 
learning. It has been shown that attention plays an important role in learning and thus may 
influence plasticity (Stefan et al., 2004). Hence stimulation capable of producing time-
varying ‘interesting’ (or ‘salient’) sensations via multiple electrodes (as opposed to a 
single electrode), may improve neuroplasticity effects via the maintenance of attention to 
the salient stimulus. In addition, a patterned sensory stimulation has been shown to be 
effective in inducing plasticity in reciprocal Ia sensory inhibition in comparison to 
monotone stimulation (Perez et al., 2003). The technique proposed here aims to target 
superficial sensory cutaneous nerve fibres originating from receptors in the skin rather 
than in deeper nerve bundles (trunks) which require stronger electrical stimuli to activate 
because of their greater depth. The two features described above, namely time varying 
signals and multi-channel stimulation has led to the novel electrical stimulation concept 
which has been named Sensory Barrage Stimulation (SBS).  
The remainder of this chapter looks into the practicality and effects of the SBS approach. 
However similarly to techniques described in Chapter 1 the challenges are how to 
determine the optimal parameters of this form of stimulation and how to evaluate its 
effectiveness. 
Although the specific focus of this thesis is on the treatment of overactive bladder, the 
evaluation of this novel stimulation technique was explored in two different experimental 
models of peripheral stimulation, chosen because of their relatively easily measurable 
endpoints. In both models the response to SBS has been compared with a standard form 
of TENS.  The two models chosen were the habituation of normal volunteers to sensory 
stimuli and the effect of SBS versus TENS on subjects with upper limb spasticity.  
3.2.  Development of multichannel electrical stimulation technique 
To deliver the stimuli with the features specified in the introduction section, the ShefStim 
apparatus (Heller et al., 2012) was modified.  As described below, modifications were 
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made to support an external programming interface for the stimulator to allow the 
stimulator to be controlled during the experiments, and firmware modifications were 
made to enable a repeating complex pattern of stimuli to be delivered. These allow the 
ShefStim apparatus to activate individual or subset of electrodes, at specified current 
amplitudes and time durations and thus creates a virtually infinite number of patterns 
The pattern in which the stimuli are delivered is uploaded to the ShefStim’s FLASH 
memory in a form of a table. The pattern is represented by a set of records in, which is 
repeated throughout the stimulation.  A purpose made Windows application was 
developed to create a dataset for the table and to visualise the pattern (Section 3.2.3). 
The electrodes used during the spasticity study were in the form of an electrode array as 
used in the foot drop application (Heller et al., 2012) or, for the habituation study, with 
discrete electrodes interfaced to the stimulator using a purposed made breakout accessory.  
The ShefStim hardware was controlled either by a PC or a laptop, which were electrically 
isolated from the subject environment using a homemade PC isolation interference of 
4kV boundary. The ShefStim remote control can provide control and adjustment of 
stimulation level, but in this study was only used for status checking (error messages, 
etc.). The block scheme of the ShefStim system is shown in Figure 3.1. 
 
Figure 3.1 The block scheme of the ShefStim system 
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3.2.1. The 64 electrode array 
The array consists of 64 individual 8x8 mm square electrodes with a 3 mm gap between 
each on a flexible printed circuit board (Figure 3.2). An adhesive hydrogel sheet ST GEL-
high impedance grade SCBZAB-05M (Sekisui Plastics, Japan) with a resistivity of 1.3 
kΩ*m and a thickness of 0.5 mm was laid over the surface of the electrode array to act as 
the interface between the electrodes and the skin. This relatively high resistivity, low 
thickness hydrogel layer avoids ‘blurring’ of the stimuli that could occur due to current 
flow along the layer as opposed to through it (Cooper et al., 2011). The overall dimension 
of the electrode array is 91x91 mm. 
 
Figure 3.2 ShefStim apparatus with a 64 cathode electrode array 
3.2.2. The breakout accessory 
The breakout accessory consisted of two separate boxes connected to the ShefStim 
apparatus (Figure 3.3). The smaller box connected to the ShefStim apparatus provides the 
anode connection and the bigger box provides individual cathode connections. Standard 
safety sockets (2 mm pin) are used for electrode connections. This allows the use of a 
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wide range of commercially available electrodes. Although the ShefStim provides 64 
channels of maximum output 10 mA/channel, the accessory is designed to provide 32 
channel with double output for a channel. This is provided by connecting two ShefStim 
output channels to one channel of the breakout accessory socket. This combining of 
channels works because each ShefStim channel is a constant current source. It could not 
be used for a constant voltage stimulator. 
 
Figure 3.3 The ShefStim system with a breakout accessory box. The overall system consists of the 
modified stimulator, a remote control, an isolated PC interference and the breakout accessory. 
3.2.3. Stimulation pattern design 
A bespoke software tool to allow an easy and visual design of the stimulus pattern was 
made. Each pattern is created as a sequence which allows the activation of between 1 to 
64 channels at the same time. The stimulation current to be delivered from each channel 
can be set between 0 to 10 mA and pulse width 100 µs to 600 µs. The maximum 
instantaneous output of the stimulator is limited to 90 mA. Each sequence can deliver 
between 1 to 500 pulses at a frequency of 10 to 125 Hz, with amplitudes which gradually 
increase or decrease in their intensity in predefined ramp window of up to 3 s. Frequency 
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below 10 Hz can be provided using a pattern with no stimuli periods between the active 
sequences which would serve as a pulse repetition rate.  
3.3.  Study 1: Salience and habituation features of SBS 
The specific features of Sensory Barrage Stimulation to deliver ‘interesting’ or ‘salient’ 
stimuli and thus enhance the effects of neuroplasticity as indicated in Section 3.1 is 
indirectly evaluated further in this Study 1. There is a virtually infinite number of stimuli 
which can be delivered using the modified ShefStim apparatus. Consequently the 
evaluation of all stimulation patterns which might be created remains a challenge. It has 
been hypothesised that SBS stimulation patterns might induce more plasticity when 
compare to conventional stimulation due to their ‘salience’ and directing the attention to 
the stimuli. 
Thus this project has compared several SBS patterns to a conventional TENS stimulation 
using a pair of electrodes with reference to:  
1. Performance of cognitive tasks and two-point discrimination  
2. Differences in skin conductance responses as measures of autonomic arousal 
3. Subjective description of the cutaneous sensation produced by patterns 
It is hypothesized that more ‘interesting’ or ‘salient’ patterns produce more distraction to 
the subject hence interfere with the task performance and increase the autonomic arousal. 
Thus the study aims to determine if SBS patterns are more likely to produce this 
distraction and ideally determine the best SBS pattern to achieve this.   
3.3.1. Materials and Methods  
Ethical approval for this study was obtained from the Ethic committee at University of 
Sheffield (Appendix D). Study design and data collection were carried out by BMed. 
student Miss Tabitha Izmirova (Department of Neuroscience, University of Sheffield, 
2011), Mr Martin Slovak carried out development of stimulation technique and the data 
analyses. The supervision of the study was carried out by Dr Tom FD Farrow from the 
Academic Clinical Psychiatry, University of Sheffield and Prof Anthony T. Barker from 
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the Department of Medical Physics & Clinical Engineering, Royal Hallamshire Hospital, 
Sheffield.   
3.3.1.1.  Participants  
In total, 67 healthy, right handed volunteers (34 male and 33 female, mean age 28 years 
± 11.5 years; range 18-60 years) gave informed consent and participated in the study. 
Participants had no reported history of any serious psychological or neurological 
condition, no reported reading difficulties (of relevance because of the nature of the 
neuropsychological tasks), no contraindications to electrical stimulation (e.g. fitted 
pacemaker or other electronic device) and no skin disease or broken skin on their left 
forearm. The experimental session was carried out at the Academic Clinical Psychiatry, 
Northern General Hospital, Sheffield.  
3.3.1.2.  Study design 
During the experimental session each participant received five 8 min. periods of 
stimulation, consisting of four different SBS patterns and one conventional TENS signal 
in a pseudo-randomised order. During each of these stimulation periods the participant 
completed a cognitive sensory tasks whilst their autonomic arousal was recorded using 
the skin conductance response.  The stimuli were delivered to the subject’s forearm on 
grounds of convenience.  The level of stimulation was set to produce significant sensation, 
but below the point where stimulation causes pain or motor response. The study flow 
diagram is shown in Figure 3.6 in Section 3.3.1.9. 
3.3.1.3.  Electrodes placement 
Both type of stimulation were delivered using the ShefStim and breakout accessory as 
described in Section 3.2.2. The electrodes consisted of a set of 24 individual cathode 
hydrogel electrodes (CareFusion Disposable Disk Electrodes REF 019-415000) and a 
larger anode electrode (CareFusion Disposable 2’’x4’’ Ground REF 019-4222). The 24 
cathode electrodes were separated into four vertical (distal to proximal) columns of six 
equidistant electrodes as shown in Figure 3.10. The larger sized anode was placed on the 
skin between the body of the left biceps and triceps. Body landmarks and rubber bands 
were used as an aid to consistent placement of electrodes across the participants scaled 
approximately pro-rata to arm size. The TENS stimulation used electrode no. 1 (cathode) 
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and no. 2 (anode) as shown in Figure 3.4. A cohesive bandage was wound over the 
electrode to maintain a firm mechanical pressure (and hence good electrical connection) 
between the skin and electrodes.  
As the stimulation was carried on a sensation level the cathodes were placed not less than 
35 mm apart, thus the produced sensation will be distinctive to the targeted area. This 
distance was based on the relatively poor two point discrimination of the forearm, which 
is between 35-40 mm in healthy volunteers (Nolan, 1982).  
 
Figure 3.4 The placement of electrodes (cathodes) used in the habituation study 
3.3.1.4.  Patterns 
There is virtually an unlimited number of patterns which could be created using the SBS 
system. The four patterns used in the study were chosen, in pilot experiments, to feel 
perceptually different, whilst using the same stimulation features as described below. 
1) Only one electrode activated at a time.  
2) Number of pulses per electrode activation was set to n = 3 to achieve a strong 
perception of sensation in a brief period 
3) Constant frequency of pulses delivered f = 50 Hz 
4) Constant pulse width of pulses delivered t = 150 µs  
60 
 
It was noted during pilot experiments that applying the same level of stimulus current to 
electrodes in different positions produces different level of sensation. It is possible that 
this might be related to the distribution of cutaneous sensory nerves. Sensation threshold 
was expressed for each electrode site, relative to the mean value for the arm, in pilot 
measurements on 10 heathy volunteers (Figure 3.5). A clear anatomical pattern has been 
identified showing sensitivity increases from distal to proximal sites. In the study, the 
stimulus intensity used was mapped according to this variation and then adjusted as a 
global percentage. This global percentage adjusted each of the electrodes so that the 
adjustment is relative to the mapped variation identified. 
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Figure 3.5 Top left and right – position of the electrodes on the forearm, Bottom – perception 
threshold current normalised to the overall mean threshold, shown for electrodes 1-6 as an example 
Two of the patterns were designed as predictable (the participant can identify the 
repetitive pathway of the stimuli) and two as unpredictable (the participant cannot 
distinguish if the pattern is being repeated). The patterns were named after their perceived 
sensation. 
The unpredictable pattern (“fly”) was designed to emulate the sensation of an insect 
moving on the forearm in a random direction, but it could be sensed also as a “snaking” 
sensation. The second unpredictable pattern (“random”) caused an intermittent sensation 
by a consecutive activation of all 24 electrodes in a random order. The first predictable 
pattern (“lines”) had some similarities to the fly pattern, but this was a repetitive pathway 
from one side to the other side and the participant could easily identify the movement of 
stimuli. The second predictable pattern “ring” simulated the movement of the ring 
sensation, which was going up and down on the forearm in a way such that it produced a 
sensation of a ring or bracelet moving on the forearm.     
TENS stimulation was performed by delivering stimuli between electrode no. 1 and 
electrode no. 2 at a frequency of 10 Hz,  as commonly used in transcutaneous PTNS (de 
Seze et al., 2011) or in sacral stimulation (Walsh et al., 1999) for the treatment of OAB.  
3.3.1.5.  Psychiatric tasks 
All the participants underwent five different tasks in the same order. During each task, 
they were stimulated by one of the patterns for 8 min, with the order of these patterns 
being randomised between subjects.  The tasks are briefly described below.  
Colour task – The Stroop test 
The participant was presented with a list of written colours, some of them in the same 
colour as the word and some in a different colour e.g. (BLUE, BLACK, GREEN, RED). 
The participant’s task was to read the colour of text, rather than reading the word (Stroop, 
1935). It was hypothesised that the pattern of the electrical stimuli would distract the 
participants, and by making them focused on stimuli rather than the task would cause 
them to erroneously read the word rather than the text colour.  
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Puzzle task - Tangoes Shape Builder 
The participant was presented with a set of cards – tangoes (Rex Games Inc.: Smart 
tangoes, 2012) on each of which was a shape (e.g. a boat). The participant’s task was to 
build the presented shape as fast as possible using several plastic pieces of different sizes 
and shapes. The time taken to complete each puzzle was recorded as the outcome of this 
task.  
Text task – Count the letter 
This task consisted of 15 short paragraphs from fictional literature. Above each paragraph 
was a specified letter which appeared in the text (Barlett, 2004). The participant’s task 
was to count the number of times this letter appears in the paragraph. The participant was 
instructed to be as quick, but as accurate, as possible and also that it was not necessary to 
read the text. This task requires participant to select only important (‘salient’) information 
(the letter) and ignore the non-salient information (the text). It was hypothesised that 
under a combination of time pressure and the challenge to attention created by a SBS 
pattern would lead to an increase in participant’s errors.    
Visual task – Spot the differences 
The participant was presented with pairs of pictures every two minutes. The participant 
task was to find and mark the difference between the pair of pictures (Smart-Kit, 2012). 
The outcome of the task was a number of spotted differences.  It was hypothesised that 
the challenge to attention created by a SBS pattern would lead to an increase in 
participant’s errors.    
Sensory task – two point discrimination on the finger 
The participants were asked to wear an eye mask so they could not observe the test. At a 
random time interval the participant was touched using a thin piece of pencil lead on a 
fingertip. The participant’s task was to identify which finger was touched and whether 
the touch was performed by one or two pieces of pencil which were 4 mm apart. The 
outcome of the task was a number of correct responses, defined as correct answers to both 
finger identification and number of touches.  It was hypothesised that, again, the challenge 
to attention created by a SBS pattern would lead to an increase in participant’s errors.    
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3.3.1.6.  Debrief questions 
After each of the tasks the participant was asked to fill in feedback related to the task 
difficulty (not further analysed in this thesis) and stimulation sensation perceived. The 
participant was also presented with a list of 40 descriptive words and marked those which 
corresponded to the sensation perceived in a particular pattern. Each descriptive word was 
assigned to one of the following groups (Table 3.1). These groups were blinded to the 
participant and words were randomly spread across the page. The words were obtained 
from the McGill Pain Questionnaire (Melzack, 1975), and the Leeds Assessment of 
Neuropathic Symptoms and Signs (Bennett, 2001). 
Table 3.1 Word description of the pattern and assigned groups 
Pain Sharp, Sore, Shooting, Stabbing, Hurting, Unbearable, Burning, 
Stinging, Piercing 
Neutral Pulsing, Jumping, Tingling, Spreading, Pressing, Radiating, 
Vibrating, Pins&needles 
Positive Exciting, Relaxing, Pleasant, Interesting, Stimulating, Comfortable 
 
Intense 
sensation 
Throbbing, Vigorous, Intense, Penetrating, Prickling, Heavy 
 
Slight pain Pinching, Hot, Tender, Tight, Smarting, Aching 
 
Negative 
experience 
Dull, Annoying, Itching, Numb, Squeezing 
 
Moderate 
sensation 
Bursting, Beating, Tickling, Pounding 
 
The data from the debrief questionnaires were analysed as a subjective description of the 
perception of the pattern. The relative number of words in each group for a particular 
pattern then determined a score for the group.  
3.3.1.7.  Skin conductance responses as a measure of autonomic arousal 
During each task the dermal activity was continually recorded using an in-house build 
system. A pair of electrodes was attached on index and middle finger on left hand. The 
system measure the changes in impedance based on the voltage changes for a defined 
constant current (Z = U/I). Decompositions and optimization of these data were 
performed by Ledalab V3.4.1 (Benedek and Kaernbach, 2010) in Matlab R2011a. The 
Ledalab software produced minute-long epochs of skin conductance response showing 
the number of skin conductance responses (nSCR) and the integration area of skin 
conductance responses (ISCR).     
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3.3.1.8.  The experimental procedure 
Just before the experiment, or at home prior to the experiment, the participant filled in 
several standard questionnaires to assess his/her sensory profile and demographic 
information (not further analysed in this thesis).  
The experiment started with an identification of the global stimulus intensity level at 
which patterns were to be delivered. As the goal was to achieve a strong but comfortable 
sensation, but with no muscle stimulation response. Following that the subject underwent 
all the tasks with one stimulation pattern randomly assigned to each task. After each of 
the tasks the participant completed the debrief questionnaire.  
3.3.1.9.  Statistical analysis 
The One way ANOVA tests were used for task performance and skin conductance 
measures. When the significant difference between particular groups wanted to be 
identified the unpaired Student’s T-test was used.  
The debrief questionnaire groups were further coalesced to two opposite groups, namely 
‘intense’ and ‘neutral’. The intensity score was calculated as a sum of ranks from the 
“intense sensation” and “positive” groups. The neutrality was calculated as a sum of ranks 
from the “moderate sensation” and “neutral” groups. The ranks were obtained from the 
order of the total number of words used in each of the groups for all the patterns. 
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Figure 3.6 Study 1 flow diagram 
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3.3.2. Results 
3.3.2.1.  Demographic 
Sixty seven participants (34 male and 33 female, mean age 28 years ± 11.5 years; range 
18-60 years). Body mass index (n = 41, the rest of the participant did not want to provide 
their weight information) ranged from 16.7 to 30.5 (22.8 ± 3.0).   
3.3.2.2.  Stimulation current used 
Gender was found to be a determining factor for the stimulation intensity used to achieve 
sensation described as “strong, but comfortable” (males = 3.8 mA, females = 3.3 mA; p 
= 0.012) for the pattern stimuli. These gender related differences were also significant for 
the TENS stimulation (males = 4.8 mA, females = 3.7 mA; p < 0.001). 
3.3.2.3.  Effects measured using the task performance 
There were no significant pattern-specific effects on task performance (p > 0.1; multi-
variate ANOVA) except for a significant difference between patterns as a whole and the 
TENS stimulation condition for the sensory two-point discrimination task (p = 0.023; post 
hoc Fisher LSD test; Figure 3.7). Specifically, two-point discrimination task performance 
in the TENS stimulation condition (9.0 ± 1.8 errors) was significantly worse than for the 
unpredictable “fly” pattern (4.2 ± 1.0; p = 0.005; Student’s T-test), the predictable ‘lines’ 
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pattern (4.2 ± 1.9; p = 0.009) and the predictable ‘ring’ pattern (3.8 ± 0.8; p = 0.01), but 
not significantly different from the unpredictable ‘random’ pattern (6.9 ± 1.9; p = 0.06).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Results of two point discrimination 
3.3.2.4.  Effects measured using skin conductance responses  
The mean number of nSCR was calculated as a mean of all tasks for a specific pattern 
(Figure 3.8 on right). TENS stimulation had the lowest nSCR in each minute of 
stimulation; however this was not statistically significant. Integration of skin conductance 
responses (ISCR) also showed no significant difference between patterns (Figure 3.8 on 
left). There is a significant difference of ISCR at the first minute when compare to the 
second and consequent minutes in each of the pattern (p > 0.033), but there is no 
difference between second and any other consequent minute of the experiment.  
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 Figure 3.8 nSCR and ICSR means for all of the tasks using different stimulation patterns 
3.3.2.5.  Subjective description of the cutaneous sensation produced by patterns 
In the subjective description of the pattern sensation, each word was associated with one 
of the groups in Table 3.1. The total number of words in each group was calculated (Table 
3.2) and gave the score for each of the patterns (Table 3.3). The fly pattern had the highest 
pain and positive score. Single stimulation was described by the lowest number of words, 
but obtained the highest negative experience score.  
The most interesting pattern was defined as to be intensive, but not be neutral, therefore 
the intensity and neutrality scores were calculated (Figure 3.9). The highest intensity 
scores with lower neutrality scores were obtained for the random and fly patterns. Ring 
and lines patterns obtained higher neutrality scores then the intensity scores.  TENS 
stimulation obtained the lowest score in both of the scores. 
Table 3.2 Number of words used in the description of patterns using descriptive groups 
Pattern Pain 
Intense 
sensation 
Negative 
experience 
Slight 
pain 
Moderate 
sensation 
Neutral Positive 
FLY 22 46 24 7 37 169 119 
LINES 18 47 23 13 40 171 102 
RANDOM 19 53 27 15 35 157 108 
RING 14 37 25 15 38 171 103 
TENS 10 33 31 11 27 119 92 
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Table 3.3 Ranking of each group based on number of words used 
Pattern Pain 
Intense 
sensation 
Negative 
experience 
Slight 
pain 
Moderate 
sensation 
Neutral Positive 
FLY 5 3 2 2 3 4 5 
LINES 3 4 1 4 5 5 2 
RANDOM 4 5 4 5 2 3 4 
RING 2 2 3 5 4 5 3 
TENS 1 1 5 3 1 2 1 
 
Figure 3.9 Intensity and neutrality score used for subjective description of patterns 
3.3.3. Discussion 
The aim of this study was to investigate the salience of the SBS patterns. The importance 
of salience was hypothesised to be based on the linkage between plasticity and attention. 
Therefore the SBS patterns were designed to be more ‘salient’ and thus more difficult to 
habituate/ignore than a conventional single channel TENS. 
In this study it was hypothesised that the distraction of the SBS pattern might lead to a 
decrease in task performance and differences in the performance will lead to the most 
‘salient’ pattern. However, the tasks performance analyses have shown no significant 
differences except for the two point discrimination task, where the TENS single channel 
stimulation showed the opposite of what was hypothesized (more errors in the task made). 
An explanation for this might be that in the discrimination task the multichannel pattern 
0 2 4 6 8 10 12
TENS
RING
RANDOM
LINES
FLY
Sum of scores [-]
Intensity Score
Neutrality Score
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helped the subject be alert during the task (because this task was the last one in the session, 
an eye mask was worn during it and some of the participants felt tired). Therefore the 
stimulation improved the performance, rather than distracted the attention. The overall 
explanation for no significant difference in task performance might be linked to 
stimulation levels administered (subjectively “strong but comfortable”). This might be 
distracting (i.e. salient) at rest, but insufficient to impact on the focused activity of task 
performance.  
The ISCR and nSCR demonstrated habituation effects versus time (first minute 
significantly higher than the others), but no significant difference between the stimulation 
patterns delivered. Although it was noted that TENS had the lowest number of nSCR and 
thus suggesting lowest autonomic arousal.  
The main limitation of this study was a lack of control group. A group without stimulation 
would be useful to determine how much the actual stimulation has affected the outcomes 
and how the performance of cognitive tasks and skin conductance differ during each of 
the stimulation period. 
The findings of this study do not indicate that the SBS patterns directly influence the 
attention of the participants. However, random and fly patterns showed higher sensation 
ranking of intensity then neutrality, whereas lines and ring patterns showed the opposite. 
This correlates with the predictability (or lack of predictability) of these patterns, 
indicating that more “interesting” patterns are unpredictable. This findings also 
suggesting that the participants are able to distinguish between the sensations of these 
patterns and thus further patterns of stimuli can be developed according to sensation 
which might be e.g. relaxing as showed in the Study 2.  
3.4.  Study 2: A pilot clinical trial comparing TENS and SBS in patients 
with spasticity at the elbow 
Spasticity is a disorder of  sensorimotor control, resulting from an upper motor neurone 
lesion and presenting as intermittent or sustained involuntary activation of muscles 
(Pandyan et al., 2005). It can interfere with functional recovery and lead to contractures, 
which impact significantly on patients’ everyday living activities. As indicated below, the 
treatment pathway for these patients is similarly challenging to that of OAB patients. 
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Pharmacological treatment is the first line treatment option but this is often not well 
tolerated due to side effects such as weakness, dizziness and drowsiness. 
Non-pharmacological approaches such as muscle vibration, extracorporeal shock wave 
therapy, and various forms of magnetic or electrical stimulation have been tried in the 
treatment of spasticity (Kheder and Nair, 2012). However, there is insufficient evidence 
to justify using these modalities routinely (Amatya et al., 2013). TENS applied to the 
sural nerve was reported to reduce spasticity in patients with hemiplegia (Potisk et al., 
1995). Similar effects were noted in patients with spinal cord injury immediately after 60 
min of 100Hz stimulation using TENS (Ping Ho Chung and Kam Kwan Cheng, 2010). 
Several long term studies showed promising results (Cuypers et al., 2010, Armutlu et al., 
2003), although a study with multiple sclerosis patients did not demonstrate a reduction 
in spasticity (Miller et al., 2007) but did help to reduced pain.  
It has been proposed that TENS reduces spasticity via modulation of spinal inhibitory 
circuits or those of the central nervous system (Ping Ho Chung and Kam Kwan Cheng, 
2010).  
The aim of this pilot trial was to assess the feasibility of using SBS for the treatment of 
spasticity affecting the elbow flexor muscles and to compare this with conventional TENS 
stimulation applied using two electrodes.  
3.4.1. Methodology of the study 
The study was designed as a crossover double blind randomized trial comparing SBS and 
TENS. The stimulation was delivered during two single 60 minutes sessions delivered 
one week apart.  The principal clinical investigator of this study was Dr Sivaraman Nair, 
the data were collected by MSc Clinical Neuroscience student Mr Joseph Chindo, and 
Prof Anthony Barker, Mr Mark Reeves and Dr Ben Heller provided technical advice in 
the development of the equipment used in the study. The design of the system software 
and hardware, the stimuli patterns and data analysis were carried out by Mr Martin 
Slovak. 
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3.4.1.1.  Participants 
The study was approved by the Yorkshire & The Humber regional ethics committee 
(Appendix E). Between March and June 2013, 17 potential participants, with spasticity 
of the flexor muscles of the elbow of grade 2 or more on the Modified Ashworth Scale 
(MAS) (Bohannon and Smith, 1987), were identified from the Neurology clinics at the 
Royal Hallamshire Hospital, Sheffield. 
3.4.1.2.  Study visits 
The potential participants were provided with an information sheet and contacted two 
weeks later. If they decided to participate in the study they were invited to attend two 
study visits spaced one week apart. At the first visit the participants were screened for 
inclusion and exclusion criteria (Table 3.4) and gave their informed consent. The eligible 
participants were randomized into one of two groups. Group 1 underwent SBS at their 
first study visit and TENS one week later. Group 2 underwent the same interventions in 
the opposite order, TENS first and SBS one week later.  
Table 3.4 Inclusion and exclusion criteria for the pilot trial of SBS in the treatment of spasticity 
Inclusion criteria 
1) Male or Female aged 18 and above 
2) Experiencing spasticity at elbow of grade 2 or more on the modified Ashworth 
scale 
3) Neurologically stable for  6 months 
 
Exclusion criteria 
1) Cognitive impairment that would interfere with their ability to comply with the 
experimental protocol or provide informed consent 
2) Any dermatological, rheumatologic or orthopaedic complications that might 
interfere with stimulation of the affected arm 
3) Pre-existing severe cardiovascular disease; active cancer or renal disease; end 
stage pulmonary or cardiovascular disease; psychiatric illness including severe 
alcohol or drug abuse and depression 
4) Inability to perform the baseline assessments 
5) Severe tactile hypersensitivity as assessed by a non-stimulation approach 
6) Participation in other, spasticity related, studies 
3.4.1.3.  Interventions 
The design of the moving SBS pattern is shown in Figure 3.10 and was chosen to mimic 
a stroking sensation.  For SBS the electrode array was divided into eight strips (each eight 
electrodes long). Each individual strip was activated for approximately 0.3 s with a burst 
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of fifteen 250 µs current pulses at 50 Hz applied simultaneously to all electrodes in the 
strip. The next strip was then activated while the previous one deactivated and this cycle 
was repeated until the last strip had completed its sequence of stimulation pulses.  This 
was followed by a pause of approximately 2.5 s, when no current was delivered.  In 
combination this provided a pattern mimicking the sensation of vertically stroking the 
arm proximally to distally. This sensory pattern was chosen because there is some 
evidence in the literature that mechanical stroking may have beneficial effects in 
spasticity to mimic this sensation, it was hypothesised that such sensation might help to 
relax the participant (Brouwer and Andrade, 1994). The pulse repetition rate of 50 Hz and 
the on/off periods were chosen because, in pilot studies, they gave the most convincing 
subjective sensation of stroking. All electrodes delivered the same current and this was 
adjusted by the operator according to just below each individual participant’s motor 
threshold.    
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Figure 3.10 Moving Sensory Barrage Stimulation pattern 
TENS was delivered using a commercial stimulator (Multi-TENS, NeuroTrac, 
VerityMedical Ltd., UK). The parameters of the stimulation were set as pulse repetition 
of 100 Hz as used in previous studies (Miller et al., 2007, Perez et al., 2003, Ping Ho 
Chung and Kam Kwan Cheng, 2010), 250 µs pulse width with an “on phase” of 6 seconds 
including a 1 second rising edge ramp, a 1 second falling edge ramp  and a 4 seconds “off 
phase” in which no current was delivered. To mimic the physical setup of SBS and to 
blind participants to which system was being applied, the cathode electrode (50x50 mm, 
VS50, VerityMedical Ltd., UK) was placed centrally underneath the array used for SBS 
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stimulation. This electrode was connected to the TENS stimulator. The participants were 
not informed as to which type of stimulation they received.  
The arrays (both for SBS and TENS) were placed on the middle of the triceps brachii on 
the dorsal aspect of the affected arm and strapped with a cohesive bandage to ensure 
consistent contact between the electrode and the skin (Figure 3.11). An anode electrode 
(100x50 mm, VS10050, VerityMedical Ltd., UK) was placed proximally on the deltoid 
muscle of the shoulder on the same arm for both types of stimulation.   
 
Figure 3.11 Position of the sensory barrage stimulator on the left elbow. 
Both interventions were applied for 60 minutes at a level just below the threshold for 
motor contraction. The intensity was gradually increased until a visible motor contraction 
was observed and then decreased to a level where it just ceased. If this level could not be 
achieved due to discomfort, then the strongest comfortable intensity was used.  
3.4.1.4.  Outcomes  
The assessment protocol was the same for both the SBS and TENS study visits.  
Participants were assessed before the stimulation was applied, immediately after 
stimulation and one hour after the stimulation was finished.    
The primary outcome metric was the Modified Ashworth Scale (MAS) for the elbow 
(Pandyan et al., 1999). Secondary outcome measures used were the power of elbow 
extension (PEE) and flexion (PEF) based on the Medical Research Council grades 
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(Council., 1981) and a Visual Analogue Scale (VAS) of the perceived effect on spasticity 
rated by the participant on a 13 cm line with the left end being the worst imaginable 
spasticity and right end being no spasticity. VAS was subsequently normalized to a 
percentage where 0% represented the participant experiencing no spasticity and 100% 
representing the worst spasticity they could envisage.  The participants who had a 
reduction in spasticity of at least one grade on the MAS when combined with a 30% 
decrease of spasticity relative to the baseline value on the VAS was considered to have 
had a clinically significant improvement. The clinical assessments were performed by the 
same clinician throughout the study.  The clinician was blinded as to the intervention 
applied to the participant. 
3.4.1.5.  Pendulum test 
It was thought desirable to perform an objective assessment of spasticity independent of 
the participant or clinician performing the clinical assessment of the Modified Ashworth 
Scale. A promising method, using a pendulum test, had been previously reported to show 
a significant correlation with spasticity (Lin et al., 2003). Therefore a similar apparatus 
was built.   
The system comprised of the pendulum apparatus and the data acquisition system. The 
pendulum apparatus consisted of a pendulum arm pivoted about a rotary potentiometer 
attached firmly to a Table. The 100 cm long shaft of the pendulum arm had a 1.5 kg 
weight at one end and a sliding height adjustable wrist support at the other end. The 
pendulum arm was attached to a low friction rotary potentiometer (Penny&Gilles Ltd, 
UK) at approximately 60 cm (measured from the bottom) and create a pivot of the 
pendulum. The potentiometer was connected to the data acquisition unit (National 
Instruments NI-6009, Austin, Texas, USA). The pendulum arm was attached to a Table 
using clamps (Figure 3.12 left). The participant’s wrist was attached to the pendulum 
wrist support and strapped with Velcro tape (Figure 3.12 right).  
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Figure 3.12 Pendulum apparatus 
The pendulum data acquisition system consisted of the data acquisition unit (National 
Instruments NI-6009, Austin, Texas, USA) and in-house written software using LabView 
(Figure 3.13). In accordance with IEC 60601-2-10 for medical electrical devices, a battery 
operated laptop was used to isolate the participants from any potential pathway to mains 
power or earth. The clinician present at the patients’ visits operated the software. The 
captured data were seen on the screen of the laptop during the pendulum motion. The 
post-capture analysis was carried out using Matlab R2011a (MathWorks, USA).  
 
Figure 3.13 Labview software for capturing raw pendulum data 
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3.4.1.6.  Experimental procedure 
The participant lay on a height-adjustable hospital bed in the supine position. The Table 
with the pendulum apparatus was placed next to the bed on the side of the affected arm. 
The height of the bed was adjusted such that the centre of rotation at the elbow and 
pendulum arm were in line. This setup was different to the one in the referenced study 
(Lin et al., 2003) where the apparatus was fixed to a bed and the centre of pendulum and 
elbow rotation were not in line. The wrist support was adjusted to a comfortable height 
and the wrist was fasten using Velcro tape. 
The lower part of the pendulum arm was slowly moved, such that the elbow joint angle 
between the forearm and upper arm was 50º. The pendulum arm was secured using a pin 
release mechanism on the leg of table. As muscle tone can depend on previous movements 
(Lin et al., 2003), the 50º elbow joint position was maintained for 2 minutes. The data 
collection was started and the pin released without notifying the participant. The subject 
was instructed to relax as much as possible and not to interfere with the pendulum’s 
movement. During the swing movement the investigator was able to observe correct data 
collection in a form of a graph on the screen of the laptop. Once the pendulum arm has 
stopped swinging the data collection was terminated and the test was repeated. Altogether 
there were five repeats of the test for each of baseline, immediately after the stimulation 
and one hour later, for each of the participants.  
3.4.1.7.  Offline pendulum analysis 
Representative pendulum data are shown in Figure 3.14. In this example, pendulum 
motion started at 50° and stopped after 14 swings. Due to gravity, the weight of the 
pendulum arm should have stopped at the 0° position, however for some of the 
participants the motion stopped in a slightly different position e.g. -10°. Therefore the 
baseline angle was considered to be the one when the pendulum stopped, in order to 
minimise errors in the further analysis.   
More prominent spasticity would be expected to cause a decrease in the number of 
swings, the magnitude of swings and the total time of pendulum motion.  
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The magnitude of the pendulum motion without the load of the participant forearm would 
decrease over time, however the damping effects were considered negligible in the data 
analysis, with undamped oscillations continuing for over several minutes.  
 
Figure 3.14 An example of the pendulum data from one participant 
A previous study  (Lin et al., 2003) used a complex analysis of a biomechanical model of 
the elbow joint and accessory, and derived a formula to quantify the damping coefficient. 
The main aim in this study was to quantitatively compare the motion before and after the 
intervention, therefore only simple measures derived from the system were obtained.  
3.4.1.8.  Outcomes of the pendulum test 
Three parameters were derived from the curve: 
The First Reversal Angle (FRA) is the first forearm peak angle in flexion. It is expected 
that the forearm will swing towards -50° (Figure 3.14).  
The Area Under the Curve (AUC) is the total area of the modulus of the angle-time 
curve. 
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The Maximum Velocity to First Reversal (MVFR) is the maximum gradient of the 
angle-time curve between the start of pendulum movement to the peak of first reversal.  
3.4.1.9.  Analysis of the data 
Baseline data were compared with those immediately and one hour after the interventions, 
using the Wilcoxon signed rank test because of the non-parametric nature of the outcome 
measures. TENS and SBS were compared using the Mann-Whitney’s test at each 
assessments period. The Friedman non-parametric test was used to compare the pendulum 
data.  GraphPad Prism version 6.00 for Windows (GraphPad Software, San Diego 
California, USA) was used for the analyses. All analyses was performed using intention 
to treat.  
3.4.2. Results 
In total, 17 patients were approached to participate in the study and ten consented. Four 
did not wish to participate, two were not able to participate due to problems with transport, 
and one had an implanted device - an exclusion criteria for the study. The study flow 
diagram is shown on Figure 3.15. 
 
Figure 3.15 Study flow diagram 
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3.4.2.1.  Demographic 
Among the 10 recruited participants there were five men and five women. Their ages 
ranged from 18 to 65 years (40±17 years). The aetiology of spasticity was: cerebral palsy 
(4), stroke (3), traumatic brain injury (2) and multiple sclerosis (1). The duration of 
spasticity symptoms varied from six to 38 years. All tolerated the interventions well and 
completed the study.  
Adverse events reported after SBS were one case of muscle spasm and one of an ache 
localised over the triceps muscle. One participant reported experiencing a sensation of 
pins and needles over his little finger after TENS.   
3.4.2.2.  Stimulation current 
Across all participants the average current during a pulse was in the range of 8 to 16 mA 
with a mean of 10.9±2.2 mA (mean ± SD) for TENS (excluding the ramp period). The 
average total current from the eight simultaneously activated SBS electrodes was in the 
range of 7.2 to 15.2 mA with a mean of 12.9±2.5 mA. 
3.4.2.3.  Primary outcome 
Immediately after the stimulation the MAS (Table 3.5) showed significant reduction for 
both TENS (p = 0.016) and SBS (p = 0.0039). The VAS (Table 3.6) also reduced 
significantly for both TENS (p = 0.027) and SBS (p = 0.0059).  At one hour after the 
stimulation with TENS, there was no significant change in MAS compared to baseline 
whilst the patient’s perception (as recorded with VAS) continued to show a significant 
change. One hour after SBS a significant reduction in spasticity both on the MAS and 
VAS was noted. There was no statistically significant difference in the MAS score 
between TENS and SBS immediately after (p = 0.63) and one hour after (p = 0.063) 
stimulation. However a trend was noted for a better response with SBS at one hour after 
stimulation compared to TENS. 
82 
 
Table 3.3.5 Modified Ashford Scale results 
MAS 
TENS SBS 
(n = 10) (n = 10) 
Baseline - Mean (SEM) 2.8 (0.2) 2.8 (0.2) 
Immediate - Mean (SEM) 1.9 (0.3) 1.7 (0.3) 
One hour - Mean (SEM) 2.1 (0.4) 1.6 (0.4) 
   
Baseline - immediate   
Mean difference (SEM) -0.9 (0.2) -1.1 (0.2) 
95% two side CI -1.4 to -0.4 -1.5 to -0.7 
P value 0.016 0.0039 
   
Baseline – one hour   
Mean difference (SEM) -0.7 (0.3) -1.2 (0.2) 
95% two side CI -1.3 to –0.1 -1.7 to -0.7 
P value 0.063 0.0039 
 
Table 3.6 Visual Analogue Scale results (percentage of maximum imaginable spasticity) 
VAS  
TENS SBS 
(n = 10) (n = 10) 
Baseline - Mean (SEM) 61.7 (7.2) 70.1 (8.6) 
Immediate - Mean (SEM) 47.1 (8.9) 38.6 (8.5) 
One hour - Mean (SEM) 41.4 (6.7) 38.1 (9.5) 
   
Baseline - immediate   
Mean difference (SEM) -14.6 (5.3) -31.5 (8.2) 
95% two side CI -26.6 to -2.6 -50.0 to -12.9 
P value 0.027 0.0059 
   
Baseline – one hour   
Mean difference (SEM) -20.3 (7.6) -32.0 (9.5) 
95% two side CI -37.6 to -3.0 -53.4 to -10.6 
P value 0.025 0.0098 
 
3.4.2.4.  Secondary outcome  
 There were no significant changes in the MRC grades of elbow flexion and extension 
with TENS and SBS although confidence intervals indicate a slight improvement (less 
than one grade) in TENS and SBS (Table 3.7 and Table 3.8). 
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Table 3.7 MRC elbow extension power summary of the results 
MRC power elbow extension 
TENS SBS 
(n = 10) (n = 10) 
Baseline - Mean (SEM) 4.3 (0.4) 4.3 (0.5) 
Immediate - Mean (SEM) 4.4 (0.5) 4.6 (0.3) 
One hour - Mean (SEM) 4.6 (0.4) 4.7 (0.3) 
   
Baseline - immediate   
Mean difference (SEM) 0.1 (0.2) 0.3 (0.3) 
95% two side CI -0.3 to 0.5 -0.3 to 0.3 
P value >0.99 0.5 
   
Baseline – one hour   
Mean difference (SEM) 0.3 (0.2) 0.4 
95% two side CI -0.2 to 0.8 -0.1 to 0.9 
P value 0.5 0.25 
 
Table 3.8 MRC elbow power flexion summary of the results 
MRC power elbow flexion 
TENS SBS 
(n = 10) (n = 10) 
Baseline - Mean (SEM) 4.0 (0.4) 3.9 (0.5) 
Immediate - Mean (SEM) 4.2 (0.5) 4.5 (0.3) 
One hour - Mean (SEM) 4.5 (0.4) 4.4 (0.3) 
   
Baseline - immediate   
Mean difference (SEM) 0.2 (0.2) 0.6 (0.3) 
95% two side CI -0.4 to 0.8 - 0.003 to 1.2 
P value 0.69 0.13 
   
Baseline – one hour   
Mean difference (SEM) 0.5 (0.2) 0.5 (0.3) 
95% two side CI -0.001 to 1.0 -0.1 to 1.1 
P value 0.13 0.25 
 
3.4.2.5.  Clinically significant improvement 
A reduction in spasticity of at least one grade on the MAS when combined with a 30% 
decrease of spasticity relative to the baseline value as assessed by the participant using 
the VAS was considered to be a clinically significant improvement. Immediately after 
TENS there were 2/10 responders and after SBS in 6/10 participants (Table 3.9). One 
hour after the interventions, these effects persisted in both TENS responders and in four 
of SBS responders, however two additional TENS and one additional SBS participants 
fulfilled the defined criteria at this point and were considered as responders as well 
resulting in 4 TENS responders and 5 SBS responders.  
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Table 3.9 Participants showing clinically significant improvement versus treatment and time ( = 
responder, - = non-responder).  
Pt no. 
TENS SBS 
Immediate 1 hour Immediate 1 hour 
1 - - - - 
2 -    
3 -    
4 - - - - 
5 - - -  
6 - -  - 
7 - -  - 
8 - -   
9   - - 
10     
 
3.4.2.6.  Pendulum data  
Altogether 292 tests out of an estimated 300 were analysed. Eight waveforms were not 
collected due to a technical fault. Further technical problems did not capture peak 
measurements in 37 tests and these had to be corrected to their approximate values. These 
corrections to the AUC were in a range of 4 to 17 degree seconds, which was considered 
negligible as the mean AUC values were at least an order of magnitude higher. Due to 
the same technical issue, three FRA test measurements were also corrected. An abnormal 
trajectory was observed in 12 tests such that the swing motion became larger with time. 
These tests were excluded from the analysis.  
The means of the test data for each pendulum outcome, in each of the participants are 
summarised in the Appendix F. An example of the data collected are shown in Appendix 
G. The mean values of all pendulum outcomes are in Table 3.10 and 3.11.  The Friedman 
non-parametric test showed no difference in any of the pendulum outcomes for both 
interventions.   
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Table 3.10 Mean ± SEM of pendulum outcome at each assessment for TENS intervention. FRA – 
First Reversal Angle, MVFR – Maximum velocity to First Reversal angle, AUC – Area Under the 
Curve 
TENS FRA [deg] MVFR [deg/s] AUC [deg*s] 
Baseline 32.8 ± 2.4 134.4 ± 2.6 253.0 ± 55.3 
After intervention 31.0 ± 2.8 130.5 ± 2.2 238.1 ± 51.4 
P value (Base-After) 0.322 0.160 0.492 
One hour after 30.2 ± 2.8 129.2 ± 4.4 270.0 ± 53.2 
P value (After-One) 0.625 >0.999 0.322 
 
Table 3.11 Mean ± SEM of pendulum outcome at each assessment for SBS intervention. FRA – First 
Reversal Angle, MVFR – Maximum velocity to First Reversal angle, AUC – Area Under the Curve 
SBS FRA [deg] MVFR [deg/s] AUC [deg*s] 
Baseline 32.0 ± 3.4 130.6 ± 4.8 211.7 ± 42.9 
After intervention 32.3 ± 3.3 127.5 ± 4.8 201.4 ± 38.1 
P value (Base-After) >0.999 0.496 0.625 
One hour after 34.8 ± 3.3 135.3 ± 3.5 269.7 ± 66.1 
P value (After-One) 0.910 0.164 0.491 
Table 3.12 and Table 3.13 express the change in each pendulum outcome in each 
individual from baseline to immediately after and one hour after the intervention 
(indicated by red colour font). Increases of more than 24% for FRA, 16% for MVFR and 
44% for AUC were considered a significant improvement. This was based on the mean 
variation of the pendulum tests calculated as a percentile ratio of two standard deviations 
and means in each test.  
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Table 3.12 Percentage change of the pendulum outcomes in TENS intervention 
Pt 
FRA MVFR AUC 
After One hour After One hour After One hour 
1 6% -2% -1% 1% -7% 35% 
2 3% -3% 7% -2% -29% 23% 
3 -2% -4% -6% 1% 20% 37% 
4 -17% -26% 5% -13% 7% -37% 
5 12% -7% 1% -14% 80% 67% 
6 -29% -16% -7% -10% -23% -12% 
7 -5% 1% -6% 5% -16% -31% 
8 -6% -7% -3% 0% 6% -8% 
9 -25% -6% -6% -1% -50% 20% 
10 5% -19% -10% -7% -9% -3% 
 
Table 3.13 Percentage change of the pendulum outcomes in SBS intervention 
Pt 
FRA MVFR AUC 
After One hour After One hour After One hour 
1 -5% -15% -2% 3% -14% -17% 
2 53% 61% 7% 12% 140% 326% 
3 -1% 19% -6% 12% 48% 234% 
4 -3% - -9% - -40% - 
5 20% 25% 9% 11% 47% 98% 
6 1% -46% -8% -20% -15% -63% 
7 4% -1% 1% 1% -23% -62% 
8 -9% -4% -10% 1% -5% -7% 
9 -27% -10% -4% -2% -63% -49% 
10 -2% -7% 0% -1% -29% -24% 
The pendulum outcome data did not appear to show a significant treatment improvement. 
Comparing the responders in the pendulum data (red values Table 3.12 and 3.13) with the 
responders in Table 3.9. only the Participant #2 in the SBS intervention was consistent. 
The Participant #5 in the SBS intervention show a possible trend towards this correlation, 
as all three outcomes positively changed, however he was not considered as a responder 
only one hour after the intervention (Table 3.9). Participant #5 in the TENS intervention 
(non-responder, Table 3.9) and Participant #3 in the SBS stimulation (responder, Table 
3.9) might showed improvements in AUC, but not in the other two pendulum parameters. 
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3.4.3. Discussion 
Of the 17 potentially eligible subjects, 10 could participate in this study and all completed 
the trial protocol. All participants tolerated the interventions well and there were no 
significant adverse events. This study demonstrated the feasibility and practicality of 
using SBS; a new type of electrical stimulation for the treatment of spasticity. 
TENS stimulation, below motor threshold, has been reported to have positive effects on 
spasticity in spinal cord injury (Ping Ho Chung and Kam Kwan Cheng, 2010), in chronic 
hemiplegia after stroke (Potisk et al., 1995, Sullivan and Hedman, 2007) and in multiple 
sclerosis (Armutlu et al., 2003) patients. Although optimal TENS stimulation parameters 
have not yet been determined, 100Hz seems to be effective (Armutlu et al., 2003, Potisk 
et al., 1995).  In our study, TENS reduced spasticity as measured on MAS immediately 
after 60 minutes of stimulation, however the effect did not persist at one hour. In 
comparison, the novel concept of sensory barrage stimulation, which allows delivery of 
stimuli at multiple sites and with spatio-temporal patterns, continued to show a significant 
response both immediately and one hour after stimulation. A combination of 
improvement in both MAS and in the participants’ VAS outcome measures was assumed 
to be a clinically robust way of evaluating the effects of stimulation, and altogether this 
identified seven SBS responders compared to four in the TENS group in the immediately 
after and one hour after datasets are combined. Although the Wilcoxon signed rank test 
showed significant differences in MAS and VAS immediately after TENS, SBS showed 
greater differences in mean values compared to baseline with higher statistical 
significance and persisted for at least one hour after stimulation. These results give a 
promising indication that SBS is better than TENS in reducing spasticity. 
The extension and flexion power did not show significant improvement, although this 
could possibly be explained by already high grades, indicating a low severity muscle 
weakness in 6 out of 10 participants, who displayed normal extension power (MRC grade 
of 5) throughout the full test procedure with both TENS and SBS.  
The pendulum outcome data did not appear to be sensitive and consistent enough to show 
improvements as reported by VAS or MAS. A further development allowing 
determination of optimal parameters (weight, length) of the pendulum and its influence 
on sensitivity is required.  
88 
 
SBS might also be beneficial in rehabilitation techniques where peripheral electrical 
nerve stimulation has been proposed to enhance motor deficits or tactile sensation 
(Sullivan and Hedman, 2007, Cuypers et al., 2010)  as well as in combination with 
standard rehabilitation programmes (Lin et al., 2003, Kaelin-Lang, 2008). This study only 
investigated the short-term effects of stimulation. Although patients tolerated SBS well, 
further investigations are required to assess the tolerability and acceptability of several 
sessions of stimulation. If patients are more likely to benefit from several sessions it 
would be preferable that they were managed at home, as this would be both more cost-
effective and convenient for the patient. We think that this should be practical both for 
SBS and TENS. Future studies on TENS and SBS need to use more patient reported 
outcome measures and functional goals. 
3.4.3.1.  Study limitations  
The limitation of this pilot study was the absence of a placebo group. Future studies 
should be placebo-controlled, although there are challenges in using a placebo group in 
studies using electrical stimulation, because the active stimuli can be felt. Participants 
should also be stratified based on different pathologies and severity of symptoms, which 
was not practical with the limited size of this study. 
3.5.  Conclusions  
Sensory Barrage Stimulation, as introduced in this chapter, is a novel concept of 
stimulation which aims to enhance the effects of conventional TENS, using stimulation 
below the motor threshold level. The spasticity study showed promising support for this 
approach and the salience and habituation study utilised SBS with time varying stimuli. 
However it remains to be demonstrated that this will enhance the process of plasticity by 
focusing attention. The approach of evaluating this feature using measurements of 
performance during cognitive tasks has not produced a significant evidence for this claim.  
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The assessment of an electrical 
stimulation waveform developed to treat 
overactive bladder symptoms 
 
 
 
 
 
The work in this chapter has been published in: 
M Slovak et al., The assessment of a novel electrical stimulation waveform recently 
introduced for the treatment of overactive bladder. Physiol Meas 2013; 34 479 
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4.1.  Introduction 
Sacral neuromodulation is a well-established form of neuromodulation for the treatment 
of overactive bladder symptoms (Bartley et al., 2013). Stimulation of the pudendal nerve 
originating from the S2,S3 and S4 sacral nerve roots has emerged as a superior alternative 
(Peters et al., 2005). Both of these stimulation sites are relatively deep in the body, 
covered by overlying tissue, and hence are difficult to stimulate using surface electrodes. 
They are therefore usually accessed using implanted wire electrodes as it is in the sacral 
neuromodulation.  
To non-invasively target these deep branches, which are involved in bladder control, has 
remained a challenge. Recently however, a novel stimulation technique using a 
‘transdermal amplitude modulated signal’ (TAMS) has been introduced (Figure 4.1 
right). This TAMS waveform has been described (Shen et al., 2011) as ‘a high frequency 
sinusoidal carrier waveform (210 kHz) amplitude-modulated by low frequency, 
monophasic rectangular pulses (1 ms pulse width)’. Preclinical studies have evaluated the 
effect of TAMS stimuli of the pudendal nerve on the bladder in cat models (Shen et al., 
2011, Tai et al., 2011, Tai et al., 2012). This latter paper reported that ‘TAMS uses a 210 
kHz sinusoidal carrier waveform that has a minimal skin impedance and is optimal for 
stimulating nerves under skin and muscle’ (Tai et al., 2012). However, there is no 
literature to support this statement, based on comparative human studies. Low skin 
impedance would be an important advantage in all transcutaneous electrical stimulation 
techniques, not just those used for overactive bladder therapy, because it will result in less 
electrical energy being required to deliver the charge required for stimulation. In addition, 
and more importantly, if a particular electrical stimulation waveform is more effective in 
stimulating deep nerve structures such as the pudendal nerve this would have major 
implications for the whole field of non-invasive electrical stimulation.  
The TAMS waveform has been used in a commercial neuromodulation system, which 
has been introduced into clinical practice as the VERVTM Patient-Managed 
Neuromodulation System (PMNS, Ethicon Endosurgery Inc.). This system transmits the 
TAMS waveform through two hydrogel electrodes applied to the skin in the sacral region 
(Monga et al., 2011a). The results of an initial open study (Monga et al., 2011a) have 
shown beneficial effects, although placebo control studies are still required to 
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demonstrate a direct effect of the electrical stimulation. Further outcomes of the VERV 
system are discussed at the end of this chapter.  
As mentioned previously the claims made for this waveform could also be beneficial in 
other applications where deeper nerve structures are to be electrically stimulated.  
However because there is no literature describing the specific physiological effects of 
stimulation using the TAMS waveform in human a more basic investigation is required. 
An initial evaluation using a simplified equivalent multilayer model for skin impedance 
in a SPICE model did not identify specific benefits of the TAMS waveform. However, 
this did not consider any non-linear tissue properties, for example at the nerve membrane. 
Further assumptions would be needed to investigate this problem theoretically and may 
not lead to a robust conclusion. Therefore, the main aim of the work in this chapter was 
to experimentally compare the TAMS waveform with a conventional electrical 
stimulation waveform both in terms of electrical parameters and acute physiological 
effects on healthy volunteers. This will provide a direct assessment of some of the claims 
for TAMS.  
4.2.  Materials and Methods  
This study has been designed to compare the TAMS waveform with a conventional 
electrical stimulation waveform, both at sensation and motor stimulation intensity levels. 
The study was reviewed by the Clinical Research Office of Sheffield Teaching Hospitals 
NHS Foundation Trust and an ethic waiver was obtained. Ten (five male + five female, 
age range 23–62) healthy volunteers participated in the study. The study flow diagram is 
shown in Figure 4.7 further in the text.  
4.2.1. Equipment  
Figure 4.1 shows schematically the two waveforms delivered in the experiment. A block 
diagram of the experimental setup is shown on Figure 4.2.  
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Figure 4.1 A Sketch of the conventional and the TAMS waveforms redrawn from (Shen et al., 2011) 
 
Figure 4.2 Block diagram of the experimental system 
A purpose designed constant current stimulator (Appendix H), able to deliver both the 
TAMS and conventional stimuli was developed in accordance with IEC 60601-2-10 for 
medical electrical devices (nerve and muscle stimulators). The stimulator consisted of a 
9 V battery and a voltage step-up circuit, which created a 160 V voltage source. Further 
circuitry provided a constant current stimulator. An assessment characteristic is shown 
on Figure 4.3. and shows a good stability of the output current with a variable load. The 
decrease at around 62 kΩ, caused by the voltage source limit, is above the expected load 
in this experiment.  
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Figure 4.3 a stimulator constant current source characteristic 
A function generator (Textronix AFG 3102) was used to generate the two waveforms 
under the test in this experiment and to drive the stimulator. The system was designed to 
deliver charge-balanced pulses by including a series capacitor in the electrode lead of 
value 1 µF to avoid electrochemical reactions. A battery operated oscilloscope and laptop 
were used both to ensure electrical isolation of the subject and to avoid measurement 
errors due to capacitive coupling and earth loops. The oscilloscope was connected to a 
purpose made accessory box (Measurement accessory, Figure 4.2) consisting of a serial 
combination of a 1 µF capacitor a 100 Ω resistor in order to measure the charge (voltage 
on the capacitor), current (voltage on the resistor) and the voltage across between the 
electrodes.  
4.2.2. Experiment 
Participants underwent stimulation at four intensity levels (sensation threshold, strong 
sensation, motor threshold and the intensity that produced 50% of maximal motor 
response), as described below in Section 4.2.4. Stimulation electrodes (Carefusion 
Disposable Disk electrodes, type 019-415000) electrodes were placed in different 
positions for the sensory and motor tests.  For the sensation tests, the electrodes were 
placed near the wrist, 3 cm apart (Figure 4.4). 
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Figure 4.4 Placement of stimulation electrodes for the sensation measurements. A – anode, C – 
cathode 
For the motor tests, electrodes were placed just above the elbow sulcus 3 cm apart (Figure 
4.5). 10 Hz stimulation was used for the sensation tests, and 1 Hz was used for the motor 
tests (the latter to avoid tetanic contraction). Stimulation electrodes were placed on the 
subject for at least 10 min. before the measurements to allow the electrode–tissue 
interface to stabilize. EMG signals were recorded using an XLTEK Neuromax 1004. A 
Medelec recording electrode (SE20 intra-electrode distance 20 mm) was placed over the 
abductor digiti minimi muscle (ADM). A ground electrode (CareFusion 5×10 cm ground 
electrode, type 019-422200) was placed between the stimulation site and the recording 
electrodes. Participants were instructed to relax, with their arm resting on a soft foam 
support. 
 
 
Figure 4.5 Placement of stimulation and recording electrodes for the motor measurements. A – 
anode, C – cathode, G – ground pad, + active electrode, - reference electrode 
4.2.3. Experimental protocol  
The following stimulation levels were used by adjusting the stimulator output intensity, 
the sensation levels being subjective to each subject whilst the motor levels were objective 
being based on EMG measurements (see below):  
 Sensation threshold 
95 
 
 Strong but comfortable sensation 
 Motor threshold  
 50% of supra maximal motor response 
To determine the sensation threshold level, the stimulation current was gradually 
increased by the experimenter until the subject first reported sensation. The strong but 
comfortable sensation level was chosen by subjects for the TAMS waveform, and the 
intensity of the conventional stimuli were adjusted until subjects reported the same 
subjective sensation when the stimuli were switched between conventional and TAMS. 
Control buttons of the generator were used to switch between the waveforms applied. 
Motor threshold levels were defined as an EMG response of 200 μV pk–pk, if noise levels 
were high then 300 μV was used instead for both of the waveforms. The maximal motor 
response was generated using the inbuilt conventional stimulator of the XLTEK and its 
amplitude measured using the on-screen cursors. Data was then collected at 50% of this 
amplitude for both waveforms. 
4.2.4. Data collection 
After the stimulation intensity was set to the appropriate level for the measurement being 
made, the voltage across the stimulation electrodes (V), current through the electrodes (I), 
delivered power (P) and delivered charge (Q) waveforms were recorded using a battery 
operated oscilloscope (Tektronix THS 720) connected to the relevant points in the 
measurement accessory. The voltage was measured between the stimulation electrodes 
on the oscilloscope channel CH1 and current was calculated as 
 𝐼[𝐴] =
𝑈𝑟 [𝑉]
𝑅 [𝛺]
 (4.1) 
The Ur voltage was measured across resistor R = 100 Ω on the oscilloscope channel CH2. 
The recorded waveforms were then processed offline to give mean values for each pulse. 
The waveforms were uploaded using serial connection commands and HyperTerminal 
application.    
The measurement of power was performed as a multiple of the channels CH1 and CH2. 
Electrode-skin impedance was calculated retrospectively as instantaneous voltage across 
the electrodes divided by current through the electrodes (bulk body impedance is assumed 
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to be negligible for this purpose). The delivered charge was derived from the voltage (VC) 
on a 1 μF capacitor (C) connected in series with the subject, calculated as  
 
 𝑄 [𝜇𝐶] = 𝐶[𝜇𝐹] ∗ 𝑉𝑐 [𝑉] (4.2) 
   
In addition, the impedance presented by the body and electrode-tissue interface was 
calculated as, 
 𝑍 [Ω] =
𝑉 [𝑉]
𝐼 [𝐴]
 (4.3) 
at five time points (0.1, 0.3, 0.5, 0.7 and 0.9 ms, in each case averaged over five cycles of 
the 210 kHz waveform) during a representative pulse for each subject to investigate any 
intra-pulse waveform differences.  
Sensation obtained during the motor threshold and 50% of maximal motor response tests 
were recorded by the subjects on a visual analogue scale (VAS). The VAS was 100 mm 
long, with the left end of the VAS representing no sensation and the right end representing 
very uncomfortable or painful sensation (Figure 4.6). The sensation score was defined as 
the distance in mm of the position marked by the participant from the left end. Participants 
were blinded as to which waveform was being applied and the order of stimulus 
waveform was randomized. 
 
Figure 4.6 Visual analogue scale 100 mm long 
4.2.5. Data analyses 
The paired Student’s t-test was used in the resultant statistical analysis, and no correction 
was made for multiple testing in order to maximize the likelihood of the study to detect 
differences between the two waveforms. 
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Figure 4.7 Study flow diagram 
4.3.  Results 
10 participants completed the test. Voltages across the electrodes, current through the 
electrodes and delivered charge waveforms were recorded for all subjects at four different 
levels of stimulation. Four of the eighty power waveforms were not recorded due to 
unexpected technical problems in the data collection. Where these waveforms were not 
obtained the equivalent paired recording from the other stimulation type was excluded 
from the analysis.  
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Skin impedance was compared by the shape analysis and by the comparison of means (as 
described in Section 4.3.1). Current through the electrodes, voltage across the electrodes 
and delivered power were compared by the average of the whole pulse waveform. 
Delivered charge was compared as the maximum delivered amount.   
Representative measurements of current, voltage and power are showed in Figure 4.8 for 
both types of the stimuli. The mean values ± SEM of all recorded parameters are presented 
in Table 4.1 altogether with p values. None of the electrical parameters showed a 
significant difference (all p values ≥0.250) by paired Student’s T-test.   
 
 
Figure 4.8 Representative measurements of current through the stimulating electrodes, voltage 
across the electrodes and delivered power for TAMS (on left) and conventional stimuli (on right) 
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Table 4.1 Mean values ± SEM of recorded electrical parameters at four intensity levels (n=10 
subjects) and P values of paired Student t-test 
4.3.1. Intra-pulse skin impedance waveform differences 
Mean skin impedance showed no significant differences between TAMS and convention 
stimulation (Figure 4.9, paired t-test, all p values ≥ 0.368). To analyse changes in the 
shape of waveform intra-pulse analyses of the ratio of average current and voltage 
conventional waveforms were performed in five different time points of the pulse.  
 
 
 
 
 
 
Figure 4.9 Mean skin impedances measured at four intensity  
 
Sensation 
threshold 
Strong 
sensation 
Motor 
threshold 
50% of 
Max. 
     
Mean current 
[mA] 
TAMS 1.11±0.12 1.92±0.28 3.81±0.77 6.32±0.98 
Conv. 1.10±0.12 1.93±0.28 3.84±0.68 6.26±0.92 
P value 0.769 0.539 0.793 0.710 
      
Mean voltage 
[V] 
TAMS 25.92±3.66 36.68±5.19 42.51±4.80 58.12±4.53 
Conv. 26.12±4.02 36.92±5.07 42.45±4.57 58.19±4.74 
P value 0.721 0.275 0.942 0.936 
      
Mean charge 
[μC] 
TAMS 1.14±0.13 1.98±0.28 3.83±0.84 6.62±1.04 
Conv. 1.13±0.13 1.98±0.28 3.84±0.77 6.45±0.93 
P value 0.732 0.725 0.883 0.430 
      
Mean 
impedance 
[kΩ] 
TAMS 22.98±1.19 19.66±1.23 12.54±1.19 10.91±1.61 
Conv. 23.02±1.27 19.76±1.24 12.33±1.30 10.80±1.51 
P value 0.896 0.368 0.503 0.642 
      
Mean power 
[mW] 
TAMS 33.69±9.75 76.28±23.82 198.8±69.07 405.9±91.84 
Conv. 33.30±9.80 76.08±22.51 187.6±60.51 386.6±87.48 
P value 0.770 0.907 0.250 0.277 
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The results of Student’s T-test p values are shown in Table 4.2. After Bonferroni 
correction ((p ≥ 0.03) there were no significant differences in the shape analysis. 
Table 4.2 P values of paired t-test in the shape analysis (not corrected for multiple testing)   
 
Sensation 
thres. 
Strong sens. Motor thres. 50% of Max. 
0.1ms 0.998 0.034 0.533 0.068 
0.3ms 0.848 0.312 0.312 0.802 
0.5ms 0.816 0.183 0.183 0.573 
0.7ms 0.397 0.163 0.163 0.569 
0.9ms 0.330 0.186 0.186 0.715 
4.3.2. Sensation 
The mean sensation recorded at the motor threshold level in all of the participants was 
34.9 ± 6.6 mm for the TAMS stimuli and 39.2 ± 7.1 mm for the conventional stimuli 
(paired t-test p = 0.242). At 50% of supra-maximal response the results were 49.2 ± 5.0 
mm for the TAMS and 50.3 ± 5.2 mm for conventional stimulation (paired t-test p = 
0.687). The graphical presentation is showed on Figure 4.10. 
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Figure 4.10 Sensation level for both types of the stimuli in ten subjects 
4.4.  Discussion 
TAMS has been recently introduced as a novel stimulation waveform for the treatment of 
OAB, however there is no background literature on the physiological effect of this 
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specific stimulation waveform in man. Shen et al (Shen et al., 2011) suggests that the 
well-known decrease in skin impedance with frequency (Rosell et al., 1988),  observed 
with sinusoidal excitation, can also be obtained using the TAMS waveform. However, 
this study has shown no difference in impedance when stimulating with TAMS as 
compared to conventional waveforms. High frequency sinusoidal signals, having no net 
DC component penetrate skin more easily due to tissue capacitance, mainly but not 
exclusively within the stratum corneum. The TAMS waveform, in contrast to sinusoidal 
signals, is offset relative to zero and hence has a net unidirectional component (Figure 4.1 
left). As a result, charge build up in tissue capacitance occurs in the same way as with 
conventional unidirectional stimuli and the frequency dependent impedance changes 
associated with non-offset sinusoidal signals are not seen. This can be observed in Figure 
4.6 which show the same rise in stimulator output voltage during the pulse for both 
stimulation waveforms as the electrode and skin interfacial capacitances charge up. Nerve 
membranes have an electrical time constant, typically of the order 150 µs (Barker et al., 
1991, Reilly, 2011), caused by their capacitance and the relatively high internal resistance 
of the cell body and this acts as a low pass filter to incoming stimuli. Because the TAMS 
waveform high frequency component is well above this filter frequency it is integrated at 
the nerve membrane in the same way as is the conventional stimulus waveform. This 
results in the mean current required to achieve stimulation being the same for both signals. 
It should however be noted that the peak current delivered by the TAMS waveform needs 
to be twice that of the conventional waveform in order to deliver the same mean current. 
The decrease in impedance at higher levels of stimulation, shown in Figure 4.9, is 
consistent with established tissue non-linearity as a function of current (Dorgan and 
Reilly, 1999).  
The TAMS waveform has been further studied in a multilayer volume conductor model 
with a nerve represented by a cable model (Medina and Grill, 2014). This study partly 
utilised the data presented in this chapter and their model also showed no difference 
between conventional and TAMS waveform stimulation. Their further analyses failed to 
show any differences in a strength-distance curve that would allow stimulation of deep 
nerve structures at a lower threshold then those more superficial. This corresponded to 
the experimental work presented here where no significant differences in sensation levels 
between the two stimuli tested was obtained. This suggests that the same nerve structures 
were being targeted by both of the waveforms.  
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In conclusion, this study has shown no significant differences in either electrical, or 
physiological, metrics between TAMS and conventional stimuli waveforms. Hence it is 
unclear what advantages TAMS may have over conventional stimuli.  
 
Postscript 
The commercially available system VERVTM Patient-Managed Neuromodulation System 
(PMNS, Ethicon Endosurgery Inc.), which used TAMS waveform up to date have not 
been fully available on the market.  
After the work described in this chapter was completed, results of a randomised double 
blind sham stimulation trial of VERVTM system were published (Ethicon Endo Surgery, 
2014). This showed that there was no significant difference between the active and sham 
version of VERVTM system (the same device but no stimulation) in any of the parameters 
measured (urinary frequency, urgency incontinence, mean voided volume and various 
OAB questionnaire). Also the number of responders (greater than 50% decrease in the 
mean number of urgency incontinence episodes) in active version of VERVTM system 
(31/80) vs. (38/83) in the sham version did not proof benefits of this system (Monga et 
al., 2011a, Monga et al., 2011b, Monga and Linsenmeyer, 2011).  
The results in this Chapter showed that there is no difference between TAMS waveform 
(used in the VERVTM system) and conventional stimuli. Thus in order to target the deep 
nerve structures (e.g. pudendal nerve, S3 spinal cord root) which would potentially be 
able to produce an effect on overactive bladder symptoms high intensity of stimuli would 
be needed. However due to the discomfort cause this would be very difficult to achieve 
and thus presumably VERVTM system produced only low amplitude stimuli. This might 
then explain the no difference between the active and sham version of VERVTM system.   
The results of the VERVTM clinical trial shows also that a placebo response in overactive 
bladder patients can be high.  
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Numerical modelling of posterior 
tibial nerve stimulation 
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5.1.  Introduction 
As introduced in Chapter 1 there are two techniques available for the stimulation of 
posterior tibial nerve as a treatment of overactive bladder symptoms. The percutaneous 
form of Posterior Tibial Nerve Stimulation (PTNS) is more established and several 
studies have shown its benefit in the treatment of various lower urinary tract symptoms 
(Finazzi-Agro et al., 2010, Peters et al., 2010). However this technique has the 
disadvantage of being invasive and requires patient visits to clinics, which is expensive. 
In contrast to this, the transcutaneous form of PTNS is less well established, but has the 
advantages of being completely non-invasive, can be administered by the patients at home 
and is low cost. The work in this chapter numerically models these two techniques in 
order to compare their potential physiological effects.  
The percutaneous form of PTNS is relatively well established in clinical practice and a 
commercial device (Urgent-PC, Uroplasty Inc, USA) is available on the market. The most 
recent systematic review has concluded that there is strong evidence of efficacy for 
frequency and urgency urinary incontinence (Moossdorff-Steinhauser and Berghmans, 
2013). However, further high quality studies are needed to improve the level of evidence 
for the outcomes of urgency and nocturia.  
Nonetheless, despite the significant body of evidence for the percutaneous form of 
stimulation, the National Institute for Health and Care Excellence (NICE) has changed its 
original statement on its use (which originally recommended the use of PTNS for the 
treatment of OAB symptoms). The current recommendation says percutaneous tibial 
nerve stimulation for the treatment of OAB symptoms should not be offered unless there 
has been a multidisciplinary discussion, failure of conservative management including 
OAB drugs, and the patient does not want botulinum toxin or percutaneous sacral nerve 
stimulation (National Institute for Clinical Excellence, 2013). This places PTNS therapy 
towards the end of the patient’s treatment pathway. It is not clear whether this view has 
been reached, at least in part, because of the cost effectiveness of percutaneous PTNS. 
The NICE guidelines further state that the transcutaneous form of PTNS should not be 
offered, because there is insufficient evidence for it to be recommended.  
Despite these NICE recommendations, the evidence for percutaneous PTNS can be seen 
as persuasive (Moossdorff-Steinhauser and Berghmans, 2013), but the associated 
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treatment costs is high, around £3200 per patient annually (Walleser Autiero et al., 2014). 
Due to these costs percutaneous PTNS might not be suitable for large-scale clinical 
implementation even if evidence of efficacy becomes stronger. However, transcutaneous 
stimulation might be a suitable alternative if of comparable efficacy, due to its lower cost.  
Both techniques, presumably, are designed to act in the same way, namely physiological 
effects produced by the stimulation of posterior tibial nerve. A relevant question to ask is 
whether these effects can be achieved by both techniques and are comparable. This might 
ultimately allow transcutaneous PTNS to be supported by using evidence from its 
percutaneous form. The description of the commercially available technique of PTNS is 
that it is designed to stimulate the posterior tibial nerve approximately 5 cm posterior 
from the medial malleolus (Uroplasty Ltd, 2013) at an intensity level just below a 
muscle/toe contraction. The aim of the modelling work presented in this chapter is to 
determine what stimulation current is needed in order to produce the same physiological 
effect obtained with percutaneous stimulation when the transcutaneous form of PTNS is 
used. In addition, the optimal position of the electrodes for the transcutaneous form of 
PTNS is explored.  
5.1.1. How to determine the same physiological effect?  
Potentially, the monitoring of nerve action potentials produced by the stimulation of the 
posterior tibial nerve would give insight into these effects, but this presents a number of 
technical challenges, primarily due to electrode positioning, small signal size and signal 
to noise. Therefore, a theoretical method of modelling the stimulation was chosen instead.   
The physiological effects might be quantified by studying differences in the excitation of 
axons between the transcutaneous and percutaneous forms for a particular current 
intensity. This can be performed by quantifying the excitation caused by a known current 
applied percutaneously and then calculating the current needed to cause the same size of 
excitation in the transcutaneous form.   
To quantify the excitation of a nerve axon, the so called activating function is used 
(Rattay, 1986, Rattay, 1988). This is the spatial derivate of the electrical field along the 
nerve fibre.  A gradient of sufficient size is able to exceed the threshold level change in 
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transmembrane potential resulting in membrane depolarisation and subsequent 
propagation of a nerve action potential via the normal mechanisms. 
5.2.  Numerical modelling 
To obtain an activation function and to study the distribution of electrical current in the 
tissue, electromagnetic field computer models are used. These models aim to find an 
approximate solution to Maxwell’s equations such that they satisfy a defined set of 
conditions (Morris, 2012).  
There are several mathematical simulation techniques available. Finite Element Method 
(FEM) and Finite Difference Time Domain (FDTD) method are the most common 
methods used and these are available in a number of commercial software packages. 
These methods could analyse arbitrary shaped 3D structures. FEM algorithms solve 
Maxwell’s equations implicitly through the solution of a matrix, such that the entire 
volume of the simulation domain is discretised. FDTD algorithms solve Maxwell’s 
equations in a fully explicit way. FDTD analysis requires that the objects being simulated 
are placed within a box-like volume which truncates space and defines the simulation 
domain. FDTD uses a time stepping algorithm which updates the field values across the 
mesh cell time-step by time-step, thus explicitly following the electromagnetic waves as 
they spread through the structure (Morris, 2012). 
SEMCAD X has been chosen for the modelling presented in this thesis. This is because 
the package includes realistic body phantoms, an essential requirement because of the 
effect of tissue conductivity on field distributions and because of the availability of the 
software licence within the department. The low frequency solver used for the modelling 
as described below in section 5.2.1 uses FEM method.  
The modelling work described further below starts with an introduction to the software 
package and a description of the model used. Following that it goes on to describe 
homogeneous models of increasing geometric realism to evolve an understanding of the 
source of the fields involved. It then moves to the partially defined model in order to 
gradually understand the complexity of the full model.  And finally the full anatomic 
models of both transcutaneous and percutaneous stimulation are considered along with 
the effect of different electrode positions and sizes. This leads to the aim of this chapter, 
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to explore what stimulation current is needed in order to produce the same physiological 
effect obtained using both forms of PTNS. 
5.2.1. SEMCAD X 
SEMCAD X (IT’IS Foundation, Switzerland) is a commercially available full wave 3D 
electromagnetic and thermal simulation software package. The great advantage of this 
software is the availability of whole-body human anatomical CAD models created by the 
IT’IS Foundation currently known as Virtual Population (Christ et al., 2010). Hence the 
creation of the physical representation of the anatomy around the posterior tibial nerve 
(ankle) was greatly simplified.  
SEMCAD X places the geometrical model into an automatically generated XYZ grid and 
the user is able to specify its resolution (Figure 5.1). The computational approach is based 
on FEM that defines the anatomical structures as solids and the user defines impedance 
in terms of Electrical Conductivity, Magnetic Conductivity, Permittivity and 
Permeability. However, only the electrical conductivity was used in this exercise as 
explained further. To determine the application of the electrical field and its distribution 
in the tissue only Electrical Conductivity is defined and the ‘Electro Quasi Static Ohmic 
Current Dominated’ solver was used. This solver finds a solution to simplified Maxwell’s 
equations based on Gauss’s law (5.1). Other aspect of Maxwell’s equations are neglected. 
ωɛ« σE                            ∇·σE∇φ = 0                                             (5.1) 
ω – Angular frequency 
ɛ - Absolute permittivity 
∇ - Three dimensional gradient operator 
σE - Electrical conductivity 
φ – Scalar potential function 
This solver was chosen because of the following:  
 Electro Quasi-Static solver neglects the temporal change of the magnetic flux B. 
Eddy current are negligible and would not affect the solution of the model 
significantly. 
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 Electrical stimulation uses short pulses of particular frequency. However the 
model consider only one pulse which is equal to direct current (DC). Therefore 
the condition in 5.1 is satisfied.  
The equation only consider the electrical conductivity therefore other properties such as 
permittivity and permeability were ignored.  
The geometrical model is represented by two solid structure types, namely materials with 
resistive and dielectric properties (dielectrics) and metal (considered to be a Perfect 
Electrical Conductor or PEC) i.e. electrodes and wires. 
 
Figure 5.1 An example of a simple model of a conductive material block with two electrodes on top  
This approach results in a calculated electrical potential and current density distribution 
throughout the grid. The resolution of the grid can be predefined by the user and refined 
in regions where higher levels of detail are required.   
The equation (5.1) is solved using iterative technique until defined conditions are 
satisfied. These conditions were set for the modeling in this chapter to ‘medium’ 
convergence criteria. These criteria monitor the size of the changes between each the 
iterative solutions. This explicitly defines the convergence criteria as relative value of 
1*10-8, absolute value of 1*10-50 and divergence value of 1*1050. Divergence can be 
interpreted as a slope of the curve of iteration change.   
ANODE 
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SEMCAD X modelling objects are assigned a voxelling priority, which is important for 
handling areas where two objects might overlap. In these overlap areas, voxels are 
assigned the material parameters with the highest priority. The part of the object with the 
lowest priority will thus became invisible for the solver. This process was specifically 
used for the design and integration of the electrodes within the model (Section 5.2.5) 
5.2.2. Creation of the physical model 
As mentioned previously, one of the main advantages of SEMCAD X is its capability to 
use Virtual Population models. To model the posterior tibial nerve stimulation a right 
ankle section was dissected from ‘Duke’ (Figure 5.2), a 34-year-old male adult from the 
Virtual Population project (Christ et al., 2010). The ankle section was placed into a grid 
and oriented such that the posterior section is approximately parallel with the z-coordinate 
and the sole of foot lies approximately on the x-axis.   
 
Figure 5.2 The ankle section used, highlighting the bone structures, the approximate position of the 
posterior tibial nerve, and surface and needle electrodes placed close to the nerve. Other structures 
are not shown for simplicity. 
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The resolution of the model enabled construction of all large anatomical structures such 
as bones, muscle, fat, SAT, tendon ligaments and skin. However, voxels of smaller 
structures such as veins and arteries are not contiguous in some places or end prematurely 
due to the resolution of the MRI scan on which the Virtual Family models are based (for 
peripheries 1.0 x 1.5 x 1.0 mm-3(Christ et al., 2010), Figure 5.3). These discrepancies will 
cause electrical discontinuities and thus affect the results. Hence a specific design for the 
nerve to minimise these abnormalities was created, as described below. 
 
Figure 5.3 Discrepancies of the arteries (red) and veins (blue) in the model 
The “Duke” model does not contain the tibial nerve or any other nerve structures except 
spinal cord and optic nerve (this was a recognised limitation of the model (Christ et al., 
2010)) and hence it was necessary to create a nerve according to anatomical knowledge. 
An alternative would be to use a model of higher resolution which includes smaller 
structures, which has very recently became available (Gosselin et al., 2014), but was not 
available during the work described here. However, from initial exploration it was noted 
even this more detailed model only shows peripheral nerves with limited accuracy. 
5.2.3. Model of the nerve  
This section describes the process by which the tibial nerve was created.  A peripheral 
nerve consists of numerous structures. Nerve fibres (also called axons) are collected into 
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bundles wrapped in connective tissue called perineurium (Figure 5.4). The posterior tibial 
nerve at the site of the stimulation is relatively large (approximately 4 mm in diameter) 
and contains several of these bundles which are surrounded in turn by a connective tissue 
sheath called the epineurium (Figure 729. (Davies and Coupland, 1967)). The majority of 
the nerve fibres are myelinated. In addition, a nerve contains fat cells and blood vessels.  
 
Figure 5.4 A transverse cross section of a peripheral nerve, redrawn from Gray’s Anatomy (Davies 
and Coupland, 1967) p. 1133 
It is assumed that PTNS targets the myelinated fibres rather than the unmyelinated and 
small diameter c-fibres, which have a much higher stimulation threshold. A myelinated 
fibre is covered with a layer of insulation called myelin sheath with regular exposed 
sections known as nodes of Ranvier.  
The modelled nerve has to include a description of its electrical and geometric 
characteristics as well as its geometry. It would be intrinsically difficult to define the 
voxels to model a nerve as shown in the Figure 5.4 because of its small diameter and 
convoluted path. Such detailed resolution also would not be consistent with the dissected 
section of the “Duke” model, where only larger structures can be seen.   
Instead, the modelled nerve in this work has been defined as a generalised bundle of axons 
and epineurium. This is based on previous mathematical analysis (Altman and Plonsey, 
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1988) who described the anisotropic resistivity of the whole nerve in both the radial 
(transverse) and longitudinal (axial) direction for axons and epineurium. Axons are 
relatively conductive along their length and hence have relatively low resistance to 
current flow in the longitudinal direction. The epineurium conductivity is assumed to be 
similar to that of myelin and therefore is less conductive.  
Further simplification of the modelled nerve and its electrical characteristics need to be 
made and, along with the geometrical characteristic of the nerve, are described in the 
following two sections.   
5.2.3.1.  Geometrical characteristic 
The diameter of the nerve model has been based on a diagram of the transverse section 
through the right leg 6 cm above the tip of the medial malleolus in Grey’s Anatomy Figure 
725. (Davies and Coupland, 1967). The posterior tibial nerve descends alongside the 
posterior tibial artery to a position between the heel and medial malleolus, where it divides 
into the medial and plantar nerves. The model described here did not consider these two 
branches because their bifurcation occurs below the stimulating electrodes and the model 
did not extend into this region. The nerve diameter was chosen as 4 mm. 
The exact XYZ coordinates of the nerve were chosen to maintain its appropriate position 
relative to the artery and veins visible in the model. Altogether, 13 points spaced 10-20 
mm apart along the z-coordinate were taken to create two solid spline tubes using the 
SolidWorks 3D CAD package. The nerve was then exported into the SEMCAD ankle 
section and placed at the correct anatomical position. The nerve structure is shown on 
Figure 5.5 (green structure) alongside the arteries (red) and veins (blue).  
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Figure 5.5 The phantom of the ankle used and the modelled posterior tibial nerve 
5.2.3.2.  Electrical characteristic  
The electrical characteristics of the generalised nerve bundle of axons and epineurium 
were calculated as follows.  The values for longitudinal and transverse resistivity below 
were taken from a mathematical model (Altman and Plonsey, 1988). The transverse 
resistivity was ρ = 110.5 Ωm, (equivalent conductivity σT = 0.00904 S/m). The 
longitudinal resistivity was derived from resistance per unit length as ρ = 1014.8 Ω*cm, 
(equivalent conductivity σL = 0.0985 S/m – ten times higher than the transverse 
conductivity.  
According to the mathematical model by (Altman and Plonsey, 1988) the cross-section 
of a typical peripheral nerve (Figure 5.6 A) can be generalised into two concentric  
bundles (Figure 5.6 B), called, in this work, inner and outer nerve tubes. In the model the 
inner nerve tube contains all the nerve fibres and the outside nerve tube represents 
epineurium as 30% of the total bundle cross-section area. The value of 30% is based on 
an experimental work by (Tasaki, 1964). As the overall nerve is being modelled with a 
diameter of 4 mm the inner tube diameter is thus 3.35 mm with the remainder of this 
diameter (0.65 mm) forming the outer tube. 
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However these figures result in a small annular diameter (~0.325 mm) for the epineurium 
(Figure 5.6 B). This is challenging to model as the size of voxels is limited by the 
computational capacity (smaller voxel = more voxels in the model = more computational 
capacity required) of the modelling computer. Additionally a low number of voxels 
representing structures of different conductivities are likely to cause discrepancies (the 
voxel size and gridding setup is further discussed in section 5.2.3).   
Hence an approach has been taken to change the ratio of the outer and inner diameters 
such that the cross sections will be of the same size whilst maintaining the overall 
diameter of the nerve at 4 mm. The inner tube diameter used was thus 2 mm and outer 
tube was 4 mm in outer diameter (Figure 5.6 C). This will allow more voxels to be placed 
in the outer tube without changing its size and thus total number of voxels.  
 
Figure 5.6 Cross section of the nerve – A) typical cross section of a nerve, B) simplified section of a 
nerve, C) resized sections of the nerve 
To derive electrical conductivity values of the inner and outer nerve section based on 
longitudinal conductivity σL and transverse conductivity σT (Altman and Plonsey, 1988) 
would be challenging to solve mathematically. Whilst longitudinal conductivity for the 
inner and outer nerve tube can be easily derived from the equation 5.2, the transverse 
conductivity cannot readily be represented easily by a mathematical formula because of 
the cylindrical shape of the nerve. Thus a SEMCAD X modelling approach was used to 
determine the values of the inner and outer nerve tubes.  
𝑅𝐿𝑂𝑁𝐺 =
𝑅𝐼𝑁 ∗ 𝑅𝑂𝑈𝑇
𝑅𝐼𝑁 + 𝑅𝑂𝑈𝑇
=
𝜌𝐼𝑁 ∗ 𝜌𝑂𝑈𝑇 ∗ 𝑙
𝜌𝐼𝑁 ∗ 𝐴𝑂𝑈𝑇 + 𝜌𝑂𝑈𝑇 ∗ 𝐴𝐼𝑁
 
(5.2) 
This approach was based on the assumption that the transverse magnitude of the current 
vector in the vicinity of the nerve would not be affected if the transverse conductivity of 
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the external medium is the same as the conductivity of the nerve. In another words the 
nerve will be electrically invisible to the current flow.  
A nerve section consisting of the inner and outer nerve tubes were placed into the middle 
of a brick shaped volume conductor, with a positive electrode and a negative electrode on 
each side (Figure 5.7). The conductivity of the brick was set as that of transverse 
conductivity (σbrick = 0.00904 S/m) required for the nerve. The inner tube conductivity 
was set as the longitudinal σIN (0.0985 S/m), as this inner tube should represent 
conductive axons.  The outer tube conductivity, representing epineurium was set initially 
to an arbitrary value, but such that it would be much lower than that of the inner tube 
(σOUT = 0.006 S/m).  
 
Figure 5.7 Model of a nerve between an anode and cathode 
The graph in Figure 5.8 shows a cross-sectional current density through the nerve along 
the x-axis. This represents the current flow in the x-direction, and to satisfy the transverse 
conductivity the value of the current density should not change when it enters the nerve 
(the nerve will be electrically invisible). The blue line shows that the current density 
increases (i.e. the nerve is too conductive) and at 0.005 S/m this changed to the opposite 
direction.  Using an iterative process an optimal value was determined to satisfy the 
transverse conductivity of 0.00542 S/m. To satisfy the required longitudinal conductivity 
value of 0.0985 S/m, the inner conductivity was derived from the formula 5.1 as 0.378 
S/m. This characterised the modelled nerve as shown on Figure 5.9.  
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Figure 5.8 Distribution of the current density in the model along a x-axis in the middle section of the 
nerve  
 
Figure 5.9 Scheme of the modelled nerve with the calculated conductivities A) a cross section of the 
nerve in transverse direction B) a cross section in longitudinal direction (lines representing the 
axons).  The axons drawings are only for a diagrammatic purposes, individual axons are not included 
in the model.  
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In the middle of the inner nerve tube (representing the axons) is placed a field extraction 
line which represents a single axon and allows to produce the distribution of electrical 
field along this axon using a Line Extractor Tool in SEMCAD X. Further post processing 
in Matlab as described in Section 5.2.4 produced the activating function of this axon.  
5.2.4. Electrical conductivities of tissue types 
The anatomical structures in the model need to have their electrical conductivities 
specified. These values have been sourced from a database of dielectric properties 
(Gabriel et al., 1996).  
Table 5.1 Material properties 
Structure Type Conductivity [S/m] 
Artery Dielectric 0.307087 
Blood vessel Dielectric 0.307087 
Bone Dielectric 0.020157 
Connective Tissue Dielectric 0.382706 
Fat Dielectric 0.041671 
Marrow Red Dielectric 0.118807 
Muscle Dielectric 0.321157 
SAT* Dielectric 0.041671 
Skin Dielectric 0.000200 
Tendon ligament Dielectric 0.382706 
Vein Dielectric 0.307087 
Nerve inner Dielectric 0.378000 
Nerve outer Dielectric 0.005420 
*SAT – Subcutaneous Adipose Tissue 
The anatomy of the virtual leg is voxeled such that each voxel belongs to one type of 
structure, however any other structure (such as the externally generated and inserted 
nerve) placed into the model will overlap these voxels. To ensure SEMCAD voxelates 
these structures correctly the inner and outer nerve tubes were set to higher priorities 
within the SEMCAD gridding options such that they over-ride the underlying tissue.  
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5.2.5. Modelling of electrodes 
A typical surface stimulation electrode consists of a conducting, flexible, self-adhesive 
hydrogel layer laid on the skin with a metallic connection to the external surface. This 
creates a contact which conforms to the uneven surface of the body.  
To create such an electrode in the model, an object that conformed to this surface would 
need to be created. As this surface geometry varies with anatomic site such an approach 
would require a different electrode surface for each anatomical position of the electrode. 
An alternative approach to overcome this was adopted. The electrode was created as a 
hydrogel cylinder (σ = 2 S/m) which overlapped the body structures (light blue, Figure 
5.10) over its entire cross-section. The model electrical conductivity priority was set to a 
lower level than that of the surrounding structure thus making the hydrogel layer 
electrically invisible where overlapped with the body structures.   On the top of the 
hydrogel cylinder a Perfect Electrical Conductor (PEC) layer (equivalent to a metal sheet) 
was placed to provide a uniform distribution of the current from the source (dark blue, 
Figure 5.10) 
 
Figure 5.10 Electrode montage 
Additionally the electrode in the model must provide the source of the stimulation and to 
allow the measurement of the voltage/current applied. SEMCAD cannot deliver a 
constant current, which is the normal output of an electrical stimulator, as it solves the 
relevant equations in terms of potential. Hence it is necessary to measure the current in 
the electrode for an applied potential. To determine the electrode current a block of 
conductive material (arbitrarily chosen with σ = 1 S/m and 1 cm2 cross section is placed 
between two layers of PEC (hydrogel cylinder plate and source rectangular plate) as 
shown in green on Figure 5.10. The source rectangular layer (PEC, brown) is pre-set to 
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an arbitrary potential amplitude (cathode electrode 0 V, anode electrode +10 V). This 
montage allows a uniform distribution of the current in the measurement block as well as 
on the external surface of the hydrogel layer in contact with the tissue. The current is 
measured using the SEMCAD X line extractor tool of current density J in a random place 
of a known size of 1 cm2 cross-section of the measurement block. The current I is thus 
calculated from 
 𝐼 = 𝐽 ∗ 𝐴 (5.2) 
In the percutanous model of PTNS a combination of a 34 gauge needle electrode (0.19 
mm diameter) is used as the cathode and a surface electrode (35 mm diameter) for the 
anode. The needle electrode was modelled as a cylinder and a cone to form a bevelled tip 
using a PEC (metal) material. 
5.2.6. Gridding 
The modelling requires the modelled object to be gridded. The grid needs to be 
sufficiently fine to resolve the smallest geometrical structures in the model. In this model 
the smallest structure is the nerve and, in the percutaneous model, the needle. Therefore 
the grid of these structures requires the finest gridding. The resolution of the grid and thus 
the total number of voxels is limited by the computational capacities available, thus there 
needs to be a balance between finer resolution and computational capacity. The gridding 
method used for the modelling consisted of a specific non-uniformed mesh, with the finest 
gridding around the nerve and the electrodes.   
The capacity of the PC used (Intel Xeon CPU E5420 @ 2.5GHz, 20GB RAM) enabled 
grid sizes up to 145 MCells to be solved within RAM. A typical solve time for the full 
anatomical model described in section 5.3.5 is 10-12 hours.  
The boundary conditions specify the values that a solution needs to take along the 
boundary and could be set either to Dirichlet or Neumann. Dirichlet conditions specify 
the value of the solution and Neumann conditions specify the value of the derivative. 
Dirichlet conditions were used for the modelling in this chapter. This incorporates 
continuity at a tissue/tissue boundary of the domain and infinite impedance in the volume 
external of the anatomy to accommodate the tissue/air interface.  
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5.2.7. Processing of the data 
Once the grid is generated, the SEMCAD Low Frequency Solver is used to solve the 
defined model until the residual convergence tolerance is reached, at which point the 
solution is regarded as changing negligibly with successive iterations. After the 
simulation is complete, the calculated results are available for extraction. The tools used 
further in this chapter are the slice view of the electrical field E or current density J and 
extrapolation of the electrical field tangential to the field extraction line (axon/nerve). 
This field extrapolation is performed every 0.01 mm and produce a distribution of 
electrical field along this line. Once the electrical field tangential to the nerve is 
extrapolated, the data are processed in Matlab 7.10 (R2011a) in order to obtain derivatives 
of the electrical field along the nerve and thus the activating function. The Matlab 
processes involved extrapolation of the data to equally spaced coordinates of 0.01 mm. 
This is because SEMCAD X did extrapolate this data equally in one of the XYZ 
coordinate system but the field extraction line is variable in all XYZ coordinates.  The 
noise generated by the differentiation process was minimised numerically (Chartrand, 
2011).     
The results section includes the activating functions defined as a spatial derivative of 
electrical field E along the nerve l, therefore the symbol for activating function used 
throughout is dE/dl.   
5.3.  Results  
The presented results begin with a simplified version of the transcutaneous electrical 
stimulation model. Subsequently, the model gradually adds more features towards the full 
PTNS model for both the transcutaneous and percutaneous form. In addition, a variety of 
montages for the transcutaneous form of PTNS are presented later in this chapter.   
5.3.1. A simple block of conductive material 
The simplest model to help understand the current and voltage distributions in electrical 
stimulation is in a homogeneous volume conductor. Thus a brick model was created in 
order to understand the distribution of the electrical field versus depth. Two round surface 
electrodes (5 cm in diameter) as described in Section 5.2.5 were placed on the top of a 
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brick formed of a conductive material (σ = 0.5 S/m) and dimensions of 7.5x7.5x30 cm. 
The anode voltage source was set to +10 V and the cathode to 0 V.   
A cross-sectional view of the modulus of the electrical field through the centre of the 
electrodes is shown in Figure 5.11. Because the volume conductor is uniform, J is 
proportional to E and hence the current density distribution would have the same shape. 
As the contours of the electrical field are the modulus of the electrical field, only absolute 
values can be seen. The outside edges of the electrodes represent a negative electrical 
field (with respect to the horizontal axis) and on the inside edges of the electrodes there 
is a positive electrical field. Deeper into the brick model in the vertical direction the 
electrical field gradually declines.   
 
Figure 5.11 A cross-sectional distribution of the electrical field in the horizontal direction 
Thus the electrical field can be seen to decline with depth below the electrodes and the 
higher peaks of the electrical field seen close to the electrodes became more diffuse 
(Figure 5.12).  
This simple model corresponds to the analytical solution for a negative (blue) and a 
positive (red) charge in Figure 5.12. The highest density of the electrical field contours is 
directly between the two points, similarly to two electrodes in Figure 5.11. Less dense 
contours and decline of the electrical field could be seen further from the points respective 
electrodes.  
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Figure 5.12 Electrical field surrounding two points of opposite charge 
 
Figure 5.13 Distribution of the electrical field along the lines at different depths 
This decrease in amplitude, and flattening of the electrical field profiles, changes the 
gradients of electrical field and thus the activation function (Figure 5.14) of nerves at 
different depth because, in this model, the activating functions are represented by 
derivatives of the electrical field tangential to a line in various depths of the brick model.  
To produce the same maximal gradient of an electrical field at a depth of 25 mm as it is 
produced at a 5 mm depth, the source of the stimulation (i.e. stimulus current or voltage) 
would need to be at least 10 times bigger (Table 5.2) in this uniform model. The 
approximate site of the stimulation also changes with depth from the edges of the 
electrodes towards the centre of the individual electrodes (Table 5.2).  
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Figure 5.14 Activating functions of simplified nerve fibres in different depths 
Table 5.2 Relationship of the gradient produced in different depths of penetration 
Depth of 
penetration 
dE/dl [V/m2] Position of peak value of  dE/dl 
from the centre of the cathode 
electrode [cm] 
5 mm 1.084 2.35 
10 mm 0.370 2.11 
15 mm 0.202 1.87 
25 mm 0.101 1.41 
These findings generate the information needed to understand more complex models. 
Thus to summarise: 
 The electrical field and current density is larger on the edges of the electrodes.  
 The activating function of a nerve function is dependent on their depth below the 
electrodes.  
  Although distribution of electrical field in other planes was not shown for 
brevity, the electrical field would also gradually decline if the electrodes are 
positioned distally from the axon in other planes.  
124 
 
5.3.2. Transcutaneous electrodes – cylindrical model – straight nerve 
The model in this section uses the straight nerve equivalents of the posterior tibial nerve 
as defined in Section 5.2.3. In order to understand effects of nerve geometry in a simple 
model in this section and next section, the models are solved with uniform conductivity 
σ = 0.1 S/m. The shape of the cylinder is similar to the anatomy of the ankle and was 
defined as 22 cm in height and 15 cm in diameter. The model used the same 
transcutaneous electrodes as in the previous brick model, placed 10 cm apart (Figure 
5.15). Three straight nerves (5 mm depth, 20 mm depth and a sloped nerve) were placed 
into a cylindrical model of uniform conductivity. However the model was solved three 
times, for each of the nerves separately, thus have no influence in each of the solution. 
 
Figure 5.15 Uniform conductivity model with three different nerves  
The findings from the previous model showed that the electrical field becomes weaker in 
depth, thus flattening the activation function (5 mm nerve vs 20 mm nerve depth). This is 
seen in this cylindrical model as well (blue and green, Figure 5.16, Figure 5.17). The 
sloped nerve slightly altered the electrical field and thus flattened the activation function 
(red, Figure 5.18) where the nerve was deeper below the cathode electrode. 
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Figure 5.16 Distribution of the electrical field tangential to the nerve 
 
Figure 5.17 Activiating function of three nerves in a cylindrical model 
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5.3.3. Transcutaneous electrodes – cylindrical model - posterior tibial nerve 
Human nerve axons are however not straight as shown in the previous section. The 
peripheral nerves usually follow arteries and veins and thus create curved structures. The 
next cylindrical model as described previously, contains a section of the posterior tibial 
nerve (Figure 5.18) as defined in method Section 5.2.3. This enables the methodology of 
the inserted curved nerve to be tested. The section of the posterior tibial nerve is placed 
at approximately the same position, relative to the electrodes, as in the further models of 
this project. This allows to study the changes in electrical field distribution in a uniform 
conductivity cylinder due to a realistic nerve geometry without other anatomical 
structures being involved. The choice of anode and cathode position, relative to the nerve, 
has been determined by that used in the clinical trial of Posterior Tibial Nerve Stimulation 
as presented in Chapter 6 and on which the subsequent clinical trial in this work has been 
based.  
 
Figure 5.18 A cylinder with a section of the posterior tibial nerve (red electrode – anode, blue 
electrode – cathode) 
It should be noted that the nerve does not run parallel to the cylinder z axis. To aid the 
reader’s understanding of the activating function and electrical field along the nerve at a 
particular point in the cylinder, the activating function relative to the z-axis [cm] instead 
of along the direction of the nerve is shown in Figure 5.19. Also as described in the section 
5.2.5 priority of the hydrogel layer was set to a lower level than that of the surrounding 
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structure thus making the hydrogel layer electrically invisible where overlapped with the 
cylinder.  
As defined previously, stimulation is produced when the membrane potential is exceeded; 
this process is called depolarisation. This happens when a rapid increase from a negative 
to positive potential is presented. The activating function shows this by a peak as shown 
in a uniform conductivity model, although there can be several gradients. The maximal 
peak is considered to be the site of the stimulation. At this point this model does not 
consider what value of the maximal gradient is needed to exceed the membrane potential 
and thus cause the stimulation (this is because it would be difficult to define it and it has 
not yet been relevant). The activating function in Figure 5.19 shows that the site of 
stimulation would be below the cathode at z = 14 cm. However, it should be noted that 
there is a significant negative gradient below the anode, which is approximately six times 
higher than that below the cathode. This is caused by the nerve being closer to the anode 
than the cathode. Therefore, if the polarity of the electrodes is reversed, then to achieve 
the same size of gradient the stimulation source needed can be six times lower. The site 
of stimulation then would be at z = 5 cm.  Another observation (which is important to be 
noted for further models) is that at around z = 8 cm another gradient, which is visible but 
not dominant can be seen. This is at the position where the nerve bends slightly inside the 
cylinder in the y plane (Figure 5.18, right) and in combination with the high electric field 
produce a higher gradient. 
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Figure 5.19 Activating function of the posterior tibial nerve in a transcutaneous cylindrical model 
5.3.4. Transcutaneous electrode montage – leg model and PTNS uniform 
conductivity 
When the nerve is placed into a phantom of the leg, both the external shape of the leg and 
anatomical structures within it (e.g. muscle, bones) will affect the distribution of the 
electrical potentials. This next model uses the same electrical conductivity (σ = 0.1 S/m) 
for all the anatomical structures, except the nerve and hence they have no impact on the 
distribution of electrical potentials. The changes of the electrical potentials as compared 
to the cylindrical model are therefore only related to the anatomical shape of the leg. 
Indeed, the distribution of the electrical field is similar to that in the cylindrical model 
previously (Figure 5.20, blue). Four notches are highlighted as rapid changes in the 
electrical field in Figure 5.20 (as #1-4) and these are discussed further in order to 
understand their origins where position of z coordinates is found in Figure 5.21. Notch 
#1 (Figure 5.20) shows a maximum negative electrical field as the nerve passing through 
the high electrical field region at the edge of the anode. Notch 2# shows a decrease on 
electrical field because the nerve section is between the edges of the electrodes and the 
electrical field is thus disperse into the tissue. The similar effect was previously observed 
in the cylindrical model for the straight nerve close to the surface (5 mm, Figure 5.16).  
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Notch #3 is again related to the increasing E field near the edge of the electrode and a 
small notch #4 is caused by the dispersion of the field below the electrode. This dispersion 
relates to the electrical field vector (electrical field lines), which for the middle of the 
electrode curves perpendicularly to the surface of the electrode and also perpendicularly 
to the nerve. Thus the vector of electrical field along the nerve at the centre of the 
electrode decreases. This notch would be more significant if the nerve will be placed 
closer to the electrode as observed in the simple block model where the electrical field 
decreases to 0 V/cm at the centre (5 mm depth, Figure 5.13).  
The maximal gradient dE/dl is seen in a similar place to the cylindrical model at z = 13.5 
cm. If the polarity of the electrodes was swapped then an approximately three times higher 
gradient would be obtained at the edge of the electrode (z = 8 cm). There are another two 
gradients between z = 8.5 and z = 11 cm, which by their magnitudes are lower than the 
two gradients mentioned, but their position is similar as the gradient in the previous 
cylindrical model of a uniform conductivity.  This gradient relates to the notch #1 and #2 
and slight bend in the nerve towards the surface.  
The glitch on the cathode electrode edge at ~ z = 12 cm is a model artefact related to a 
high electrical field on the edge of the electrode. These artefacts are discussed and 
corrected further in Section 5.3.5.1.  
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Figure 5.20 Activating function of the posterior tibial nerve in the uniform conductivity leg model 
 
Figure 5.21 Cross-section of the uniform conductivity leg model (red electrode – anode, blue 
electrode – cathode) 
This model indicates that anatomical shape of the leg has only a slight impact on the 
electrical field distribution when compared to the cylindrical model. The maximal 
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gradients and thus the site of stimulation would be near the edges of the electrodes. In 
particular the gradient below the anode is at the edge of the electrode and dominates 
because the nerve is superficial.  
5.3.5. Transcutaneous PTNS electrode montage – PESTOB   
The model above already contains all the anatomical structures and the electrodes are 
placed in the same positions that will be used in the clinical trial methodology (Chapter 
6). This section thus moves into the full anatomical model of transcutaneous PTNS, which 
allows exploration of the activating function of the montage used in the trial and 
comparison of this to the percutaneous model, which then follows.  
The solved model shows that the electrical field below the cathode is relatively weak in 
comparison to the rest of electrical field along the nerve (Figure 5.22, blue line). The 
highest electrical fields anywhere in the model are seen immediately underneath both 
electrodes, and penetrating approximately 5 mm into the tissue (shown as the yellow area, 
Figure 5.23). The activating function is dominated by a positive peak around z = 8.8 cm 
(Figure 5.22, red line). This gradient peak was previously shown to be presented in both 
the cylinder and in the uniform conductivity leg but is larger in this full model.  
Figure 5.23 and 5.24 shows that there is a high electrical field along the anode electrode. 
This path of high electrical field corresponds to the layer of SAT and causing the current 
to flow closer to the surface. This helped to create a significant gradient around z = 9 cm 
which is the site of the stimulation.  
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Figure 5.22 Activating function of the transcutaneous PESTOB model 
 
Figure 5.23 Cross-section of the transcutaneous PESTOB model in two planes (red electrode – anode, 
blue electrode – cathode) 
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Figure 5.24 Cross-section of the transcutaneous PESTOB model in two planes (red electrode – 
anode, blue electrode – cathode) 
Similarly to the uniform conductivity leg model, the activating function shows the 
gradient dE/dl below the edge of the anode electrode (approximately twice as large as 
elsewhere along the nerve) would be expected to cause stimulation if the polarity of the 
electrodes is exploited.  
Although the above findings and more precise measurements will determine the 
maximum gradient, it was noted that the activation function presents noticeable multiple 
points of inflexion (particularly between z = 8 cm and z = 11 cm), which may affect the 
solution of the model. It is assumed that these points of inflexion are caused by a 
combination of discontinuities of conductivity at tissue boundaries and modelling 
artefacts. In the former case significant artefacts are presented as hot spots and are 
dependent on the position of the grid relative to the structures and thus affect the 
activating function. Furthermore, these were dependent on the exact position of the grid 
and might affect the results. The model was gridded to the maximum possible scale of 
145 million cells determined by the PC computational capacity, therefore a finer grid 
could not be used, although would help to address these artefacts. 
To illustrate this problem in more detail, three activating functions from the same model, 
but using three different grids are shown in Figure 5.25. Whilst the differences in the 
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absolute numbers of voxels is relatively small, such changes will alter the position of the 
grid lines relative to the discontinuities of conductivities at tissue boundaries. The 
calculated maximum value of dE/dl of these activating functions in the model of 133 
MCells, 141 MCells and 146 MCells are 0.248 V/cm2, 0.222 V/cm2 and 0.235 V/cm2 
respectively. This indicates that the solution obtained varies by at least 10% as a function 
of  the actual grid position and the grid size along the nerve.  
For this reason a method of multiple solutions from a range of spatially displaced grids 
were combined in order to average these discrepancies in the model and thus provide a 
unified solution.   
 
Figure 5.25 Activating functions of three different grid settings 
5.3.5.1.  Minimizing discrepancies - grid displacement method  
To minimize the discrepancies as observed in the previous solution N – the number of 
activating functions from a range of N grids was combined. This allowed shifting of the 
grid slightly between the structures. Thus several solutions could create a combination of 
activating functions calculated from grids that intersect slightly differently with the 
anatomical structures.   
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The combination process was implemented as an average value at each point for N 
activating functions. In order to determine the N, the relationship between the number of 
combined solutions (N activating functions) and the numerical difference between N and 
N-1 activating functions was obtained (Figure 5.26). This numerical difference between 
the two nearby combinations was calculated as a mean average of differences between 
the activation functions at the each point.  
Figure 5.26 shows that the mean difference between the activating function of combined 
solutions decreased with the increase in the number of activation functions (solutions) 
used. Figure 5.27 shows an effect of increasing the number of combined activation 
functions on the solution (maximum derivative of the activation function), which does 
not change significantly for N > 20.  Both graphs helped to determined that 20 activating 
functions for a range of grid between 108-146 MCells is an appropriate compromise 
between computational time/data processing and effect on results.    
 
Figure 5.26 Mean difference in activating functions 
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Figure 5.27 Mean difference in solutions 
A combination of N=20 activating functions is thus used as a solution for further models.  
5.3.6. Transcutaneous electrodes PTNS montage – grid displacement method results 
The combined activating function is shown in Figure 5.28. The maximum peak of this 
activating function was presented at z = 8.77 cm and had a value of 0.2011 V/cm2. The 
stimulation current in the model which produced this gradient was 8.8 mA. If each of the 
N = 20 activation functions was taken as a separate solution then the mean peak would 
be at z = 8.79 ± 0.001 cm (mean ± SD) and had a value of peak 0.231 ± 0.013 V/cm2. In 
comparison to the original solution (without combined solutions in Figure 5.22) this 
gradient became slightly flattened.  If the reverse polarity of the electrodes was used then 
the maximum gradient of 0.409 V/cm2 would be presented at z = 7 cm.  
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Figure 5.28 Activating function of transcutaneous PESTOB model (grid displacement method) 
Although the activating function oscillations/points of inflexions on Figure 5.27 are not 
much smaller than on Figure 5.22, the grid displacement method is a more reproducible 
solution.  
5.3.7. Percutaneous – needle electrode model  
In this model a combination of a 34 gauge needle electrode (0.19 mm diameter) and a 
surface electrode (35 mm diameter) is used. The electrodes were placed according to the 
description for the commercially available percutaneous stimulation system (Urgent PC, 
Uroplasty Ltd.). The needle electrode was placed 5 cm proximal from the medial 
malleolus and 2 cm posterior to the tibia. The surface electrode was placed on the medial 
aspect of the calcaneus (Figure 5.29).  
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Figure 5.29 Position of the electrode for percutaneous PTNS (red electrode – anode, needle 
electrode – cathode) 
The solution of this model showed that the distribution of the electrical field around the 
anode surface electrode and proximal to the needle is similar to the transcutaneous form 
(Figure 5.30). The electrical field gradient in this are decreasing towards its bottom peak 
around z = 8 cm. Further however there is a rapid increase of the positive electrical field 
caused by the close proximity of the cathode needle electrode to the nerve causing a 
localised increase in the stimulating function (Figure 5.31). Hence the activating function 
shows a dominate peak gradient at z = 14.95 cm and had a value of 0.346 V/cm2. The 
simulation current in this model was 3.3 ± 0.04 mA (mean ± SD). This current was based 
on them mean current used in the study of percutaneous PTNS for the treatment of 
overactive bladder symptoms (van der Pal et al., 2006b).  
 
 ANODE 
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Figure 5.30 Activating function of the percutanous model 
 
Figure 5.31 Cross-sectional distribution of the electrical field in the percutaneous model (red 
electrode – anode, blue electrode – cathode) 
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5.3.8. What current is needed to produce the same physiological response? 
A study investigating the percutaneous stimulation approach (van der Pal et al., 2006b) 
used a mean pulse current intensity of 3.3 mA as used in this model. Such current 
produced a peak gradient of 0.346 V/cm2 in the SEMCAD model.  
The primary aim of this modelling work was to determine the current needed to produce 
the same peak value of activating function between the percutaneous and transcutaneous 
forms of PTNS. Thus, the following is calculated:  
Maximum gradient of percutaneous MPERC = 0.346 V/cm
2 
Maximum gradient of transcutaneous MTRAN = 0.201 V/cm
2 
Simulation current measured on transcutaneous electrodes ISIM = 8.8 mA 
𝐼𝑇𝑟𝑎𝑛𝑠𝑐. =  
𝑀𝑃𝐸𝑅𝐶
𝑀𝑇𝑅𝐴𝑁
∗ 𝐼𝑆𝐼𝑀 =
0.3469
0.2011
∗ 8.8 = 15.2 𝑚𝐴 
From the equation above, the current needed to produce the same physiological response 
is 15.2 mA (approximately five times higher than for the percutaneous form).  
This chapter will further explore whether a variation in the electrode position and size of 
the electrode significantly reduces the stimulation current needed in order to produce the 
same activating function gradient.   
5.3.9.  Further transcutaneous montage 1 – smaller electrodes 
Current density, and thus electrical field, is proportional to the cross-sectional area of the 
electrodes. Electrodes with a smaller diameter would be expected to increase local 
electrical field for a given stimulation current density and might move the localisation of 
the stimulus to below the electrodes rather than between the electrodes as seen in the 
previous transcutaneous model. Thus a model with 50% smaller area of electrodes was 
created (Figure 5.32) and solved. 
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Figure 5.32 Position of the smaller 35 mm electrodes montage in the transcutaneous model (red 
electrode – anode, blue electrode – cathode) 
Figure 5.33 shows the activating functions of the previous transcutaneous montage with 
electrodes of 50 mm size and the solution for the smaller 35 mm electrodes. The activating 
functions are normalised to the same intensity of the current (15.2 mA) in order to make 
a comparison between the two montages. The activating function of the 35 mm electrodes 
shows a dominating peak of gradient (0.330 V/cm2) at z = 8.7 cm. This peak is similar to 
the previous gradient in the 50 mm electrodes model (~5% smaller). Further, there is 
another gradient peak which became more apparent below the cathode electrode at z = 
14.2 cm, with a peak value of 0.228 V/cm2 (~20% bigger). If the polarity of the electrodes 
is swapped then the peak will around 0.776 at z = 6.4 cm.  
These results show that the cathode gradient may become more dominant with smaller 
electrodes. However, 50% smaller electrodes setup reduced the gradient peak to 87% of 
the bigger electrode gradient peak and the reversal polarity gradient peak increased to 
110%. As another peak around z = 14.2 cm became more apparent there is no simple ratio 
which will suffice to predict relative change of the gradient with smaller size of 
electrodes. Presumably a further reduction in the electrode diameter would be needed in 
order to localise the stimulus below the cathode electrode for the specific anatomy being 
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modelled. The smaller electrodes might have a practical disadvantage as position laterally 
from the centre of the nerve will become more critical.  
 
Figure 5.33 Activating functions of the PESTOB montage 50 mm electrodes and 35 mm smaller 
electrodes 
5.3.10. Further transcutaneous montage 2 – posterior to foot 
Another montage which was previously used in the studies of transcutaneous PTNS 
(Ammi et al., 2014)  placed the electrodes posterior to foot on the ankle, on the Achilles 
Tendon (Figure 5.34). The model in the study placed the anode electrode above the 
cathode, however for the consistency of this work the anode is placed below the cathode. 
Further comparisons can be made by swapping the polarity as suggested below.  The 
same size of the electrodes as in the first transcutaneous PTNS model are used (50 mm 
diameter). The anode electrode geometry was changed such that the contact area will be 
that of the circle shaped electrode. This was due to a narrow part of Achilles tendon at the 
position of anode.  
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Figure 5.34 Position of the electrodes for the posterior montage (red electrode – anode, blue 
electrode – cathode) 
Both activation functions in Figure 5.35 represent the distribution of electrical potentials 
again for the 15.2 mA stimulation current calculated in Section 5.3.8. This posterior 
electrode montage produced the highest gradient of 0.161 at z = 11.4 cm. In comparison 
to the PESTOB 50 mm electrodes montage the stimulation would be less effective.  If the 
electrode polarity is swapped then the peak gradient will be 0.253 at z = 8.2 cm.  
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Figure 5.35 Activating functions of PESTOB montage 50 mm electrodes and electrodes placed 
posterior to the ankle 
5.3.11. Summary 
The modelling of the percutaneous form of posterior tibial nerve stimulation showed the 
maximum gradient 0.346 V/cm2 at z = 14.95 cm for a typical stimulation current of 3.3 
mA. The stimulation current needed to achieve the same physiological response 
(represented by the value of this maximum gradient) as in percutaneous PTNS is 
summarised in Table 5.3.  
Table 5.3 Current needed to produce the same activating function gradient as in the percutaneous 
form 
Montage 
Current needed 
[mA] 
Multiples of percutaneous 
form current needed [-] 
Percutaneous form 3.3  
Transcutanous 50 mm 15.2  4.6 
Transcutanous 50 mm - reverse 7.5 2.3 
Transcutanous 35 mm 15.9 4.8 
Transcutanous 35 mm – reverse 6.8 2.1 
Posterior to ankle 32.6 9.9 
Posterior to ankle – reverse 20.8 6.3 
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The most effective approach seems to be to reverse the polarity of the electrodes from the 
originally modelled transcutaneous 50 mm position, i.e. the cathode on the medial side of 
the heel and anode above. This reversal of electrodes, and the resultant significant 
decrease in the stimulation current used (by a factor of approximately 2) has the dual 
advantage of decreasing the electrical energy that needs to be applied and of the expected 
resultant decrease in cutaneous sensation due to the stimulation. 
The placement of the electrodes behind the medial malleolus (posterior to the ankle) as 
suggested previously in the literature does not have an advantage in terms of requiring a 
lower stimulation current.  
Model verification and validation are important processes in numerical modelling. An 
experimental validation would be beneficial and seems to be the most practical pathway 
for this Chapter. However, due to the time constraints and resources available for this 
thesis this was not achieved and is left for further work. Nonetheless this model has 
usefully informed understanding about the model from homogeneous volume conductor 
towards the full PTNS model. 
The modelling in this chapter provides evidence that similar field gradients at the nerve 
due to percutaneous posterior tibial nerve stimulation can be achieved using the 
transcutaneous form. It has enabled an estimate to be made of the relative currents that 
are needed in the two methods. However it should be noted that the position of stimulation 
along the nerve is somewhat different for the electrode montages considered and the 
electrical current needed to produce the same effect is larger.  
 
146 
 
 
A pilot clinical trial of 
Transcutaneous Posterior Tibial Nerve 
Stimulation for the treatment of overactive 
bladder 
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6.1.  Introduction 
Chapter 1 has identified the potential for using Posterior Tibial Nerve Stimulation for the 
treatment of overactive bladder syndrome symptoms. Specifically the transcutaneous 
approach using surface electrode seems to be attractive, because it is completely non-
invasive, low cost and can be self-administered by patients at home.    
There is only inadequate evidence available to support this approach as seen in Chapter 
1 - reviews have identified only limited evidence of its efficacy, and the lack of placebo 
control studies in this area is of particular concern. The technology that can be used for 
this approach (a TENS stimulator) is widely available on the market and does not require 
any further development. Thus it seems ideal to evaluate this approach in a placebo 
controlled study. The further aims and objectives of this pilot clinical trial are described 
in the following sections.  
6.1.1. Extend the De Sèze study to a different patient group   
The most promising transcutaneous PTNS study to date in the literature was conducted 
by (de Seze et al., 2011). It reported clinical improvement of its primary outcome measure 
(a combination of warning time, an urgency subscale and frequency from a 3 days voiding 
chart) in 82.6% of MS patients after one month of treatment.  
The study evaluated effects after 30 and 90 days. The largest improvement was seen at 
day 30. After this time clinical efficacy parameters remained stable or declined slightly. 
The study mentioned that the efficacy of transcutaneous PTNS appeared in the first week, 
but they did not make a formal clinical assessment at this time. To confirm this 
observation the study design in this thesis should include an assessment after one week 
and apply the treatment for a total of 4 weeks with the same stimulation parameters as de 
Seze. Their study focused only on MS patients. However, idiopathic OAB symptoms 
affected patients present a larger clinical problem and hence this patient group has been 
chosen for this study.  
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6.1.2. Inclusion of a placebo control group 
The investigation of placebo effects is arguably essential in the evaluation of new 
therapies and this is particularly the case with electrical stimulation techniques. However, 
because of the sensations caused by the stimulation, the production of sham electrical 
stimulation can be difficult.   An interesting methodology was reported in a study of 
children with OAB, where in one arm of the study, the same type of stimulation was 
applied over the scapula, where no effects on lower urinary tract control would be 
expected to occur (Lordelo et al., 2010). Similarly Hasan et al. applied TENS over the 
T12 dermatome which acted as placebo (Hasan et al., 1996).  
Electrical stimulation below motor threshold levels causes a tingling sensation due to the 
stimulation of cutaneous sensory nerve structures. Thus an alternative option may be to 
gradually decrease the stimulation intensity to zero after a few seconds of usage and tell 
the subject that stimuli sensation might fade with time. This is an approach widely used 
in techniques such as Transcranial Direct Current Stimulation (Russo et al., 2013). In 
reality, the subject may habituate to the stimuli such that they are genuinely not able to 
recognise whether the stimulation still persists or not. This habituation is likely to depend 
on the frequency used, the strength of the applied stimuli and on personal subjective 
responses.     
Another approach to the investigation of placebo effects may be to apply stimulation over 
the same area of the skin but with zero stimulation current (Hagstroem et al., 2009). 
However, for this to be an effective placebo the patient must be naive to electrical 
stimulation and unaware that it causes sensation.  
Leroi et al. performed a randomised sham-controlled trial in which patients were not told 
that they might receive sham stimulation (Leroi et al., 2012). Patients were then 
randomized into active and sham stimuli groups. This methodology was approved by their 
local ethics committee, although the editors of the journal in which they subsequently 
published strongly discourage further investigators to use this methodology as it might 
represent a breach of the Declaration of Helsinki. However this could be an appropriate 
method to overcome the technical problems of sham stimuli if approved by the 
appropriate ethics committee. 
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There is just one study, that evaluates a placebo effect using  transcutaneous PTNS 
(Bellette et al., 2009). This study used treatment sessions in the clinic rather than at home, 
and chose as its placebo electrodes applied to the skin without any stimulus being 
delivered. Patients were told that they may or may not feel the stimulation. They found 
improvement in 30% patients in the placebo group.  
In summary, the complete absence of stimulation cannot be relied on as an adequate 
placebo because patients may well not be naive to the fact that electrical stimulation 
causes sensation and hence will be able to deduce that they are in the placebo group. 
Instead, the method chosen for this study is to use the approach of (Lordelo et al., 2010), 
i.e. a comparable intensity of electrical stimulation in the placebo group but applied to a 
site that is regarded as being irrelevant to bladder control.   
6.1.3. Is bilateral stimulation more effective?  
The majority of studies used unilateral stimulation, applied to just one ankle, and do not 
specify which ankle (left or right) should be stimulated. Therefore one arm of the study 
will investigate whether bilateral stimulation can be beneficial, when compared to both 
control and unilateral leg stimulation in a three arm study. 
6.1.4. How long do the effects of stimulation last? 
There is no clear evidence about the duration of the effect after transcutaneous PTNS in 
OAB treatment. A study (van der Pal et al., 2006a) used percutaneous (6 patients) and 
transcutaneous (5 patients) PTNS and the authors suggested that subsequent maintenance 
treatment is necessary. All patients had subjective deterioration and 9 of 11 patients had 
objective deterioration of their symptoms over a period of 6 weeks. The study in this 
thesis assesses patients for four weeks after treatment has ceased to assess the carryover 
of any therapeutic benefit.   
6.1.5. Investigation of sympathetic pathways in the automatic nerve system 
There are several studies which have investigated automatic nervous system dysfunction 
in overactive bladder patients (Ben-Dror et al., 2012, Mehnert et al., 2009, Hubeaux et 
al., 2007, Hubeaux et al., 2011) . Various measures, including heart rate variability, have 
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been used. (Hubeaux et al., 2011) showed that idiopathic OAB patients have sympathetic 
dysfunction using a hand grip exercise and cold pressure test during which changes in 
blood pressure were recorded. For this reason an investigation as to whether this study of 
idiopathic OAB patients having sympathetic dysfunction was included, based on a hand 
grip exercise and measurement of resultant blood pressure changes, and whether any 
resultant subgroup of patients is correlated with the results of the treatment. 
The main aim of this clinical trial and the hypothesis being tested is to determine whether 
transcutaneous posterior tibial nerve stimulation should be considered for further, larger, 
studies and subsequent deployment into clinical practice.   
6.2.  Material and methods 
This study was designed as a placebo randomized single-blind placebo controlled trial.  
The participants were randomly assigned to receive either unilateral PTNS, bilateral 
PTNS or shoulder stimulation using 40 minutes self-administered stimulation every day 
for a duration of four weeks. As described earlier (Section 6.1.2) stimulation on the 
shoulder was regarded as sham stimulation because there is no obvious neural connection 
to the bladder control mechanism and therefore such a site should not affect the symptoms 
of OAB. The outcome measures were recorded prior to the therapy, after the first week 
of the treatment, after the treatment was completed and four weeks after the treatment 
finished. The participants attended three visits as indicated in the study flow diagram 
(Figure 6.1).  
The study was presented to the participants as a comparison of three different stimulation 
sites in order to blind the participant to the focus on PTNS. Hence the title for the study 
was chosen as “Peripheral Electrical Stimulation for the Treatment of Overactive 
Bladder”, abbreviated to “PESTOB”.  
The study, using the placebo methodology described above, was approved by the 
Yorkshire and Humber regional committee (Appendix I) and registered in the public 
domain (http://clinicaltrials.gov/show/NCT01783392).   
Martin Slovak conducted the clinical trial and was involved in all parts of the trial 
including study design, planning, securing ethic approval, study coordinating, 
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recruitment, intervention training, data collection, data analyses and dissemination. In all 
aspects supervised by Professor Anthony Barker and Professor Christophe Chapple. Dr 
Nadir Osman and Dr Christopher Hillary were the study doctors and Mrs Suzanne Hulton, 
Mrs Alison Hyde, Mrs Anne Frost supported the trial as research nurses. The costs of the 
stimulators (6 x £50) were covered the EU Marie Curie training network TRUST. 
 
Figure 6.1 Study flow diagram 
6.2.1. Participants 
Adult (>18 years of age) patients diagnosed with the idiopathic symptoms of overactive 
bladder, with or without urodynamically proven detrusor overactivity and who had failed 
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primary therapy were enrolled into the study. The most frequent exclusion criteria were 
predominant stress urinary incontinence in females and clinically significant bladder 
outlet obstruction in males. The full list of inclusion and exclusion criteria list is included 
in the Appendix J. The participants were allowed to stay on any existing medication 
throughout the study as long as they did not change its type or dose. They were also asked 
not to alter their fluid drinking habits whilst they were involved in the study, which was 
monitored by bladder diary assessments.  
6.2.2. Participants’ identification and screening  
The participants were recruited from the urology, urogynaecology and community continence 
services of Sheffield Teaching Hospitals NHS Foundation Trust from April 2013 to October 
2014. From February 2014 the study was also advertised in order to increase the 
recruitment rate. This was done using a printed advertisement at relevant local clinics and 
online at two overactive bladder patient's supportive organizations, the Cystitis & 
Overactive Bladder Foundation (http://www.cobfoundation.org/) and the Bladder & 
Bowel Foundation (http://www.bladderandbowelfoundation.org/). In addition, potential 
participants were also identified from the Bladder and Bowel Foundation client database.  
The participants were required to attend three study visits. Before their first visit they 
were provided with the study information sheet and were initially screened against the 
inclusion and exclusion criteria by a study research nurse. Following that the participant 
had at least 24 hours to decide if he/she would like to take part in the study before the 
date for the first study visit was arranged. The participant was then attended their first 
study visit at the Urology Outpatient Department at the Royal Hallamshire Hospital in 
Sheffield.  
6.2.3. Prior the treatment period – study visit 1 
At the first visit, one of two study doctors took a detailed record of the participants’ 
symptoms, demographic data and drug history. At the same time the study doctor also 
performed a physical examination in order to determine whether the participant fulfilled 
the study inclusion and exclusion criteria.  
The participant then signed a study consent form.  
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At the same visit an autonomic nervous system test (described later in this methodlogy 
section) was performed. Following that the participant was taught how to complete a 3-
day bladder diary and the relevant questionnaires (see Section 6.2.7 for details) during 
the week to prior their second visit.     
6.2.4. Randomisation of the participants – study visit 2 
Randomisation of the participants took place at the second visit. The participants were 
stratified by the number of voids per day into one of three groups to ensure that the 
baseline number of micturitions could be closely matched between the three arms.   
Group 1 – less than 15 voids and more than 8 voids 
Group 2 – more than 15 voids 
Group 3 – less than 8 voids (urgency patients) 
A clinical scientist not involved in data collection provided a randomisation sequence for 
the study arms which was concealed in three sets of consecutively numbered opaque 
envelopes, one for each group. The appropriate envelope was opened to determine the 
study arm for that participants once they had consented and their number of baseline voids 
on their second visit was known.   
Group 3 was added later and consequently should formed a small sub-study focused on 
participants only with urgency. This was decided as a challenging consequence of 
otherwise excluded and highly motivated participants (the original criteria excluded the 
participants with less than 8 voids) at the second study visit. So, all the participants who 
fulfilled the study inclusion and exclusion criteria were randomized. The participants in 
Group 3 were only randomized into two out of the three study arms (the unilateral 
posterior tibial nerve stimulation and placebo arm). However, altogether there were only 
two participants randomized into this sub-study, but one did not comply with the study 
protocol and other decided to withdraw from the study due to significant deterioration of 
symptoms. Therefore this sub-study group is not further discussed. 
Following randomization on study visit 2, the investigator provided training for the 
participant according to their allocated group. This training was provided in two parts and 
the participants obtained a leaflet with instructions to take home (Appendix J). In the first 
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part the investigator showed the participant how to place the electrodes and control the 
stimulator unit, and provided a short demo session (~5 minutes) of stimulation. In the 
second part the participant was tasked to show that he/she was able to independently use 
the stimulator according to the protocol and performed the first full (40 minutes) 
stimulation session whilst in the clinic.  
6.2.5. Methodology of study arms 
All study arms used the same length of treatment sessions (40 minutes); the same two 
output channel device (MultiTens Neurotrac, Verity Medical Ltd., UK) and the same 
stimulation setting (10 Hz, 200µs pulse width). This stimulation setting was chosen to be 
the same as the study by (de Seze et al., 2011).  The participant placed self-adhesive 
hydrogel electrodes (50 mm round, Verity Medical Ltd., UK) on the site of body 
according to their allocated group, as described below. The stimulation was self-
administered daily by the participant for a duration of four weeks.  
It was important to record participant’s compliance with the study protocol, therefore the 
stimulator used in the study was chosen in part because it had an inbuilt logging facility. 
Further features of the stimulator allowed modification of all of the stimulation 
parameters and locking of these settings into the device. The maximum output of the 
stimulator was 60 mA per channel 
The low cost of the stimulator and electrodes were also important requirements in terms 
of the health economics of this type of therapy. The stimulation unit cost ~£50 and the 
cost of the electrodes was ~£5 per pack of four.  
6.2.5.1.  Unilateral stimulation group 
The participant was presented with a set of instructions (Appendix K). These instructions 
were consistent for each of the stimulation groups, the only difference being in how the 
electrodes were positioned. In particular, the same distance between the electrodes and 
the same level of intensity (as described further in Section 6.2.5.4) was used at all sites. 
The participants in the unilateral stimulation arm were instructed to stick the electrodes 
on the right ankle as shown in Figure 6.2.  As mentioned in the introduction Section 1.3.2, 
it is uncertain as to which leg the electrodes need to be placed and whether this matters. 
Stimulation on the right ankle was chosen from the methodology by (de Seze et al., 2011) 
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Specifically, the participants were firstly instructed to place the electrode with the black 
connector (cathode) 3 finger widths (approx. 5 cm, 2 inches) above the right ankle bone 
on the edge of the leg and then place the electrode with the red connector (anode) between 
the ankle bone and the heel of foot.  
The participant was then instructed to connect the electrode wire into the stimulation unit, 
switch on the unit and set the intensity.  
6.2.5.2.  Bilateral stimulation 
Similarly to the unilateral stimulation group, the participants placed the cathode electrode 
above, and the anode electrode below, the medial malleolus, over the posterior tibial nerve 
on both legs and set the stimulation intensity (Figure 6.3).   
Figure 6.3 Position of the electrodes for the bilateral stimulation group. Left – cathode electrode 3 
finger widths between above the medial malleolus. Right – electrodes placed on both ankles 
Figure 6.2 Position of the electrodes for unilateral stimulation Left – cathode electrode 3 finger 
widths between above the medial malleolus. Right – electrodes placed on right ankle 
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6.2.5.3.  Sham stimulation 
The participants were instructed to place the cathode and the anode electrodes on the 
lateral side of the left shoulder.  Firstly, the participant was instructed to place the 
electrode with the black connector (cathode) at the middle front side of the shoulder then 
place the electrode with the red connector (anode) 3 finger widths (approx. 5 cm, 2 inches) 
below as shown in Figure 6.4. 
 
 
 
 
 
 
 
 
 
 
6.2.5.4.  Stimulator amplitude settings  
PESTOB sought to confirm the effect of the treatment reported by (de Seze et al., 2011) 
and hence their parameter settings were used in all arms of the study, namely pulse width 
200 µsec and pulse frequency 10 Hz. In regards to the stimulation intensity level the de 
Seze paper states that: 
“The intensity level was just above the perception threshold but before that which caused 
pain” 
To try and standardise the intensity used, the participants were specifically asked to use ‘the 
maximum comfortable intensity which does not cause pain or muscular contraction, ideally 
just below that which causes muscular contraction. If the sensation is tolerable it is 
recommended that the stimulus is increased until muscular contraction is perceived and then 
Figure 6.4 Position of the electrodes for the bilateral stimulation group. Left – 3 finger widths 
between above the stimulation electrodes. Right – electrodes placed on left shoulder 
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decreased slowly until contractions just cease”. This wording was also used in the written 
instructions they were given and was chosen because it could also be used for the control 
group and was easy for patients to understand. The average current was recorded for each 
session by the stimulator, thus also allowing patient compliance to be checked.  
The participants were allowed to change the stimulation intensity throughout the stimulation 
session if the sensation of the stimulation became unpleasant or too weak as long as they 
complied with the study protocol.  
6.2.6. Study visit 3 
At the third study visit the participants returned both, the stimulator, and completed 
assessments from the week 1 and after the treatment (as described in the Section 6.2.7). 
The second autonomic nerve system response test was also performed (Section 6.2.8).   
During this visit the participants also underwent a brief interview about the change in 
his/her bladder condition and their stimulation tolerance. Typical questions were focused 
on whether he/she had perceived a benefit from the stimulation irrespective of the study 
assessments used and their willingness to continue with the therapy on their own.   
The participant were also given a further follow up assessment pack to be completed four 
weeks after their last stimulation session. Usually a further clinic appointment was 
arranged for the patient in order to continue their treatment pathway outside of the study.   
6.2.7. Study assessments and outcomes 
The study assessment tools to collect data and outcome measures were based on 
standardised questionnaires and a bladder diary as follow: 
Bladder Diary 
Accurate assessment of overactive bladder symptoms requires their objective 
interpretation using a urinary diary (Chapple, 2014). The International Consultation on 
Incontinence Questionnaire (ICIQ) established the first validated 3 day bladder diary for 
the assessment of LUTS (Bright et al., 2014). There were changes made to the layout and 
the study bladder diary did not record fluid input, as suggested by  (Bright et al., 2014).  
This is because this information was not regarded as important for the study aims because 
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any alternation of the fluid intake would be captured by the total volume voided and 
analysed individually. The bladder diary used can be found in (Appendix L). 
The following outcome measures were calculated manually by the investigator from each 
of the bladder diary:  
 Mean number of micturition per 24h  
 Mean number of urgency episodes per 24h 
 Mean number of nocturia episodes per 24h 
 Mean number of urinary incontinence episodes per 24h 
 Maximum voided volume in 72h bladder diary period  
 Voided volume per 24h 
 Mean nocturia polyuria calculated as a ratio of the total night time voided volume 
and the total day time voided volume 
The change in the mean number of micturition per 24h and in the mean number of urgency 
episodes were the primary outcomes of the study.  
Patient Perception of Bladder Condition (PPBC) 
This is a validated and well established single item global tool for the measurement of 
bladder condition (Coyne et al., 2006a). The score ranges from 0 to 5 with higher score 
indicating greater severity of the symptoms.  
Patient Perception of Change in Bladder Condition (PPCBC) 
The above questionnaire was also modified such that instead of the score range, the 
participants indicated whether they perceived that their bladder condition had changed 
from the last assessment. This assessment was named Patient Perception of Change in 
Bladder Condition (PPCBC). The participants were able to choose from improved a lot, 
improved slightly, stay the same, got worse or got a lot worse. PPCBC was later used in 
the definition of the responder 6.2.11. 
OAB-q Short Form 
The Short Form of the OAB questionnaire (OAB-q) has been demonstrated to be an 
economical and efficient alternative to the full-length form (Coyne et al., 2014). The 
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questionnaire captures the full spectrum of OAB Symptoms Bother (SB) and Heath-
Related Quality of Life impact (HRQL).  
Both scores are transformed on a 0 to 100 point scale using the equations below. A higher 
Symptom Bother score indicates greater severity of symptoms and a lower HRQL score 
indicates a greater impact of the symptoms on the patient’s quality of life.   
A minimally important difference in the OAB-q has been recommended as a change of 
10-points for both SB and HRQL, although this is based on the OAB-q long form (Coyne 
et al., 2006b). 
To allow the score to be between 0-100 following calculation took place. Lower SB score 
indicates less bothersome symptoms and lower HRQL score indicates lower quality of 
life.  
 
𝑆𝐵 𝑠𝑐𝑜𝑟𝑒 =  
(𝐴𝑐𝑡𝑢𝑎𝑙 𝑠𝑐𝑜𝑟𝑒 − 6) 
30
× 100 
(6.1) 
* 6 indicates the lowest possible score, 30 indicates the possible raw score range 
 
𝐻𝑅𝑄𝐿 𝑠𝑐𝑜𝑟𝑒 =  
(78 − 𝐴𝑐𝑡𝑢𝑎𝑙 𝑠𝑐𝑜𝑟𝑒)
65
× 100 
(6.2) 
* 78 indicates the highest possible score, 65 indicates the possible raw score range  
ICIQ OAB 
The ICIQ has established a questionnaire assessing the presence or absence of symptoms 
of overactive bladder using a 5-point scale for each condition (frequency, urgency, 
nocturia, incontinence). A score of 0 indicates no presence of a symptom and score of 4 
great symptom severity. Each symptom questions is followed by a scale to assess bother 
associated with the symptom (Abrams et al., 2006) on a scale between 0 to 10, where 0 
indicates not bothered at all and 10 indicates “a great deal”. Two scores are created from 
this questionnaire:  
 ICIQ-OAB Score – range 0-16 
 ICIQ-OAB Bother score – range 0-40 
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RAND36 
The RAND36 is a widely used health-related quality of life questionnaire. There are eight 
outcome group scales derived from the questionnaire: physical functioning, role 
limitations caused by physical health problems, role limitations caused by emotional 
problems, social functioning, emotional well-being, energy/fatigue, pain, and general 
health perceptions (Hays and Morales, 2001). 
Table 6.1 Summary of the questionnaires used with assessment period. X – Questionnaire was used 
Questionnaire 
Assessment 
Baseline First week 
After 
treatment 
Follow up 
3 days bladder diary X X X X 
PPBC X - X X 
PPCBC X X X X 
OAB-q X - X X 
ICIQ-OAB X - X X 
RAND36 X - X X 
6.2.8. Autonomic nervous system  
A test of autonomic nervous system function was performed prior to the study at the 
participants’ first visit and just after the study at the patient’s third visit. The test consisted 
of a hand grip exercise test during which blood pressure was measured. The hand grip 
exercise test is a cardiovascular test, measuring the response of the sympathetic nerve 
system to static exercise generated by the hand grip (Hubeaux et al., 2011). 
The participant was asked to maintain a hand grip at 30% of maximum over 3 min using 
a hand grip dynamometer. Blood pressure was measured at the baseline and then after 
each minute of the exercise using an Omron 705CP monitor on the opposite arm. 
A dysfunction of the sympathetic pathway in the autonomic nerve system causes a lack 
of the rapid increase in diastolic blood pressure that is observed in normal subjects. If the 
difference in diastolic blood pressure before starting the test and just before release was 
<10 mmHg the test was considered abnormal.  
Participants with a resting blood pressure greater than 160/100 mmHg were excluded 
from this test but were still able to participate in the study.  
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6.2.9. Sample size calculation 
PESTOB was designed as a three arm, single centre pilot study. It has been reported that, 
in general a sample size of 12 patients per group is suitable for such a pilot study (Julious, 
2004). Alternatively the following power calculation can be made. 
 
Assuming: 
 Average number of voids per day = 12 
 Standard deviation of voids/day = 2 (ie. 97.5% of patients have 8 or more voids 
per day assuming a normally distributed population) 
 Significant clinical improvement = decrease of 4 voids per 24 hours 
Then, from S.J. Pocock (Pocock, 1983) (P128) : 
 
𝑛 = 2𝜎2
𝑓(𝛼, 𝛽)
(𝜇2 − 𝜇1)2
 
(6.3) 
Where, 
n = number of patients on each treatment 
σ = standard deviation of population 1, 
µ2-µ1 = difference in means to be detected = δ 
f(α,β) = 13.0 (for type I and type II errors both equal to 0.05)) 
 
The formula calculated that the number of participants required in each arm is seven. 
However, to allow for dropout and participants non-compliance the plan was to recruit 
12 participants into each arm. 
6.2.10. Data Analyses 
Friedman test (a non-parametric version of a one way ANOVA) was used to compare the 
changes in frequency, urgency, incontinence and nocturia between the assessments. The 
resultant findings will be indicated by confidence intervals (Lee et al., 2014). 
Any other statistical testes used are defined in the result section.  
Participants who satisfactorily completed fewer than 80% (22 out of 28 or fewer) of the 
sessions (as determined by the stimulator log) were excluded from the analyses.  
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6.2.11. Responders 
The responder was defined as a participant who decreased their number of micturitions 
and/or urgency episodes by at least 30% and responded to the PPCBC question as 
improved slightly or improved a lot. This definition combined the objective assessment 
of the symptoms as measured by the bladder diary and the participant’s subjective 
perception of change in their symptoms. Such combination should give a better overview 
of the changes, because sometimes the participants might have only perceived a non-
demonstrable change in their symptoms or the change in the bladder diary was not 
clinically important for the participant.  
6.3.  Results 
Altogether 22 participants commenced the treatment protocol. One participant 
(randomised to bilateral stimulation) withdrew from the study after 4 sessions of 
stimulation. The reason was related to nightmares, feeling dizzy and hangover in the 
mornings since he commenced the stimulation technique. It was thought that these were 
not directly related to the stimulation as they were not experienced by other participants 
and have not been reported in other TENS studies. Another two participants (one 
unilateral and one sham stimulation) did not follow the study protocol (both did not 
complete more than 50% of stimulation sessions, as recorded by the stimulator log, and 
one also significantly altered their fluid intake) and therefore were excluded from the 
further analyses. A total of 19 participants (9 men and 10 women) were included in the 
study analyses. Study flow diagram is shown in Figure 6.5. 
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Figure 6.5 Study flow diagram 
6.3.1. Patient demographic 
The study randomization did not consider gender thus there is an unequal distribution of 
men and women in the unilateral and the sham stimulation groups (Table 6.2). The 
Kruskal-Wallis test showed no difference in age (p = 0.973) or the Body Mass Index 
(BMI) between the stimulation groups (p = 0.532).  
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Table 6.2 Demographic information about the study participants that completed the study 
 Unilateral 
stimulation 
Bilateral 
stimulation 
Sham 
stimulation 
 (n = 7) (n = 6) (n = 6) 
Sex, n(%)    
Male 
Female 
2 
5 
3 
3 
4 
2 
Age    
Mean (SD) 58.9 (4.4) 57.5 (4.9) 59.5 (2.9) 
Range 54 to 66 39 to 69 51 to 69 
Race, n    
White 6 6 4 
Asian 0 0 1 
Black 1 0 1 
Body Mass Index, kg/m2    
Mean (SD) 30.8 (2.9) 27.2 (1.5) 26.2 (3.2) 
Range 21.5 to 42.2 21.4 to 30.3 16.5 to 40.1 
A summary of the participants’ symptoms as they were recorded in the baseline bladder 
diary is shown in Table 6.3. All participants presented with a frequency of at least 8 voids 
per 24 hours. Two participants in each of the stimulation groups had more than 15 voids 
per 24 hours. Urgency (at least two episodes per 24h) was present in all participants, 
except one in the bilateral stimulation group who was affected by frequent micturition 
(~12voids per 24h). Urgency incontinence was presented in 42% (8/19) participants, and 
79% (15/19) had nocturia (more than one night time void). 73% (14/19) of participants 
presented with more than 33% of their urine volume produced during the night time 
(nocturia polyuria). This was unequally distributed between the groups and was less 
prevalent in the sham stimulation group (Table 6.3).   
All participants had failed at least one antimuscarinic drug before entering the study. The 
majority of the participants had tried a variety of the antimuscarinic drugs available but, 
due to lack of efficacy or intolerance to side effects, decided to discontinue them. 63% 
(12/19) participants were on a stable dose of either an antimuscarinic (8/19) or ß3 
antagonist (Mirabegron, Astellas) (3/19) drug throughout their study involvement. 
Some participants who had previously tried a ß3 antagonist drug were offered Mirabegron 
after the trial or counselled for consideration of Botulinum Toxin A bladder injection 
therapy.   
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Table 6.3 No of. participants presenting with various symptoms of overactive bladder symptoms, 
nocturia polyuria and type of medications taken throughout the study 
 Unilateral 
stimulation 
Bilateral 
stimulation 
Sham 
stimulation 
 (n = 7) (n = 6) (n = 6) 
Symptoms of OAB baseline    
Frequency <15 voids / 24h 5 4 4 
Frequency >15 voids / 24h 2 2 2 
Urgency 7 5 6 
Urgency incontinence 4 2 2 
Nocturia 5 5 5 
Nocturia polyuria  6 6 2 
Study OAB medications    
Antimuscarinics 4 3 1 
β3 antagonist 1 1 1 
6.3.2. Compliance with the treatment protocol and stimulation current used  
Two participants, who were not included in the analyses, claimed daily usage of the 
stimulation technique, but underwent only 13/28 (sham stimulation group) and 14/28 
(unilateral stimulation group) sessions respectively. Both stimulators’ internal logs were 
checked upon return for correct operation of recording. The non-compliant, sham 
stimulation participant did not adhere to the protocol as the frequency of usage stimulation 
dropped down significantly towards the end of the treatment period, this was probably 
due to lack of efficacy. The participant using unilateral stimulation reported a problem 
with forgetting things, which presumably contributed to their low compliance.  
The rest of the participants adhered well to the protocol (Table 6.4). Some of the 
participants underwent more than the prescribed maximum of 28 sessions. This was due 
to their last study visit (return of the stimulator) being arranged later than 28 days and 
them not following the guidance to stop the stimulation after four weeks.  
The stimulation current used was similar in both active stimulation groups, but 
approximately 50% lower in the sham stimulation group, probably because of the greater 
superficial musculature at the shoulder. 
The participants in the active stimulation groups were instructed to increase the intensity 
until a visible motor contraction of the toes was observed and then to decrease the 
stimulation intensity to just below that. However only 5/13 participants were able to 
demonstrate this at the first treatment session. This was due to the discomfort they 
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perceived by the stimulation below the motor contraction. The rest of the participants 
8/13 instead described a significant referred sensation in toes and/or sole of the foot, 
which suggested that the tibial nerve is being targeted.  
The correlation between the treatment efficacy and the visible motor contractions 
observed is further assessed in Section 6.4.5. 
Table 6.4 No. of stimulation sessions performed by participants and stimulation current used 
 Unilateral 
stimulation 
Bilateral 
stimulation 
Sham 
stimulation 
 (n = 7) (n = 6) (n = 6) 
Sessions    
Mean (SD) 27.9 (2.5) 27.5 (4.0) 26.5 (2.1) 
Range 25 to 33 23 to 34 24 to 29 
Stimulation current used 
[mA] 
   
Mean (SD) 35.4 (14.0) 30.3 (12.7) 17.7 (8.2) 
Range 16 to 60 16 to 50 10 to 33 
Motor contraction     
Was able to obtain 3 2 6 
Was not able to obtain 3 4 0 
No information 1 - - 
6.3.3. Efficacy - Primary outcomes 
Mean number of micturition per 24h  
The primary outcome, the mean number of micturitions per 24h, in each of the 
assessments is summarised in the Table 6.5. The only statistically significant difference 
was identified between the baseline and first week of assessment in the bilateral group. 
Figure 6.6 summarises graphically the change in the mean number of micturitions ± SEM 
and individual changes for each of the participants. The individual participant’s values 
are in Appendix M.  
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Table 6.5 Mean number micrutions per 24h in each of the stimulation groups at each assessment 
 Unilateral 
stimulation 
Bilateral 
stimulation 
Sham 
stimulation 
 (n = 7) (n = 6) (n = 6) 
Baseline    
Mean (SEM) 12.8 (2.3) 13.1 (1.9) 13.2 (1.0) 
Range 8.3 to 26.0 8.3 to 21.7 9.0 to 16.0 
First week    
Mean (SEM) 11.5 (1.5) 9.1 (0.8)* 11.7 (0.9) 
Range 8.3 to 19.7 6.3 to 11.7 8.7 to 14.3 
After the treatment    
Mean (SEM) 11.1 (1.3) 10.3 (0.7) 12.5 (1.5) 
Range 7.7 to 17.0 7.0 to 12.3 8.3 to 18.7 
Follow up    
Mean (SEM) 10.5 (1.1) 12.0 (2.1) 11.5 (0.9) 
Range 7.3 to 15.3 7.3 to 22.0 8.7 to 15.0 
    
P value Friedman Test 0.291 0.016* 0.414 
SEM = standard error of mean, * Dunn’s multiple comparisons test showed significance
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Figure 6.6 Mean change in number of micturitions including each participant measurements 
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After the first week of treatment the size of the decrease in unilateral and sham stimulation 
seems to be comparable (Table 6.5). Bilateral stimulation showed the largest, statistically 
significant, effects after the first week (95% CI relative to baseline, -7.8 to -0.1), but the 
effect lessened (95% CI relative to baseline, -6.6 to 1.0) after the treatment (not 
significant). Similarly the initial effect after the first week (95% CI relative to baseline, -
3.7 to 0.7) in the sham stimulation group slightly lessened (95% CI relative to baseline, -
3.7 to 2.3) after the treatment. The unilateral stimulation group showed similar effect in 
the first week (95% CI relative to baseline, -3.6 to 0.9) and after the treatment (95% CI 
relative to baseline, -5.4 to 1.9).  
The differences after the treatment indicates larger effects in the active stimulation groups 
compared to sham stimulation. Unilateral stimulation decreased the mean number of 
micturitions by 1.0 more micturitions than sham stimulation (95% CI, -3.2 to 5.3). 
Bilateral stimulation showed a larger effect with a decrease of 2.1 micturitions compared 
to sham stimulation (95% CI, -2.1 to 6.3).  
Although only slightly, the number of micturitions after follow up seemed to decrease 
even further in the unilateral and sham stimulation groups compared to after treatment 
values. However the bilateral stimulation group increased the number of micturitions in 
the follow up period by a mean of 1.7 (95% CI, -2.7 to 6.2). 
6.3.3.1.  How much did the overall voided volume change?  
It is important to determine whether the change in the number of micturitions per 24 h 
can be attributed to the change in the voided volume per 24 h. The changes in the mean 
volume might not recognise changes in the fluid intake throughout the study assessments. 
Therefore these changes were studied on an individual basis and the participants who 
altered their fluid intake significantly were excluded from the analyses.  These were the 
two participant who also did not follow the study treatment protocol as mentioned 
previously.   
Participant #13 in the sham stimulation group was not included in the calculation of 
voided volume because information about the recorded volume was missing in over 50% 
of their bladder diary. 
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Overall the mean voided volume did not change significantly between each of the 
assessments (Table 6.6). The only trend in mean voided volume was showed in the sham 
stimulation group (decrease of 463 ml between the baseline and after treatment).  
Table 6.6 Mean voided volumes per 24h in each of the groups 
 Unilateral 
stimulation 
Bilateral 
stimulation 
Sham 
stimulation 
 (n = 7) (n = 6) (n = 6) 
Baseline    
Mean (SEM) [ml] 1571 (263) 1600 (142) 2323 (282) 
Range [ml] 775 to 2647 1183 to 2020 1620 to 3317 
First week    
Mean (SEM) [ml] 1780 (266) 1695 (270) 1971 (264) 
Range [ml] 1130 to 2431 760 to 2740 1530 to 3000 
After the treatment    
Mean (SEM) [ml]  1905 (202) 1788 (227) 1860 (305) 
Range [ml] 1193 to 2917 1193 to 2502 1158 to 2767 
Follow up    
Mean (SEM) [ml] 1848 (211) 1763 (182) 1807 (218) 
Range [ml] 1193 to 2917 1193 to 2458 1378 to 2567 
    
P value Friedman Test 0.324 0.459 0.066 
 
Mean number of urgency episodes per 24h  
The mean numbers of urgency episodes per 24h in each of the assessments are 
summarised in Table 6.7. Figure 6.7 summarises graphically the change in the mean 
number of urgency episodes ± SEM and individual changes for each of the participants. 
The individual participant’s values are in Appendix M. The greatest effects, close to the 
significance level (p = 0.068), were observed in the bilateral stimulation group (Table 
6.7).  
Similarly, the mean number of micturitions per 24h and the number of urgency episodes 
seems to be more progressive in the active arms compared to sham stimulation. In 
particular, bilateral stimulation group showed a decrease of 2.5 more urgency episodes 
per 24hour in compare to sham stimulation (95% CI, -3.2 to 5.8).  
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Table 6.7 Mean number of urgency episodes per 24h in each of the stimulation  
 Unilateral 
Stimulation 
Bilateral 
stimulation 
Sham 
Stimulation 
 (n = 7) (n = 6) (n = 6) 
Baseline    
Mean (SEM) 8.9 (2.1) 7.5 (2.9) 8.6 (1.6) 
Range 2.7 to 19.7 0 to 21.3 4.0 to 15.3 
First week    
Mean (SEM) 7.2 (1.4) 3.8 (1.6) 6.8 (1.5) 
Range 1.7 to 13.3 0 to 11.3 1.0 to 10.7 
After the treatment    
Mean (SEM) 7.5 (1.8) 4.2 (1.1) 7.9 (2.0) 
Range 0.7 to 15.0 0 to 8.7 1.3 to 15.7 
Follow up    
Mean (SEM) 7.4 (1.9) 5.9 (3.1) 6.2 (1.5) 
Range 1.0 to 15.3 0 to 20.7 0.7 to 11.7 
    
P value Friedman Test 0.662 0.068 0.592 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 Mean change in number of urgency episodes including each participant’s measurements 
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6.3.4. Secondary outcomes 
Mean number of incontinence episodes per 24h  
Incontinence, any unintentional leakage of urine, was presented in 52% (10/19) 
participants in the baseline. There were six incontinent patients in the unilateral 
stimulation group, two in the bilateral stimulation group and two in the sham stimulation 
group. The mean number of incontinence episodes is summarised in Table 6.8.  
Table 6.8 Mean number of incontinence episodes per 24h in each of the stimulation groups 
 Unilateral 
stimulation 
Bilateral 
stimulation 
Sham 
Stimulation 
 (n = 7) (n = 6) (n = 6) 
Baseline    
Mean (SEM) 2.7 (1.3) 2.5 (2.1) 0.7 (0.4) 
Range 0 to 10.0 0 to 13.0 0 to 2.7 
First week    
Mean (SEM) 1.5 (0.7) 0.8 (0.7) 0.2 (0.1) 
Range 0 to 4.7 0 to 4.0 0 to 0.7 
After the treatment    
Mean (SEM) 2.4 (1.5) 0.5 (0.3) 0.5 (0.3) 
Range 0 to 11.3 0 to 1.7 0 to 1.7 
Follow up    
Mean (SEM) 2.6 (1.6) 1.7 (1.5) 0.4 (0.2) 
Range 0 to 12.0 0 to 9.7 0 to 1.0 
    
P value Friedman Test 0.590 0.333 0.437 
There was a slight decrease or no decrease in the participants of unilateral stimulation and 
sham stimulation groups. A dramatic decrease of incontinence episodes was observed 
only in one of the bilateral stimulation participants. This participant returned to baseline 
values at follow up (Figure 6.8, Appendix I). The individual participant’s values are in 
Appendix I.    
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Figure 6.8 Mean change in number of incontinence episodes including each participant’s 
measurements 
Mean number of nocturia episodes  
Nocturia episodes (a need to wake to pass urine at night) were presented in 89% (17/19) 
participants. This correlates with 73% (14/19) of participants who presented with more 
than 33% of urine volume produced during the night time (nocturia polyuria) in the 
baseline.  
There was no statistical differences in the number of nocturia episodes nor in nocturnal 
polyuria (data not shown for brevity) between the assessment periods (Table 6.9). 
However all the groups (3/6 in bilateral, 3/6 in unilateral and 2/6 in sham stimulation 
group) showed individual changes (Table 6.12).  
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Table 6.9 Mean number of nocturia episodes per 24h in each of the stimulation groups 
 Unilateral 
stimulation 
Bilateral 
stimulation 
Sham 
stimulation 
 (n = 7) (n = 6) (n = 6) 
Baseline    
Mean (SEM) 2.2 (0.6) 2.5 (0.5) 1.7 (0.4) 
Range 0 to 4.7 1.0 to 4.3 0 to 2.7 
First week    
Mean (SEM) 1.9 (0.7) 1.4 (0.4) 1.3 (0.3) 
Range 0 to 4.7 0 to 2.7 0 to 2.0 
After the treatment    
Mean (SEM) 2.3 (0.9) 1.8 (0.7) 1.3 (0.3) 
Range 0 to 7.0 0 to 4.3 0 to 2.0 
Follow up    
Mean (SEM) 2.3 (0.8) 2.2 (0.5) 1.3 (0.3) 
Range 0.3 to 5.7 1.0 to 4.0 0 to 2.3 
    
P value Friedman Test 0.540 0.554 0.310 
F
ir
s
t  
w
e
e
k
A
ft
e
r  
tr
e
a
tm
e
n
t
F
o
ll
o
w
 u
p
F
ir
s
t  
w
e
e
k
A
ft
e
r  
tr
e
a
tm
e
n
t
F
o
ll
o
w
 u
p
F
ir
s
t  
w
e
e
k
A
ft
e
r  
tr
e
a
tm
e
n
t
F
o
ll
o
w
 u
p
-6
-4
-2
0
2
4
M e a n  c h a n g e  in  n o . o f  n o c tu r ia  e p is o d e s  ±  S E M
  
  
  
  
  
  
  
  
  
 C
h
a
n
g
e
 i
n
 n
o
. 
o
f 
n
o
c
tu
r
ia
 e
p
is
o
d
e
s
 
Figure 6.9 Mean change in number of nocturia episodes including each participant measurements 
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Questionnaires assessments 
There was no missing data in the questionnaires from the 19 subjects analysed. The mean 
values for baseline scores suggests the unilateral stimulation group participants are the 
most affected by the OAB symptoms as shown in four of the five questionnaires (Table 
6.10).  The greatest changes were seen in the OAB-q Symptom bother and HRQL scores 
in the bilateral stimulation group. These changes reverted to baseline at the follow up 
assessment.  
Table 6.10 Mean values of questionnaires 
 Unilateral 
stimulation 
Bilateral 
stimulation 
Sham 
stimulation 
Mean (SEM) (n = 7) (n = 6) (n = 6) 
PPBC    
Baseline 3.9 (0.3) 3.6 (0.5) 3.2 (0.2) 
First week 3.6 (0.3) 3.2 (0.3) 3.2 (0.2) 
After treatment 3.3 (0.3) 3.3 (0.2) 3.0 (0.0) 
Follow up 3.6 (0.3) 3.3 (0.4) 3.1 (0.2) 
OAB-q Symptom bother    
Baseline 58.6 (8.1) 51.1 (12.3) 47.2 (7.0) 
After treatment 57.1 (8.2) 38.9 (3.7) 42.8 (3.2) 
Follow up 54.3 (9.4) 52.2 (13.5) 41.1 (6.1) 
OAB-q HRQL    
Baseline 53.3 (8.4) 40.0 (11.0) 59.2 (6.1) 
After treatment 59.0 (7.1) 50.8 (8.3) 57.2 (3.5) 
Follow up 56.3 (9.9) 40.0 (12.5) 62.6 (3.6) 
ICIQ-OAB Score    
Baseline 11.4 (0.9) 9.2 (2.0) 8.8 (0.7) 
After treatment 10.4 (1.0) 6.5 (1.3) 8.3 (0.8) 
Follow up 10.6 (1.0) 8.2 (2.1) 8.3 (1.3) 
ICIQ-OAB Bother score    
Baseline 28.0 (5.1) 20.8 (6.4) 25.0 (2.7) 
After treatment 25.0 (4.7) 17.7 (6.2) 27.7 (2.3) 
Follow up 22.7 (4.6) 18.3 (6.4) 25.0 (3.7) 
 
Patient perception of change in their bladder condition (PPCBC) 
Results of the PPCBC questionnaires are summarised in Table 6.11. The following text 
briefly summarises these findings and combined with face to face conversations between 
the investigators and the participants about treatment benefits.  
Two participants in the unilateral stimulation linked their improvement to a decrease in 
number of voids and all three to the decrease in the intensity of urgency.   
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Altogether five participants in the bilateral stimulation group showed improvement on 
the PPCBC questionnaire at the after treatment assessment, although one of these 
participants did not report improvement at their third visit when interviewed about the 
study. Another participant of this group has reported improvement in voided volume 
(although this was not confirmed by the bladder diary assessment) and an intensity of 
urgency/level respectively.  
One participant in the sham stimulation group responded as “improved slightly” which 
he described as greater control of his bladder.   
Table 6.11 Responses of the participants to the Patient Perception of Change in Bladder Condition 
questionnaire. ‘Got worse’ is in comparison to their previous assessment 
 
6.3.5. Responders to the treatment 
The above reported findings indicate larger improvement effects in the active arms of the 
treatment compared to sham stimulation. Ideally, the effect of a treatment is shown by the 
number of responders. Therefore the overall outcome changes are summarised in Table 
6.12. As previously described (Section 6.2.11), a responder is a participant who has 
decreased his/her number of micturitions and/or urgency episodes by at least 30% and 
responded to the PPCBC questions as improved slightly or improved a lot.  
 Unilateral 
stimulation 
Bilateral 
stimulation 
Sham 
stimulation 
 (n = 7) (n = 6) (n = 6) 
First week    
Got worse 0 0 0 
Stayed the same 4 2 4 
Improved slightly 3 4 2 
Improved a lot 0 0 0 
After treatment    
Got worse 0 0 0 
Stayed the same 4 1 5 
Improved slightly 3 4 1 
Improved a lot 0 1 0 
Follow up    
Got worse 1 2 1 
Stayed the same 5 3 4 
Improved slightly 1 1 1 
Improved a lot 0 0 0 
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Altogether three participants were identified in the unilateral stimulation group, two in 
the bilateral stimulation group and one in the sham stimulation group.  The following text 
describes these individual responders in more details in order to understand their 
symptom history, stimulation tolarencae and follow up:  
Unilateral stimulation:  
Participant #1, a 55-year-old woman, who could not tolerate an antimuscarinic drug due 
to side effects (dry mouth) and who partly responded to Mirabegron 50 mg (reduced 
amount of urgency) presented at baseline with 26 voids a day, accompanied one third of 
the time by urgency. A visible motor contraction of her toes was obtained at the first 
stimulation session, around 20 mA. This participant demonstrated a decrease in number 
of micturitions, urgency and incontinence episodes, which lasted for at least one month 
as demonstrated by the follow up assessment after the 4 weeks.  The participant described 
the improvement better than that she had achieved from various drug therapies over 
several years of trialling. At follow up, the participant unexpectedly demonstrated even 
further improvement in symptoms. However, several months after the study, the 
participant was consulted at a regular clinical visit and had experienced symptoms again. 
She therefore decided to recommence the study treatment on her own, which in further 
clinic assessments led to significant improvement in her symptoms.  
Participant #14 was a 66-year-old woman, who did respond to antimuscarinic drug and 
still continued to take a 10 mg dose of Solifenacin during the study. Her main symptoms 
presented at baseline were sudden urgency (which happened even if she had recently been 
to the toilet) often accompanied by a small leak. During the stimulation treatment period 
the participant was unable to obtain motor contraction of her toes due to sensation 
becoming a limiting factor even when alterations to the electrode position were made, 
however a significant referred sensation in her toes was noted. After the treatment period 
the participant’s symptoms slightly improved, however an occasional leakage 
accompanied by urgency was still present. The participant reported a positive effect, but 
did not wish to consider continuation of the therapy beyond the duration of the study. 
Participant #26, a 54-year-old man who could not tolerate any antimuscarinic drugs due 
to dry mouth presented at baseline with increased frequency (>15 voids a day) and 
nocturia (~5 voids a night) always accompanied by urgency. A visible motor contraction 
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of his toes was obtained at the first stimulation session accompanied by a referred 
sensation in his toes. After the stimulation the participant reported improvement in both 
urgency and frequency. He felt that he was able to control his bladder better. However 
the participant also speculated that the symptom improvement might be a combination of 
a recent weather change (it got warmer) and the stimulation.  The participant asked for 
the details of the stimulation technique and wished to continue the therapy on his own 
after the study. His symptoms had returned to baseline at the one month follow up 
assessment.  
Bilateral stimulation:  
Participant #3, a 47-year-old woman who was on antimuscarinic therapy throughout the 
study, presented at baseline with severe frequency (>20 voids a day), accompanied always 
by urgency and half of the time with incontinence. The participant was not able to obtain 
motor contraction of her toes due to sensation being a limiting factor, however felt 
significant sensation around the electrodes and sole of the foot. The participant greatly 
improved in all OAB symptoms as demonstrated by the bladder diary and questionnaire 
assessments (Table 6.12).  However this improvement returned to baseline after one 
month without stimulation. The participant wished to continue with the therapy on her 
own.  
Participant #23, a 59-year-old man, was severely bothered by frequency, urgency and 
nocturia but no incontinence at baseline, and entered the study after failure of 
antimuscarinic drugs (not effective and with side effects). The participant was able to 
obtain motor contraction at the first session on one leg, but found it difficult to hunt for 
the motor threshold throughout the study. The participant pointed out that stimulation was 
uncomfortable. Nonetheless he perceived and demonstrated a reduction of day time voids 
and an increase in voided volume, suggesting an increase in bladder capacity. The 
participant was keen to continue with the therapy. The improvement seemed to continue 
at the follow up assessment as reported by the bladder diary, however the participant 
reported that his symptoms got worse.    
Sham stimulation: 
Participant #17, a 55-year-old male, was severely bothered by all OAB symptoms with 
urgency incontinence and urodynamically demonstrated detrusor overactivity, and 
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entered the study after no improvement with antimuscarinic drugs. The participant felt a 
slight improvement in bladder control, which translated into a great reduction of day time 
voids as demonstrated by bladder diary. This improvement did not last in the follow up 
assessment. The participant wished to continue with the therapy on his own, although 
there was no information whether he has at the time of writing this thesis. 
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Table 6.12 Overall outcome changes from the baseline to after treatment 
Pt 
no. 
 
Change at least by 30% from baseline in red Change 
in the 
volume 
voided 
per 24h 
Change 
in Max. 
voided 
volume 
PPBC 
change 
by a 
grade 
PPCBC 
 
 
Improvement by at least 10% in red 
Gender, 
age, BMI Micturitio
ns per 24h 
Urgency 
per 24h 
Incontin
ence 24h 
Nocturia 
episodes 
ICIQ 
OAB 
symptom 
score 
ICIQ 
OAB 
Bother 
score 
OABq 
symptom 
score 
OABq 
HRQL 
score 
Unilateral stimulation 
1 F55, 38.9 -9.0 0.7 -2.0 -1.7 -6% +17% ↓ * -6% -10% 0% -10% 
5 F59, 42.2 -1.0 1.3 0.7 -0.7 22% -20% ↓ - -18% -20% 0% 8% 
14 F66, 30.0 -1.3 -2.0 -1.3 0.3 6% +20% ↓ * 6% 10% 10% 2% 
19 F63, 21.5 -0.3 -5.7 -0.4 - 10% 0% - - 0% -15% -16% -3% 
21 F59, 32.0 3.7 3.7 1.3 3.7 10% 0% -  6% 0% -3% -20% 
26 M54, 22.3 -4.3 -7.4 -0.3 -1.7 84% +100% ↓ * -12% -5% 3% -3% 
27 M56, 28.5 0.0 -0.3 - 0.0 1% 0% ↓ - -18% -20% -3% -2% 
Bilateral stimulation 
3 F47, 29.8 -9.4 -12.6 -11.3 -4.0 69% +100% ↓↓ ** -29% 0% -63% -30% 
11 F39, 28.1 -1.3 -2.0 -0.7 -1.3 -36% -4% - * -18% -18% -30% -32% 
12 M63, 21.4 0.3 -1.0 - 0.0 -2% +15% - * -6% 0% 7% 4% 
23 M59, 30.3 -4.7 -5.0 - 0.7 -7% +47% - * -29% -45% -6% -8% 
25 F69,23.6 -1.4 0.0 - 1.3 10% 0% - - 0% 3% 3% 3% 
29 M68, 29.7 -0.3 1.3 - -1.0 -5% 11% ↓↓ * -12% -18% 16% -2% 
Sham stimulation 
13 M69, 24.0 2.7 5.4 - -1.0 3% 0% - - 0% 3% 7% 3% 
15 F68, 16.5 0.0 -2.7 - -1.0 -10% +20% - - -6% 8% -3% 8% 
16 F68, 45.6 -1.0 3.0 -2.7 0.3 1% -14% - - -12% 10% 0% 0% 
17 M55, 40.1 -6.0 -6.0 0.0 -0.6 -37% -13% ↓ * -6% 5% -26% -20% 
22 M51, 29.0 -0.7 -2.4 - - -10% -20% - - 0% 10% 7% 22% 
28 M56, 25.0 0.7 -1.4 - -0.3 -16% +38% - - 6% 5% -10% 0% 
 ↓ improvement by one grade, ↓↓ improvement by two grades, *improve slightly, **improved a lot 
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6.3.6. Responders changes in the first week and follow up assessments 
The following analyses only include those participants who have been classed as 
responders at the end of the treatment period (Table 6.13).  Almost all responders 
perceived an improvement of the symptoms after the first week of the therapy, except 
participant #23 who demonstrated an improvement only as measured by bladder diary.   
The majority of the participants got worse after the one month without treatment thus 
demonstrating no obvious carry over effect. Interestingly Participant #1 has further 
improved the symptoms.  
Table 6.13 responders changes in the first week and follow up assessments 
Pt 
First week - baseline Follow up – after treatment 
Micturitions 
per 24h 
Urgency 
per 24h 
PPCBC 
Micturitions 
per 24h 
Urgency 
per 24h 
PPCBC 
Pt1 -6.3 -0.7 improved -5.3 -4.4 improved 
Pt14 -1.0 -1.0 improved +1.3 +0.3 stayed 
Pt26 -2.0 -6.4 improved +4.3 +3.0 got worse 
       
Pt3 -10.4 -10.0 improved +8.3 +12.0 got worse 
Pt23 -6.0 -6.7 stayed +1.4 -1.7 got worse 
       
Pt17 -5.3 -5.6 improved +1.7 -2.3 got worse 
6.3.7. Autonomic nervous system response test 
The autonomic nerve system response test (described in Section 6.1.5 and 6.2.8) was 
conducted in 15/19 participants at baseline and in 14/19 participants after the treatment 
(Table 6.14). No readings were obtained in three and four participants respectively, which 
led to their exclusion from the analyses. This was due to a technical problem with the 
equipment. One participant was excluded from the test due to their blood pressure being 
high (the test exclusion criteria, >160/100mmHg) before exercise.  
6/15 participants who conducted the test were taking hypertension medication during the 
study.  
Means of mean arterial pressure (MAP, defined as systolic pressure plus one third of 
diastolic pressure) increase significantly between baseline and after three minutes 
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(Friedman test, Dunn’s Multiple Comparison) in all groups at baseline (Table 6.15) and 
after the treatment except in the bilateral group after the treatment (Table 6.16, p < 0.056).  
Similarly, means of diastolic blood pressure increase significantly between baseline and 
after three minutes except the bilateral stimulation at baseline and after treatment tests, 
and in the unilateral stimulation group after the treatment test. 
Table 6.14 Number of participants who took the part in the autonomic nerve system response test at 
baseline and after treatment 
 Unilateral 
stimulation 
Bilateral 
stimulation 
Sham 
stimulation 
 (n = 7) (n = 6) (n = 6) 
Baseline test    
Conducted 5 4 6 
Not-conducted 2 2 0 
After treatment test    
Conducted 4 4 6 
Not conducted 3 2 0 
Hypertension medication 
in participants for whom 
the test was conducted 
3 1 2 
 
Table 6.15 Means (SEM) of mean arterial and diastolic blood pressure as measured at baseline 
 
Baseline 
After 1 
minute 
After 2 
minutes 
After 3 
minutes 
Post 
Unilateral       
Mean BP  98 (4) 104 (4) 105 (4) 111 (7) 97 (4) 
Diastolic BP 82 (3) 88 (3) 87 (2) 95 (7) 81 (4) 
Bilateral      
Mean BP  93 (7) 97 (6) 96 (7) 104 (5) 88 (0.9) 
Diastolic BP 74 (7) 79 (6) 78 (8) 82 (2) 72 (3) 
Sham      
Mean BP  96 (3) 107 (5) 110 (4) 116 (6) 96 (3) 
Diastolic BP 77 (3) 85 (6) 89 (6) 91 (7) 77 (3) 
Total      
Mean BP  95 (2) 102 (3) 105 (3) 111 (4) 100 (5) 
Diastolic BP 78 (2) 83 (3) 86 (3) 91 (4) 85 (7) 
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Table 6.16 Means (SEM) of mean arterial and diastolic blood pressure as measured after the 
treatment 
 Baseline 
After 1 
minute 
After 2 
minutes 
After 3 
minutes 
Post 
Unilateral       
Mean BP  90 (6) 96 (4) 99 (6) 101 (7) 94 (7) 
Diastolic BP 75 (5) 79 (4) 82 (4) 83 (5) 77 (4) 
Bilateral      
Mean BP  90 (5) 95 (8) 98 (6)  103 (10) 90 (6) 
Diastolic BP 71 (5) 77 (7) 78 (5) 82 (8) 71 (4) 
Sham      
Mean BP  94 (5) 109 (8) 114 (6) 123 (8) 100 (6) 
Diastolic BP 77 (4) 94 (10) 95 (9) 105 (11) 85 (9) 
Total      
Mean BP  91 (3) 101 (4) 105 (4) 111 (5) 95 (3) 
Diastolic BP 75 (3) 84 (5) 87 (5) 92 (6) 78 (4) 
The number of participants who were considered as positive (no autonomic nerve system 
dysfunction, diastolic blood pressure increased by more than 10 mmHg) is shown in Table 
6.17. Unfortunately, 3 out of 5 participants who were considered as responders for the 
treatment in the active arms did not complete the test and thus correlation with the 
treatment response in relation to the test results was not possible.  In the other two 
participants one completed the test as positive (Participant #14) and one as negative 
(Participant #26, blood pressure did not increase by more than 10 mmHg).  
It has been noted that the hypertension drug might supress the rise in the blood pressure 
and therefore the test would be negative (2/5 who were scored a negative test results were 
taking hypertension medication throughout the study). In comparison to the positive test 
results where 3/10 were taking hypertension medication. The Fisher’s exact test did not 
show that hypertension drug was the cause of negative test results (p = 1.0, relative risk 
= 1.167), however in such a small sample size the significance level (p>0.05) will be 
achieved only if 5/5 who scored a negative test results would be taking hypertension 
medication. Further, a negative score on the test might be linked to some participants 
relaxing briefly during the supposedly continuous squeeze as those have not been 
excluded from the analyses.     
The number of participants who obtained  positive or negative test results in comparison 
between baseline and after the treatment tests differed (Participant #14 did not performed 
the test after the treatment, Participant  #25 in bilateral stimulation changed to a negative 
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results, Participant #13 and Participant #16  in sham stimulation group change to positive 
results, Table 6.17).  
Table 6.17 Number of participants considered as positive or negative responders 
 Unilateral 
stimulation 
Bilateral 
stimulation 
Sham 
stimulation 
All 
groups 
 (n = 7) (n = 6) (n = 6)  
Baseline test     
Positive 3 3 4 10 
Negative 2 1 2 5 
Diastolic BP change 
[mmHg] 
+13 (5) +8 (6) +14 (5) +12 (3) 
After treatment test     
Positive 2 2 6 10 
Negative  2 2 0 4 
Diastolic BP change 
[mmHg]  
+8 (2) +11 (4) +28 (11) +17 (5) 
6.3.8. Cost implications  
Any new treatment option considered for adoption into clinical practice needs to be 
analysed for cost effectiveness and compared to therapies currently available. Recently a 
cost-effectiveness study of sacral nerve stimulation (SNS) for the refractory overactive 
bladder (wet) patients indicated a long term cost-effectiveness of the technique (Walleser 
Autiero et al., 2014). Based on this report, a greatly simplified analysis for the refractory 
overactive patients can be made for a duration of five years of ongoing treatment (Table 
6.18).   The success rate of self-administered transcutaneous PTNS has been assumed to 
be that of percutaneous PTNS. This rate is an estimate because there is a lack of long-
term data for both PTNS therapies. However the relative costs are so much in favour of 
transcutaneous PTNS that even if this estimate was significantly overoptimistic it would 
not alter the conclusions of this analysis. 
184 
 
Table 6.18 Treatment success rates and cost taken from (Walleser Autiero et al., 2014) and estimates 
for transcutaneous PTNS 
 Costs Success rate 
Self-administer transcutaneous PTNS £305* 19% 
Percutaneous PTNS £16205 19% 
Repeated BoNT-A £12450 59% 
SNS £28850 75% 
* calculated as 1hour Nursing time £70,1x Stimulator £50, 25x Electrodes sets /batteries £175 
Although the success in a 5 year projection might be relatively low, the self –administered 
transcutaneous PTNS thus appears to be a fraction of the cost of all other alternative 
therapies.   
The responders in this study perceived and demonstrated the initial benefit in the first 
week of the treatment. Therefore, if the technique will be considered for adoption into 
clinical practice, the initial cost of trialling the therapy in an individual subject is 
estimated to be one hour of nursing time (£70) for training and a set of electrodes (£5), 
which is similar to the cost of medication for two months (BNF, 2015b, BNF, 2015a).    
6.4.  Discussion 
This pilot study demonstrates that there are individual patients who may benefit from this 
non-invasive approach of posterior tibial nerve stimulation technique.  Although the 
effects do not seem to be large, they are comparable to the success rates observed in the 
latest OAB drug trials (Khullar et al., 2013) where typically mean number of micturitions 
episodes decrease by 1.9 (CI 95%, 2.2 to 1.7) voids per 24h. Furthermore, the non-
invasive stimulation has no significant side effects, is low cost and easy to administer, 
and hence may potentially offer an additional treatment option for patients with OAB 
symptoms. The following sections discuss the findings and challenges of this trial in order 
to help future work in this field.   
6.4.1. Study participants  
The study was focused on idiopathic overactive bladder symptoms patients.       
As this pilot trial implemented various recruitment pathways (urology outpatient, 
continence community centres, advertisement) there was variety in the history details of 
the patient’s symptoms, which led to challenges concerning their eligibility for the study.  
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For example: the inclusion criteria “Failure on primary OAB treatment, such as behaviour 
modification or fluid/diet management”. One of the patients who was excluded from the 
analyses, had presented with the idiopathic OAB symptoms and mean of 5.4 l of voided 
volume per 24h in the baseline. This high volume is indicative of excess fluid intake but 
the patient has regarded this to be normal and has never been informed that this might be 
a potential cause of the symptoms, although they had tried several medications. Other 
challenges often related to a definition of clinically significant bladder outlet obstruction 
and post void residual volume. The post residual volume was defined to be excessive over 
100 ml. However it has been perceived that the voided volume should be considered in 
order to normalise this to the total volume voided and the participant should have their 
bladder full before the voiding.  
Clearly a more specified and standardised way of assessing the patient would be desirable 
for future studies. However, the diversity of the patients’ symptoms might then lead to a 
significant limitation of recruitment rate.    
6.4.2. Methodology of the study 
In studies where participants self-administer a clinical trial treatment it is important to 
monitor their compliance. The choice of the stimulator allowed us to monitor this and the 
data demonstrated generally good compliance by the participants (Table 6.4). Those 
patients who did not comply with the study protocol were excluded from the analyses, 
although the reduced number of sessions of stimulation they did use might have had a 
beneficial effect. 
One of the uncertainties of transcutaneous PTNS is the intensity of stimulation needed in 
order to achieve an effect. The percutaneous form of PTNS aims to stimulate the tibial 
nerve by inserting a stimulation needle close to the nerve. The method is then to adjust 
the intensity such that a visible motor contraction of the toes is seen. Transcutaneous 
stimulation targets more cutaneous nerve structures which, because of the resultant 
sensation, may limit the intensity to a level below that needed to penetrate to deeper 
structures. Some participants were not able to achieve the motor contraction of toes due 
to this sensation and thus the stimulation intensity may have been inadequate if the 
posterior tibial nerve is the putative target. Nonetheless, all of the participants perceived 
a strong sensation in their toes and/or sole of their feet, which suggests that the nerve was 
186 
 
being at least partially stimulated. This is consistent with the experience of percutaneous 
PTNS at Gastrointestinal Investigation Unit of Sheffield Teaching Hospitals 
(conversation with Lynne Smith – Clinical Manager) who use percutaneous form of 
PTNS for the treatment of faecal and urinary incontinence. It was observed that a visible 
motor contraction is not able to be achieved in all of the patients even if the needle is 
repositioned. However a strong sensation in patient’s toes and/or sole of their feet is 
always present and desirable. In the context of effectiveness in this trial, only two of the 
participants (out of five who were considered as responders) were able to obtain the motor 
contraction of toes which suggests that motor contraction may not be essential as long as 
a significant referred sensation is produced. If the stimulation current and local sensation 
below the electrodes would be a limiting factor than a reverse position of the electrode 
(cathode below and anode above medial malleolus) might be used, as shown in numerical 
model in Chapter 5.   
Further to the methodology of this trial, in many sham-controlled studies the effectiveness 
of the blinding of the participants is evaluated by asking participants which arm they think 
they were allocated to. However, this was not possible in the context of this study, due to 
the fact that the participants were not informed that one of the study arms would be viewed 
as sham stimulation.  
6.4.3. Stimulation current in numerical modelling 
The mean stimulation current in the PESTOB clinical trial was 35.4 ± 14.0 mA (mean ± 
SD) for unilateral stimulation group and slightly lower current of 30.3 ± 12.7 mA (mean 
± SD) for the bilateral stimulation group. The numerical modelling showed that 
approximately half of this stimulation current is needed in order to achieve the same 
physiological effect. Although these values compare the theoretical calculations and 
experimental values, the difference might be explained by presumably larger layer of 
subcutaneous fat in this study population in compare to the virtual model used in Chapter 
5. The Virtual Population model “Duke” used in this work was a 34-year-old male adult 
with BMI of 23.1 kg/m2 in compare to clinical trial population which was the mean BMI 
of 30.8 kg/m2 in the unilateral stimulation group and 27.2 kg/m2 in the bilateral 
stimulation group.  
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6.4.4. Autonomic nervous system response test 
As proposed previously, a negative result in the hand grip exercise test may show an 
autonomic nervous system dysfunction and thus explain idiopathic overactive bladder 
symptoms in this group of patients (Hubeaux et al., 2011). The findings of study presented 
here looks similar to findings in (Hubeaux et al., 2011). However, when both tests 
(baseline and after treatment) are combined, there was 9/29 negative tests, which may in 
four cases be explained by a concomitant hypertension medication, thus suppressing the 
blood pressure increase; in two cases participants did not squeeze the dynamometer 
continuously (they briefly relaxed their grip during the 3 minute squeeze period) and one 
to impaired heart rate variability (as communicated by the participant during the study). 
It is not clear if the second was considered as an exclusion criterion by (Hubeaux et al., 
2011). 
This study did not include a control group as in the previous study, where all control 
participants scored the test as positive (Hubeaux et al., 2011). Although, their study has 
excluded cardiovascular or hypertensive diseases in both groups it was assumed that the 
same methodology of this study allow to use the Hubeaux et al study results in the context 
of his study.       
Unfortunately the autonomic nervous system response data have not been collected in 3/5 
responders in the active arms (due to a technical problem with the equipment) and thus it 
was not possible to investigate the correlation between the result of the test and symptom 
change.  In the context of the previous explanation of negative results of tests (e.g. 
hypertension drug, non continues squeeze of dynamometer), overall in this study, there 
was just one participant who might have an autonomic nervous system dysfunction, as 
indicated by a hand grip test. This participant was considered as a responder to the 
treatment.  
Further investigation with a control group and a larger study is required to draw any 
conclusion as to whether overactive bladder symptoms might be related to autonomic 
nervous system dysfunction.  
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6.4.5. Stimulation effects  
The primary outcomes of the study (mean change of micturitions and urgency episodes 
per 24 hours) show larger effects in the active stimulation groups compared to the sham 
stimulation group. In particular, the bilateral stimulation showed larger effects in the 
number of micturitions and urgency episodes. These findings were also confirmed by a 
number of responders (5/13 in active arms vs. 1/6 in the sham stimulation). Interestingly 
the larger effects in number of micturitions and urgency episodes in the bilateral than in 
unilateral stimulation group were not presented in the number of responders (two in 
bilateral and three in unilateral stimulation groups). This can be explained by the fact that 
the mean change of micturitions or confidence intervals in such a small group sample size 
is sensitive to small changes, which may not reflect a true change of the symptom. For 
example, the bilateral stimulation group non-responder participants #11 and #25 
demonstrated a reduction of ~1.3 micturitions per 24h but did not perceive any overall 
benefit, whereas unilateral stimulation group participant #21 increased by ~3.7 
micturitions per 24h (Table 5.14) and thus changed the overall group outcome values. 
This reflects the importance of determining clinically important changes, which this pilot 
trial has effectively covered by its definition of responders.    
It is perhaps noteworthy that five of the six participants who presented with a larger mean 
number of micturitions per 24h (>15voids) are responders (2/2 in the unilateral, 2/2 in the 
bilateral, 1/2 in the sham stimulation group). The only other responder in the bilateral 
stimulation group perceived improvement only in urgency, however this participant only 
presented with a mean of 9.3 micturitions per 24 h in the baseline and frequency was not 
his most bothersome symptom. The majority of the responders (2/3 in the unilateral, 2/2 
in the bilateral) were on a stable dose of OAB medications throughout the study and the 
sham stimulation responder did not take any OAB medication. These effects are not 
linked into the changes in the overall voided volume, although the responder in the sham 
stimulation group reduced the mean voided volume per 24 h by approximately one third 
compared to baseline. 
It can be argued that the primary outcome of the study (a change in the mean number of 
micturitions or urgency episodes per 24 h) might not be sensitive enough to capture a 
small change in the participants who presented with a low number of 
micturitions/episodes in the baseline. Other changes (not considered in the definition of 
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responders) where related to the intensity of urgency perceived, however it will be 
challenging to quantify these. 
Nocturia episode changes corresponded to the changes observed in 24 h micturitions. 
Similarly the incontinence episodes only improved in responders. Changes in the ICIQ-
OAB and OABq questionnaires were not statistically significant and although 
improvement of at least 10% was noted in some responders, this was not consistent across 
the group.  
In conclusion, this pilot trial demonstrates that there are patients who may benefit from 
this non-invasive type of therapy, which shows similar results to those obtained in 
percutaneous PTNS using a needle electrode (Peters et al., 2010). However, the technique 
presented here is completely non-invasive, can be self-administered by the patient at 
home and is thus low cost.  Although the effects do not seem to be large they, if confirmed 
by a larger study, could be comparable to the success rates observed in the latest OAB 
drug trials (Khullar et al., 2013).    
Furthermore, this non-invasive stimulation has no significant side effects and hence may 
potentially offer a useful additional treatment option for these patients.  Participants in 
this trial had severe OAB symptoms despite numerous drug therapies and would usually 
be offered more invasive treatments such as Botolinium Toxin injections or sacral 
neuromodulation in order to manage their symptoms.  Therefore TPNTS may be seen as 
an attractive alternative, particularly for those who are either unwilling to perform 
intermittent self catheterisation or unfit to undergo operative management. Further 
potential ways forward are discussed in the next chapter.  
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7.1.  Summary 
This thesis investigates techniques of transcutaneous electrical nerve stimulation with a 
specific focus on the treatment of overactive bladder. The thesis starts with an overview 
of the current usage of transcutaneous techniques to treat overactive bladder. The current 
consensus is that the most promising target for stimulation is the S3 area of the spinal 
cord, accessed either via stimulation over the sacral region or over the posterior tibial 
nerve. However, it is not clear which approach to stimulus delivery is the most effective. 
Little is known about the underlying mechanisms of action and which exact structures 
need to be stimulated. Furthermore, there are also several gaps in the literature. These 
mainly include: what is the placebo effect of transcutaneous techniques; what is the carry-
over effect of these techniques; what is the optimum length, frequency and duration of 
the treatment session; what are the optimum parameters for the stimuli settings (pulse 
width, frequency, intensity); is bilateral PTNS more beneficial than unilateral; and what 
is the optimal electrode position in sacral dermatome stimulation?  
The standardization and evaluation of various parameters of stimuli would be beneficial 
in order to optimize the techniques used and to achieve maximal effectiveness. However, 
a clinical evaluation of all these parameters would be both costly and time consuming.  
Therefore considerable effort was made in this thesis to find a suitable surrogate measure 
that would enable the various stimulation parameters to be evaluated quickly. Based on 
the previous research in this area, the Hoffman reflex (H reflex) was identified as a 
suitable candidate. Specifically, H reflex magnitude measurements were assessed as a 
potential measure of bladder nerve activity and thus of the subjective symptoms of 
urgency in overactive bladder patients, and hence as a surrogate measure. Unfortunately, 
the results of the study presented in this thesis showed that other actions related to bladder 
control mechanisms also influence the H reflex magnitude, as shown during the pelvic 
floor muscle study exercises in healthy volunteers. These results are new findings and do 
not support the previous conclusions that the H reflex would be a useful surrogate 
measure. Previous claims about its usefulness for observing modulation of bladder nerve 
activity need to be clarified in relation to these findings. Further work to find a suitable 
surrogate measure was not carried out during this thesis because the literature did not 
support any obvious and practical alternative avenues of investigation. Although animal 
models have their limitations, recently new approaches have been explored which might 
be suitable, but currently these were beyond the scope of this project (Brink et al., 2015).  
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The evidence for TENS effects in the treatment of overactive bladder remains limited. 
Despite the lack of clarity with regard to the stimulus parameters, it has been hypothesized 
that the lack of major effects may be due to a decrease in response following repeated 
exposure to the same stimulus. Therefore a stimulus methodology which produces more 
variable stimulation, both temporally and spatially, was developed and investigated. The 
stimulus methodology incorporated two features; large (in terms of targeted area) sensory 
stimulation combined with a spatial-temporal pattern of stimuli designed to enhance 
attention to the stimuli. This concept was named Sensory Barrage Stimulation. The 
technique was developed and delivered using a 64 channel stimulator, ShefStim, 
previously used for foot drop therapy. Firstly the salience and habituation study aimed to 
evaluate the stimulation pattern feature using measurements of performance during 
cognitive tasks, but no significant evidence for this claim was produced. Nonetheless the 
spatial-temporal patterns used in this study demonstrated that the sensation was 
distinguishable and unique for each pattern. Thus it was possible to develop a suitable 
pattern of sensation to evaluate this technique in an alternative therapy model, namely 
patients with elbow spasticity. The pattern was designed such that it mimics stroking. 
Stroking was previously reported to be beneficial in muscle relaxation. The resultant pilot 
clinical trial demonstrated the feasibility and practicality of using SBS on patients at the 
clinical setting and showed a higher efficacy response compared to conventional TENS 
stimuli assessed by the numbers of responders on these elbow spasticity patients. Home 
based application of this type of therapy would be a desirable approach and further 
development should continue with that direction.  
The pundendal nerve has been considered as another target for the treatment of overactive 
bladder symptoms (Bartley et al., 2013). This nerve originates from the S2, S3 and S4 
sacral nerve roots. It is thought to be a superior alternative  to sacral neuromodulation 
(Peters et al., 2005). As the pudendal nerve is relatively deep in the body, covered by 
overlying tissue, implanted wire electrodes (as in sacral neuromodulation) were used. It 
is difficult to target these deep branches non-invasively. Recently however, a novel 
stimulation technique using a ‘transdermal amplitude modulated signal’ (TAMS) was 
introduced for this purpose. This TAMS waveform has been described (Shen et al., 2011) 
as ‘a high frequency sinusoidal carrier waveform (210 kHz) amplitude-modulated by low 
frequency, monophasic rectangular pulses (1ms pulse width)’. Preclinical studies have 
evaluated the effect of TAMS stimuli of the pudendal nerve on the bladder in cat models 
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(Shen et al., 2011, Tai et al., 2011, Tai et al., 2012). This latter paper reported that ‘TAMS 
uses a 210 kHz sinusoidal carrier waveform that has a minimal skin impedance and is 
optimal for stimulating nerves under skin and muscle’ (Tai et al., 2012). However, there 
was no literature to support this statement, based on comparative human studies. If a 
particular electrical stimulation waveform is more effective in stimulating deep nerve 
structures such as the pudendal nerve, this would have major implications for the whole 
field of non-invasive electrical stimulation. This claim was evaluated in this thesis and no 
significance difference between a conventional stimulation waveform and TAMS 
waveform were shown when comparing skin impedance and a variety of other relevant 
electrical parameters.  
The last two chapters of this thesis cover the stimulation of the posterior tibial nerve using 
a transcutaneous form of stimulation. In comparison to the more established and 
commercially available percutaneous technique, this has the advantages of being 
completely non-invasive, low cost and performable by the patients at home. The 
numerical model used here showed that the same physiological effect (assessed by the 
activating function) can be achieved for both transcutaneous and percutaneous 
techniques. The model has enabled an estimate to be made of the relative currents that are 
needed in the two methods. However, it should be noted that the position of stimulation 
along the nerve is somewhat different for the electrode montages considered and that the 
electrical current needed to produce the same effect is larger in transcutaneous from. The 
findings in this chapter showed that the optimal stimulation electrode position (with the 
lowest current required) is such that the cathode is placed below the medial malleolus and 
the anode above.  However, the position of the electrodes for the clinical trial was chosen 
to be the same as that used in previous studies of PTNS, where the cathode is above the 
medial malleolus, in order to produce more directly comparable data with the previous 
studies and also because chronologically the clinical trial started before the outcomes of 
numerical modelling were known. According to the numerical model this combination 
required approximately double the current of the optimal electrode position. Although the 
optimal position of electrodes should be considered in further clinical evaluation, a 
referred sensation in the toes or motor contraction of the toes was observed in all 
participants, thus indicating that the target nerve was stimulated. This second PTNS 
chapter describes a randomised clinical trial of the home-based application of the non-
invasive form of PTNS in patients with symptoms of overactive bladder. The participants 
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of this trial complied well with a daily 40-minute application of PTNS using a TENS 
machine. Although the sample size is small in this study, some benefit was demonstrated, 
particularly in participants with more severe symptoms.  
7.2.  Further work 
As mentioned previously the standardization and evaluation of various parameters of 
stimuli would be beneficial in order to optimize the techniques used and to achieve 
maximal effectiveness. However challenge still remains how to do this effectively and 
ideally prior a clinical evaluation. Therefore, researchers have tended to use the previous 
parameters without any further investigation on a small scale due to limited resources 
available. 
A larger clinical trial with sufficient power to investigate the effects of transcutanoues 
PTNS or any other technique for the treatment of overactive bladder symptoms in detail 
would be both costly and labour-intensive. Recruitment rates are often limited by attempts 
to obtain homogeneity in the investigated group and overactive bladder symptoms are 
often accompanied by various pathological conditions which preclude many of these 
patients from participating. Therefore, in view of the very low cost technique (£300 
course of treatment for 5 years) and absence of side effects, NHS Trusts and patient care 
organisations may wish to now consider deploying this technique. If a standard evaluation 
protocol was used this would enable its benefits to be evaluated locally and, 
retrospectively, on a wider scale using meta-analyses. However, this is clearly a less 
scientific approach and ideally future work should be focused on a randomized 
multicentre trial based on the experience gained from the design of this pilot clinical trial. 
A promising target group for PTNS might also be in the population of elderly adults in 
residential care. Posterior tibial nerve stimulation in both percutaneous and 
transcutaneous form has been reported to show benefits in faecal incontinence, which 
affects this group of patients as well (Thomas et al., 2013, George et al., 2013). There is 
a real need for alternative methods of continence management in this population as 
current management using absorbance pads is not considered to be dignified and is 
expensive.  
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7.2.1. Trial methodology 
As discussed in section 6.4.2 and in view of the trial undertaken in this thesis a more 
specified and standardised way of assessing the patient would be desirable for future 
studies. However, the diversity of the patients’ symptoms might then lead to a significant 
limitation of recruitment rate. Thus only way forward seems to be to conduct a multicentre 
trial, which will increase the recruitment rate and make the trial results more robust. 
The sham methodology presented in the trial in this thesis (comparable intensity of 
electrical stimulation in the placebo group but applied to a site that is regarded as being 
irrelevant to bladder control) seemed to be scientifically effective. The participants in the 
trial were not told that they could be randomized into the sham arm. This sometimes was 
not well supported by the team conducting the trial, who was not originally involved in 
the trial design. In that view, it was not perceived a as being fair to the participants 
(although the local ethical committee did not consider this as a problem). Therefore the 
further trials should consider cross over design or allowing the participants an access to 
the active arm after the trial. Alternatively this could be discussed with patients before 
the trial using a Patient and public involvement (PPI) activity. PPI in the treatment and 
research development is currently essential for any further work and to securing any form 
of funding. 
Another area where PPI could be beneficial, is in the definition of stimulation protocol. 
As mentioned previously there is lack of investigation about the optimal parameters of 
the stimuli and strategy of the treatment. PPI activity groups could help to determine for 
example how many sessions of stimulation and how long (session time) they would prefer 
to do. However this needs to be balanced with previous scientific knowledge and not be 
entirely based on the patient’s convenience.      
7.2.2. What sample size would be needed for a larger clinical trial?  
To answer this questions the study aims and outcome measures would need to be decided.  
The following is a calculation based on the data presented in this study and the primary 
outcome is considered as the difference between the number of responders. The 
calculation only considers two group (active and sham stimulation groups). 
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Therefore, the aim of this calculation is to determine what sample size would be required 
in order to detect the difference between the number of responders in active stimulation 
group (5/13, 38%) and sham stimulation group (1/6, 16%) with 90% power using a cut 
off for statistical significant of 0.05.  
𝑛 =
[𝑝1(1 − 𝑝1) + 𝑝2(1 − 𝑝2)]
(𝑝1 − 𝑝2)2
=
[0.38(1 − 0.38) + 0.16(1 − 0.16)]
(0.38 − 0.16)2
= 80 
The formula used (Whitley and Ball, 2002) identified that 80 participants in each group 
would be needed.  
7.2.3. Sensory Barrage Stimulation 
The concept of Sensory Barrage Stimulation introduced in this thesis is a novel approach 
to electrical stimulation which can be potentially beneficial in stroke/spasticity 
rehabilitation and, perhaps, for OAB. However further studies in this area need to be 
undertaken. In the context of overactive bladder symptoms using this technique for 
foot/posterior tibial nerve or sacral dermatomes stimulation as identified in the literature 
review could perhaps be explored. Ideally one would evaluate a variety of stimuli using 
a non-clinical surrogate measure as was suggested originally in this thesis, but finding a 
suitable approach still remains a challenge. Nonetheless, this could be less challenging in 
another treatment population groups such as in stroke and spasticity.  
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activity 
APPLICATION: Reference Number 001645 
On behalf of the University ethics reviewers who reviewed your project, I am 
pleased to inform you that on 11/08/2014 the above-named project was approved 
on ethics grounds, on the basis that you will adhere to the following documentation 
that you submitted for ethics review: 
 
University research ethics application form 001645 (dated 01/08/2014). 
Participant information sheet 002333 (01/08/2014) 
Participant consent form 002334 (01/08/2014) 
If during the course of the project you need to deviate significantly from the above-
approved documentation please inform me since written approval will be required. 
 
Yours sincerely 
Jean Lazenby Ethics Administrator Medical School 
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Appendix B – Inclusion and exclusion criteria for study in Chapter 2 
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Appendix C – Individual measurements in the H reflex study 
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Appendix D – Ethics approval for the habituation study in Chapter 3 
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Appendix E - Ethics approval for the spasticity study in Chapter 3 
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Appendix F – Individual measurement of pendulum outcomes  
 TENS 
 First reversal angle [°] Maximum velocity to first reversal [°/sec] Area under the curve [°*sec] 
No. Base After One hour Base After One hour Base After One hour 
1 23.6 25.1 23.0 127.1 125.4 129.0 65.5 60.8 88.7 
2 38.1 39.2 36.9 136.3 145.4 133.0 356.5 253.7 438.7 
3 39.0 38.1 37.3 139.0 130.6 140.1 262.1 314.3 359.8 
4 18.0 14.9 13.3 120.1 125.5 104.4 58.5 62.4 36.8 
5 34.4 38.5 31.9 131.4 132.3 112.6 201.0 361.8 336.2 
6 28.4 20.2 23.7 130.6 121.0 117.5 84.5 64.7 74.8 
7 39.9 37.9 40.3 144.4 135.8 151.6 518.5 433.8 355.7 
8 39.1 36.6 36.5 130.8 126.7 131.1 187.3 198.3 171.8 
9 37.2 28.1 34.9 136.6 128.7 135.3 251.6 126.2 301.6 
10 30.4 31.9 24.6 147.9 133.3 137.7 554.6 505.4 535.3 
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 SBS 
 First reversal angle [°] Maximum velocity to first reversal [°/sec] Area under the curve [°*sec] 
No. Base After One hour Base After One hour Base After One hour 
1 20.8 19.8 17.8 119.1 117.3 123.1 43.3 37.3 36.0 
2 25.1 38.4 40.3 126.7 135.6 141.4 90.1 216.1 384.1 
3 38.4 37.9 45.7 130.6 122.2 146.0 196.5 291.7 655.8 
4 9.6 9.3 - 104.4 95.4 - 32.6 19.6 - 
5 29.6 35.3 37.0 112.1 122.5 124.9 215.2 315.4 425.7 
6 32.6 32.9 17.8 150.6 138.3 121.1 163.0 139.3 60.6 
7 40.6 42.4 40.3 150.0 151.0 152.0 450.1 348.7 171.2 
8 37.9 34.3 36.3 135.3 121.5 136.8 329.9 312.6 308.1 
9 41.1 29.9 37.1 139.9 134.3 137.1 267.8 99.0 136.6 
10 43.8 43.1 40.6 137.0 137.4 135.2 328.5 234.3 248.8 
222 
 
Appendix G – Typical pendulum outcome data 
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Appendix H - Stimulator schema 
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Appendix I - PESTOB study - Ethics approval 
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Appendix J - PESTOB study - Inclusion and exclusion criteria 
Inclusion criteria: 
PESTOB potential subjects must have satisfied the following criteria in order to be 
enrolled in the study: 
 Males and Females, at least 18 years of age 
 Demonstration of ability to fill in voiding diary at DAY-0 
 Documented symptoms of idiopathic overactive bladder for at least 3 months 
 Failure on primary OAB treatment, such as behaviour modification or fluid/diet 
management  
 Patients can remain on stable medication 
 Willing and capable of understanding and complying with all requirements of the 
protocol 
 Signed Informed Consent to participate in the study after full discussion of the 
research nature of the treatment and its risks and benefits. 
Exclusion criteria: 
Potential subjects who meet any of the following criteria were excluded from 
participating in the study: 
 Urinary retention or post voiding residual greater than 100 ml 
 Clinically significant bladder outlet obstruction 
 Stress predominant mixed urinary incontinence 
 Neurological disease affecting urinary bladder function, including but not limited 
to Parkinson's disease, multiple sclerosis, stroke, spinal cord injury. 
 Pelvic surgery (such as sub-urethral sling, pelvic floor repair) within the past 6 
months  
 Denovo OAB following pelvic surgery sub-urethral sling 
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 Intravesical or urethral sphincter Botulinum Toxin Type A injections within the 
past 6 months 
 Percutaneous Tibial Nerve Stimulation (PTNS) therapy for overactive bladder 
within the past 6 months 
 Any form of electric stimulation to the pelvis of lower limbs within 4 weeks  
 Vaginal prolapse greater than Stage II in the anterior compartment of the vagina 
using International Continence Society (ICS) Pelvic Organ Prolapse 
Quantification (POPQ) criteria. 
 Prior peri-urethral or transurethral bulking agent injections for bladder problems 
within the past 12 months. 
 History of pelvic radiation therapy 
 Any skin conditions affecting treatment sites 
 Lacking dexterity to properly utilize the components of the device system. 
 Presence of an implanted electro-medical device (e.g. pacemaker, defibrillator, 
InterStim®, etc.), 
 Pregnant, nursing, suspected to be pregnant (by urine pregnancy method), or plans 
to become pregnant during the course of the study. 
 Transurethral instrumentation within the preceding month. 
 Recurrent Urinary Tract Infections (>3 UTI's in the past year) 
 History of, or current, lower tract genitourinary malignancies 
 Any clinically significant systemic disease or condition that in the opinion of the 
Investigator would make the patient unsuitable for the study 
 Any other clinical  trial within 6 months 
 Patients whose resting blood pressure is greater than 160/100mm Hg will be 
excluded from the handgrip test. 
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Appendix K –PESTOB study - Instructions for use 
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Appendix L – PESTOB study – Bladder diary 
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Appendix M – PESTOB study – Individual bladder diaries values 
 
 
  Micrutions per 24 h Urgency episodes per 24 h Incontinence episodes per 24 h Nocturia episodes per 24 h 
  Baseline 
After 1 
week 
After 
treatment 
Follow 
up 
Baseline After 1 
week 
After 
treatment 
Follow 
up Baseline 
After 1 
week 
After 
treatment 
Follow 
up Baseline 
After 1 
week 
After 
treatment 
Follow 
up 
Unilateral stimulation group 
1 F55 26.0 19.7 17.0 11.7 8.0 7.3 8.7 4.3 5.0 0.3 3.0 1.3 2.0 0.3 0.3 0.3 
5 F59 8.7 10.3 7.7 8.3 3.7 5.7 5.0 6.0 0.0 1.3 0.7 4.0 1.7 1.3 1.0 1.0 
14 F66 9.3 8.3 8.0 9.3 2.7 1.7 0.7 1.0 2.0 1.0 0.7 1.3 1.0 1.0 1.3 1.7 
19 F63 8.3 8.3 8.0 7.3 9.7 5.3 4.0 4.0 1.7 0.0 1.3 0.0 0.0 0.0 0.0 1.0 
21 F59 11.3 11.3 15.0 13.3 11.3 11.3 15.0 13.3 10.0 4.7 11.3 12.0 3.3 4.7 7.0 5.7 
26 M54 15.3 13.3 11.0 15.3 19.7 13.3 12.3 15.3 0.3 3.7 0.0 0.0 4.7 3.7 3.0 4.7 
27 M56 11.0 9.3 11.0 8.7 7.3 6.3 7.0 8.3 0.0 0.0 0.0 0.0 3.0 2.3 3.0 2.3 
Bilateral stimulation group 
3 F47 21.7 11.3 12.3 22.0 21.3 11.3 8.7 20.7 13.0 4.0 1.7 9.7 4.3 0.7 0.3 3.3 
11 F39 8.3 6.3 7.0 7.7 7.0 5.3 5.0 6.7 2.0 1.0 1.3 1.0 1.3 0.0 0.0 1.0 
12 M63 10.0 8.7 10.3 10.7 6.0 3.3 5.0 6.0 0.0 0.0 0.0 0.0 1.0 1.3 1.0 1.3 
23 M59 15.0 9.0 10.3 11.7 7.7 1.0 2.7 1.0 0.0 0.0 0.0 0.0 2.3 1.7 3.0 2.7 
25 F69 12.7 11.7 11.3 13.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 2.7 4.3 4.0 
29 M68 11.0 7.7 10.7 7.3 3.0 2.3 4.3 1.3 0.0 0.0 0.0 0.0 3.0 2.0 2.0 1.0 
Sham stimulation group 
13 M69 16.0 14.3 18.7 15.0 10.3 10.7 15.7 11.7 0.0 0.0 0.0 0.0 1.7 0.7 0.7 2.3 
15 F68 13.3 14.3 13.3 13.7 4.0 1.0 1.3 0.7 0.0 0.0 0.0 0.0 2.7 1.7 1.7 1.3 
16 F68 11.7 10.7 10.7 10.7 5.7 5.7 8.7 9.0 2.7 0.0 0.0 1.0 1.7 2.0 2.0 1.7 
17 M55 15.3 10.0 9.3 11.0 15.3 9.7 9.3 7.0 1.0 0.7 1.0 1.0 2.3 1.7 1.7 1.0 
22 M51 9.0 8.7 8.3 8.7 6.7 4.7 4.3 4.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
28 M56 14.3 12.7 15.0 10.0 9.7 9.3 8.3 4.3 0.0 0.0 0.0 0.0 2.0 1.7 1.7 1.7 
